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Advisory Professor: Louise McCullough, M.D., Ph.D.

In healthy brain tissue, toxic amyloid-β (Aβ) proteins are transported by the pulsatile
flow of cerebrospinal fluid (CSF) along perivascular drainage pathways. Ischemic stroke
may disrupt this process, leading to a perivascular build-up of Aβ, termed cerebral amyloid
angiopathy (CAA). I hypothesize that an abnormal pattern of extracellular matrix deposition
within the vascular basement membrane, termed fibrosis, impairs Aβ drainage from the aged
brain after stroke. I further hypothesize that inhibition of astrocytic transforming growth
factor-β (TGF-β) signaling can reverse these phenotypes. Finally, I also hypothesize that
serum biomarkers of perivascular fibrosis can be used to diagnose CAA following
intracerebral hemorrhage (ICH). To test these hypotheses, I first performed experimental
stroke in young and aged wild-type mice, then measured basement membrane fibrosis and
CSF flow using a variety of biochemical and physiological techniques. I also evaluated the
contribution of astrocytes to these phenotypes using a primary cell culture model. Then, I
treated aged mice with a TGF-β antagonist, and measured the impact on fibrosis and CSF
flow. Finally, I explored the relevance of these findings to humans by measuring serum
biomarkers of fibrosis after ICH, and correlating them to CAA etiology, injury severity and
functional outcomes.

Overall, my findings support a role for fibrosis in impairing

perivascular Aβ drainage after stroke, which could lead to CAA and progressive cognitive
decline in stroke survivors.
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CHAPTER 1
Background and Significance

1.1: Stroke is a major risk factor for cognitive decline in the elderly.
Ischemic stroke occurs when a blood clot acutely reduces blood flow to a region of
brain tissue, leading to acute infarction of the affected area.1 This type of stroke affects
approximately 800,000 people every year within the U.S.,1,2 and is a leading cause of
acquired disability.3 With approximately 7 million stroke survivors currently alive in the
U.S.,2 there is a desperate need to better understand the long-term cognitive consequences of
stroke and to develop tailored strategies to address the unique clinical challenges in this
vulnerable population.
The most common type of stroke is a large vessel occlusion of the middle cerebral
artery (MCA). During the acute phase of injury, this type of stroke typically damages the
cortex and basal ganglia.4 Following blockage by a thrombus or embolus, acute ischemia in
these brain regions produces confusion and hemiparesis, as well as different cortical signs
depending on which side of the brain is affected.4 Tissue plasminogen activator (tPA)
represents the only available pharmacologic treatment for acute stroke, and must be used
within hours of stroke onset to be efficacious in reducing injury severity.5 However, even
when properly treated, stroke frequently leads to long-term disability, including chronic
motor, sensory and cognitive impairment.3 Recent studies in the clinical literature suggest
that in addition to acute deficits in cognitive function, stroke commonly leads to a slowly
progressive form of cognitive decline, termed ‘vascular’ dementia.6 However, this disease
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has proven challenging to model in mice, and the underlying mechanisms leading to this
phenotype are a subject of intense debate.
There is significant evidence in the clinical literature that stroke is an independent
risk factor for progressive cognitive decline. The Framingham heart study found that stroke
doubles the risk of cognitive decline, with 35% of stroke survivors progressing to dementia
within ten years of the initial insult.7 Furthermore, the Rotterdam study confirmed that stroke
doubles the risk of dementia, and that this occurs independently of pre-stroke cognitive
function and, importantly, in the absence of recurrent stroke.8 More recent work has shown
that in addition to an acute loss of cognitive function, stroke also accelerates the trajectory of
underlying progressive cognitive decline, suggesting a synergistic relationship between
chronic neurodegenerative disease and acute injury.9 Overall, these data from multiple, large
clinical studies indicate that stroke is a major, yet largely unrecognized independent risk
factor for progressive cognitive decline. However, the lack of a coherent disease mechanism
presents a major roadblock to developing potential treatments for post-stroke dementia.6
Stroke may induce acute cognitive impairment due to the initial loss of brain tissue
associated with the primary injury.4 However, this progressive impairment, described above,
requires the exploration of additional, more chronic mechanisms. This has mainly been
studied with experimental MCA occlusion (MCAO) models in mice.6 One plausible
hypothesis is that stroke initiates a neuroinflammatory cascade, which contributes to
widespread neuronal loss and dementia by autoimmune mechanisms.10 For example, one
previous study showed that young mice subjected to a small, cortical stroke developed
progressive cognitive decline over seven weeks after injury, due to a neuroinflammatory
response involving B cell activation.11 Similarly, previous work by our lab has shown that
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aging exacerbates chronic T cell responses to stroke,12 which could also impair cognitive
function. Others have shown that sterile inflammation, modeled by lipopolysaccharide (LPS)
stimulation, impairs cognitive function in mice.13 Furthermore, this can be abolished by
treatment with anti-inflammatory drugs at the time of LPS exposure, indicating a detrimental
effect of immune activation on cognition.13 However, based on the fact that cognitive
impairment continues to progress years after the peak of inflammation has subsided, there
could be other, non-immune mechanisms at play that have not been adequately explored in
animal models.
Alzheimer’s disease (AD) provides a relatively well-understood alternative prototype
for progressive cognitive decline, which serves as a useful starting point to explore additional
potential mechanisms of post-stroke dementia. In classic AD-type dementia patients, a toxic
protein called amyloid-β (Aβ) accumulates and forms plaques in the hippocampus, which is
associated with progressive impairment of cognitive function.14 Similarly, when humanized
amyloid protein is overexpressed in the brains of mice, they also begin to develop
progressive cognitive decline with aging,15 further supporting the so-called ‘amyloid cascade
hypothesis’ of neurodegeneration in AD.16,17 As hippocampal amyloid pathology forms
early in the disease course, AD patients develop deficits in hippocampal dependent tasks,
such as short-term and working memory. Additionally, in most AD patients, Aβ deposits in
the walls of cortical vessels, which can lead to a loss of vessel integrity and recurrent
microhemorrhage.18–20 This special type of vascular pathology is termed cerebral amyloid
angiopathy (CAA).19 The appearance of microhemorrhage is often associated with
impairment in multiple other ‘extra-hippocampal’ cognitive domains, including executive
function, language and facial recognition; although some patients are cognitively normal
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until late stage disease.21 While the literature supports that Aβ accumulation plays a major
role in AD pathogenesis,17 it is not known if CAA contributes to post-stroke dementia.6
Stroke patients tend to exhibit early problems with ‘cortical’ domains of cognitive
function.9,21 In particular, compared to AD, a marked loss of executive function occurs early
in post-stroke dementia, suggesting damage to the frontal cortex or white matter.22
Additionally, patients with post-stroke dementia often follow a stepwise loss of cognitive
function, suffering repeated vascular insults, including microhemorrhage and microinfarction
throughout the cortex, in a similar distribution to that seen in AD-associated CAA.9
Therefore, it stands to reason that CAA could play a major, early role in driving the
progression of post-stroke dementia. It is not known how stroke induces conditions that
could favor the formation of CAA deposits,17 but understanding this process could shed light
on the pathogenesis of both post-stroke dementia and lead to new disease-modifying
treatments.
In summary, ischemic stroke is a leading cause of dementia in the elderly, however,
the mechanism driving cognitive decline in these patients is not known. Both AD and poststroke dementia may involve the accumulation of Aβ, however, differences in the disease
course and impact on specific domains in cognitive function suggest that this accumulation
occurs in different locations; therefore, they likely occur by distinct pathophysiological
mechanisms. In particular, the cognitive symptoms and clinical course of post-stroke
dementia suggest a pattern of cortical vascular amyloid deposition that is consistent with
CAA.23
In the remainder of this chapter, the evidence that stroke induces CAA pathology in
human patients will be extensively explored. Additionally, the multiple mechanisms by
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which Aβ deposition induces vessel damage and cognitive decline will also be reviewed in
detail. Finally, a new potential mechanism by which stroke induces vascular Aβ deposition
in the cerebrovascular basement membrane will be introduced. A better understanding of
these mechanisms may lead to new diagnostic tools and therapeutic avenues for stroke
survivors at risk of cognitive decline.

1.2: CAA drives cognitive decline in aging and after stroke.
CAA is pathologically defined as the appearance of amyloid (“sugar-like”) deposits
in vessels accompanied by vessel wall hypertrophy, fibrinoid necrosis and/or hemorrhage.19
These amyloid deposits form in the brain extracellular perivascular space (PVS) and are
primarily composed of amyloid-β (Aβ), a 4 kD peptide with a unique biochemical profile.20
Importantly, the majority of dementia patients suffer from mixed brain pathologies, and have
histological evidence of both macroscopic infarction, caused by prior stroke, and
Alzheimer’s disease (amyloid deposition) at autopsy.18,24,25 This association between stroke
and CAA is clearly evidenced in the clinical literature by both histopathological and imaging
studies.
First, several postmortem histopathological studies of human patients support an
association between ischemic stroke and CAA. One study found that cerebral infarction and
amyloid pathology synergize to worsen cognitive impairment in elderly individuals.24
Importantly, this association also occurs in patients with mild-cognitive impairment (MCI),
indicating that vascular and amyloid pathologies co-exist even in the earliest stages of
dementia.18 CAA pathology is associated with executive dysfunction in MCI patients, further
supporting the notion that vascular amyloid pathology impairs specific domains of cognitive
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function.26 Overall, these studies show that stroke and amyloid pathology frequently cooccur, and are associated with both early and late stages of disease.
Further supporting the relationship between stroke and CAA, data from positron
emission tomography (PET) studies support a relationship between ischemia and amyloid
deposition using the Pittsburgh compound B (PiB) retention ratio.27 Ischemic stroke patients
exhibit significantly higher amyloid burden in the area of infarction during the subacute
phase of injury,28 which correlates with both magnetic resonance imaging (MRI) biomarkers
of CAA, and dementia, in elderly stroke patients.29 Furthermore, stroke patients with high
amyloid burden are also more likely to develop hemorrhagic transformation, suggesting that
these post-stroke amyloid deposits are associated with underlying small vessel disease.30
Finally, MRI studies also support a relationship between stroke and small vessel
disease phenotypes that are characteristic of CAA. MRI can be used to meet a probable
diagnosis of CAA by measuring several types of secondary brain injuries, termed the ‘Boston
criteria,’ including the presence of cerebral microbleeds, lacunar infarction (small ischemic
strokes), leukoairaiosis (white matter hyperintensity), superficial siderosis, cortical atrophy
and enlarged PVS.31,32 Stroke survivors with imaging biomarkers of CAA have worse
functional outcomes 3 months after stroke.33 They exhibit higher levels of leukoairiosis,
which positively correlates with cognitive decline after stroke.34,35 Additionally, stroke
survivors commonly develop enlarged visible PVS.32,33,36 Overall, these studies demonstrate
(1) that stroke patients are at a high risk of developing the secondary injuries associated with
CAA, and (2) that stroke patients with more severe CAA exhibit increased rates of cognitive
impairment after stroke.
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While these findings clearly support a relationship between stroke and CAA, this may
be complicated by the fact that stroke and AD share several major risk factors.37 Sporadic
AD and stroke share genetic risk factors, including apolipoprotein E ε4 genotype,38
methylenetetrahydrofolate reductase polymorphisms39 as well as regulators of C-reactive
protein and plasma lipids.40 In addition, the two diseases also share several modifiable risk
factors, including hypertension,41 hypercholesterolemia,42 diabetes mellitus,43 obesity,44
sedentary lifestyle45 and smoking.46 All of these shared factors could confound even the bestdesigned retrospective study, and highlight the need for more prospective studies with
baseline imaging and cognitive testing. While these shared risk factors between AD and
stroke may confound the clinical literature, they also raise the question as to how the
underlying pathophysiology of stroke and CAA are related.
In theory, the causative relationship between stroke and CAA would be best
illustrated by studies in the animal literature, because they avoid many of the confounding
variables of shared risk factors, described above, by the use of littermate controls. A few
interesting studies using wild-type rats have shown that stroke increases the levels of soluble
Aβ within the thalamus after MCAO, which may be a result of secondary injury.47–51 These
studies support the notion that stroke independently increases amyloid burden, but do not
perfectly mimic the findings seen in stroke patients involving CAA pathology and amyloid
plaque deposition in the area of infarction. However, these papers provide consistent support
for a causative relationship between stroke and amyloid deposition.
Overall, data from diverse studies using histopathology as well as MRI and PET
imaging strongly support an association between ischemic stroke, CAA and cognitive
decline. However, the causative nature of stroke on CAA progression is difficult to infer in
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these clinical studies, due to both unavoidable shortcomings in study design, as well as the
significant overlap of risk factors for AD and stroke. Additional studies of long-term
histological and cognitive outcomes in transgenic AD mice with experimental stroke are
needed to confirm the directionality of the relationship between stroke and CAA, as well as
to better understand the potential mechanism of CAA induction after stroke.

1.3: Increased vascular Aβ deposition mediates vascular pathology in CAA.
CAA is associated with maladaptive vascular phenotypes that could contribute to
cognitive decline in stroke survivors by negatively affecting neurons and other brain cells
that rely on affected vessels for perfusion. Based on a review of the existing literature, it is
clear that the vascular phenotypes and cognitive loss observed in CAA are, in large part, a
direct consequence of Aβ deposition into cerebral blood vessels. Therefore, therapies that
reduce the production, aggregation or deposition, or conversely, enhance the clearance of Aβ
from the PVS, could slow the progression of CAA.
The Aβ peptide is a metabolic product that is derived from the much larger amyloid
precursor protein (APP), which is an 87 kD integral membrane-spanning protein.52 In the
healthy brain, APP plays an important role in synapse formation,53 synaptic plasticity54 and
iron metabolism.55 Importantly, APP is degraded during the course of normal
neurotransmission, and Aβ is produced and released into the extracellular space, where it
undergoes two sequential cleavage steps by two enzymes: β-secretase and γ-secretase.56 The
major Aβ isoforms that are associated with CAA and Alzheimer’s disease are Aβ peptides
containing the amino acid residues numbered 1-40 and 1-42 (denoted as Aβ1-40 and Aβ1-42,
respectively). Both isoforms exhibit extensive beta sheet structure, which causes monomeric
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Aβ particles to assemble into dimers, oligomers and eventually large insoluble aggregates,
which are found as abnormal deposits within the vascular basement membrane.17 Aβ1-40 is
most commonly associated with CAA plaques,57 potentially due to its improved solubility
compared to the longer Aβ1-42 isoform,58 which could allow for it to travel further from the
synapse and associate with the vasculature.
While there is a strong association between CAA and dementia, there is historical
debate as to whether Aβ1-40 represents a cause or a consequence of the underlying small
vessel pathology. The most direct evidence that Aβ is causally related to small vessel disease
comes from studies of early-onset, genetic forms of CAA. For example, patients with Downs
syndrome (Trisomy 21) exhibit overexpression of APP and develop AD pathology and CAA
at increased rates.59 Additionally, in familial AD, activating mutations in γ-secretase
(presenilin-1 [PS1]) increase the generation of Aβ from APP,56,60,61 leading to extensive Aβ
plaques and early-onset cognitive decline,62 and certain PS1 mutations induce vascular
amyloid deposition and multiple hemorrhage.63–65 Finally, rare cases of familial CAA, caused
by specific mutations in the Aβ coding region of the APP gene, comprise a small group of
diseases termed hereditary cerebral hemorrhage with amyloidosis.66–69 While total APP
expression is unaffected, altered cleavage by γ-secretase leads to relative increases in Aβ1-40
compared to Aβ1-42.70,71 While the causative nature of Aβ overproduction is clearly linked to
early-onset familial CAA, the mechanism driving late-onset sporadic CAA is not as clear in
the literature.
These genetic mutations are such powerful drivers of disease, that simply inducing
their expression in mice is sufficient to recapitulate many of the nuances of CAA. For
example, one of the most widely used models of AD is the Tg2576 mutant mouse, which
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possess the APP(KM670, 671NL [Swedish]) mutation.72 This strain exhibits slowly
progressive, age-associated cognitive impairments, and begins to develop more widespread
parenchymal and vascular pathology by 9 – 10 months of age.72 In contrast, another strain,
termed APP/PS1, harbors two mutant alleles: mutant-APP(KM670N, 671NL [Swedish]), as
well as PS1(L166P).73 Due to the additional genetic manipulation, these mice develop
parenchymal amyloid pathology much earlier in life, leading to neuronal loss, astrogliosis
and cognitive impairment by 6 – 8 months of age.73 This particular mutation induces very
high production of Aβ1-42 compared to Aβ1-40, which likely explains the apparent lack of
CAA until very advanced age in this model.73
On the other end of the disease spectrum, another strain, termed TgSwDI, exhibits
CAA-like pathology very early in life.74 These animals possess three disease-associated
transgenes: APP(KM670N, 671NL [Swedish]), APP(E693Q [Dutch]) and APP(D694N
[Iowa]).74 The Dutch and Iowa ‘vasculotropic’ APP mutations were isolated from families
with hereditary cerebral hemorrhage with amyloidosis.66,75 As such, these animals develop
early elevations in Aβ1-40 and widespread vascular amyloid pathology from 3 – 6 months of
age.74 They also develop some of the earliest cognitive impairment of any AD model,
performing worse than their wild-type counterparts on cognitive tasks by 3 months of age.76
Overall, these transgenic models of familial disease support increases in Aβ1-40 as a major
driver of small vessel disease and cognitive decline in CAA.
In contrast with familial cases, the epidemiology of late-onset CAA points to
disruption of Aβ1-40 clearance as a potential driver of so-called ‘sporadic’ disease. In contrast
to genetic forms of CAA, the vast majority of CAA patients develop the sporadic form of the
disease in old age, with mild CAA pathology present in approximately half of elderly brains,
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and in 80 - 90% of Alzheimer’s disease brains.77,78 While less common, even moderate to
severe CAA is present in 8% of patients aged 75 to 84, and grows to 12.1% of patients over
the age of 85 years.20 This is likely to become even higher in the future as our population
continues to age, as preclinical studies have shown that aging impairs the clearance of
soluble Aβ1-40 from the brain.79–82 Further work in mouse models indicate that other CAA
risk factors can further impair Aβ1-40 clearance and accelerate amyloid deposition, including
hypertension,83 hyperlipidemia,84 diabetes/obesity,85 apolipoprotein E ε4 (APOE ε4)
genotype78,86 and sedentary lifestyle.87 Overall, impaired Aβ1-40 clearance is a plausible
mechanism of sporadic CAA, which could also occur after stroke.
Taken together, this review of the literature indicates that Aβ1-40 directly contributes
to cognitive decline in both familial and sporadic forms of CAA. While overproduction of
Aβ1-40 is the major cause of early-onset CAA, impaired clearance of Aβ1-40 represents an
alternative, additional driver of sporadic CAA, and is implicated in nearly all of the known
risk factors that are common in elderly CAA patients. Therefore, stroke likely also disrupts
the process of Aβ1-40 transport and clearance from the vasculature. However, further work is
needed to confirm that this occurs in animal models of stroke, which will aid in determining
which specific Aβ1-40 clearance mechanisms fail in stroke patients.

1.4: The basement membrane is the initial site of Aβ1-40 deposition in CAA.
It is clear from the existing literature that increases in Aβ1-40, whether from increased
production or reduced clearance, lead to small vessel disease and cognitive decline in CAA.
However, the impact of Aβ1-40 on vessel function remains understudied. Cerebral arteries
penetrate from the surface of the cortex and branch into descending arterioles, which further
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split to form capillary beds, where nutrients and waste products are exchanged with the brain
parenchyma.88,89 Cerebral capillaries are comprised of a monolayer of endothelial cells
surrounded by a unique extracellular structure called the vascular basement membrane,90
which also contains pericytes and astrocytic endfeet.90 Together, these structures coordinate
cerebral blood flow and neuronal activity to optimize cognitive function, in a synergy termed
the ‘neurovascular unit’ (NVU), which becomes impaired in CAA.91 The current literature
suggests that CAA begins within the basement membrane, and leads to cognitive decline due
to repetitive brain injury as well as impaired NVU regulation.
In early CAA, Aβ1-40 preferentially deposits within distinct regions of the
cerebrovascular tree.92 CAA is predominantly observed within the cerebral cortex and
cerebellum, and generally spares the deeper nuclei of the cerebrum and brainstem, as well as
the white matter.77 Within these affected brain areas, CAA first spreads through the
leptomeningeal and superficial cortical vessels, and later involves the majority of small
arteries, arterioles and capillaries within the cortex.93 The initial deposits associated with
CAA form along the outer layer of basement membrane, providing a ‘seed’ for the eventual
growth of CAA plaques.94 However, it is not known why certain individuals develop these
initial basement membrane deposits.
In advanced CAA, Aβ1-40 deposits invade the deeper layers of the vessel wall. In
particular, the walls of small arteries, arterioles and capillaries are often replaced entirely by
amyloid deposits, while sparing the inner endothelial lining.77,95 During this process,
astrocytes aggregate and become dystrophic around large capillary plaques, indicating
potential involvement of these perivascular glial cells in modulating CAA pathology.94
Finally, advanced CAA induces several pathognomonic vasculopathies, including duplication
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of the vessel lumen, destruction of the vessel wall, hyalinosis, formation of microaneurysms
as well as fibrinoid necrosis.19,95,96 Taken together, these findings indicate that CAA begins
within the basement membrane of cortical vessels, and involves perivascular astrocytes as
well as invasion of deeper portions of the vessel wall, leading to severe and widespread
vasculopathy throughout the affected brain structures.
CAA vasculopathies can be broadly separated into changes favoring both
hemorrhagic and ischemic injury, which both contribute to impaired cognitive function via
progressive loss of brain tissue. In hemorrhagic injury, CAA reduces vessel wall integrity
and leads to the formation of microaneurysms, which can spontaneously rupture and lead to
both microbleeds95 and intracerebral hemorrhage (ICH).97 Additionally, small ischemic
injuries, termed ‘microinfarctions’ can also occur during CAA,98,99 and results from invasion
of the small vessel lumen by vascular amyloid deposits, leading to occlusive disease and
leukoairiosis on imaging.100,101 Together, both microbleeds and microinfarction contribute to
loss of cognitive function via impairing white matter connectivity,102–104 inducing cortical
atrophy,105 as well as promoting local inflammatory responses.106,107 Overall, induction of
ischemic and hemorrhagic brain injury occur via different mechanisms, but similarly
contribute to cognitive decline in CAA patients.
In addition to focal brain injury, there is also significant evidence that CAA induces
chronic disruption of the NVU. Preclinical studies have shown that Aβ1-40 inhibits cerebral
autoregulation, leading to vasoconstriction of cerebral arteries in isolated preparations and
intact cortex.108 In advanced CAA, vascular amyloid deposits impair vasomotor function in a
dose-dependent manner.109 In addition, Aβ1-40 can also induce direct damage to the cells of
the NVU due to increased free radical formation.110 Specifically, Aβ1-40 damages
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neurons,111,112 vascular smooth muscle cells,113 pericytes114 and endothelial cells.115 These
changes impair NVU function which may disrupt neurotransmission along axons.116 The net
results of NVU disruption in human CAA patients include impaired perfusion of small vessel
beds,117,118 reduced vessel integrity 119–121 as well as reduced neurovascular coupling 122–124.
In conclusion, while CAA is a major cause of focal brain injury, Aβ1-40 also contributes to
progressive cognitive decline via altered autoregulatory responses as well as direct
cytotoxicity to cellular components of the NVU.
In summary, Aβ1-40 deposition is initiated at the cerebrovascular basement membrane
and then spreads to invade the vessel wall. This deposition leads to microhemorrhages as
well as microinfarction, which both contribute to stepwise cognitive decline in CAA patients.
Additionally, Aβ1-40 impairs cerebrovascular reactivity and induces cytotoxicity, causing
dysfunction of the NVU and contributing to progressive cognitive decline. Therefore, a
better understanding of the molecular, cellular and physiological processes that contribute to
the initial deposition of Aβ1-40 within the basement membrane is critical to formulating
therapies to slow CAA progression. Furthermore, successful prevention of basement
membrane Aβ1-40 deposition deposition could prevent amyloid-induced vasculopathy and
improve cognitive function in stroke survivors. In theory, this could be accomplished by
targeting the various transport mechanisms that are involved in depositing and removing Aβ140

from the PVS.

1.5: Cerebrospinal fluid is a potential source of perivascular Aβ1-40 deposits in CAA.
Previous work has shown that the vascular basement membrane is the initial site of
amyloid pathology in CAA. However, the physiological route of Aβ1-40 deposition is not
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known. This deposition may occur due to alterations in the perivascular transport of
cerebrospinal fluid (CSF), which acts as a ‘lymphatic’ fluid that is pumped through the
cerebrovascular basement membrane. This process is key for removing waste products from
the PVS in healthy individuals.125 However, this function may become impaired, or even
maladaptive, in aging and stroke, potentially favoring the deposition of CSF-derived Aβ
within the basement membrane. Therefore, I hypothesize that the CSF is a major potential
source of Aβ1-40 that becomes deposited within the basement membranes of CAA patients. I
further hypothesize that aging and stroke reduce the flow rate of CSF, further contributing to
impaired transport of Aβ1-40 through the basement membrane.
CSF is produced within the choroid plexus (CP), a cuboidal epithelial monolayer that
lines the brain ventricles.126 This unique epithelial layer displays a high degree of polarity,
with a basement membrane on its basolateral surface, and apical microvilli with ciliary
projections extending into the ventricle lumen.127 The CP secretes approximately 600 mL of
CSF per day in healthy individuals,128,129 which is supported by several factors including
dense vascularization,127 high rates of blood flow,130 enriched mitochondrial content127 and
the presence of high surface area secretory microvilli.127 In healthy individuals, the CP
provides a barrier between the plasma and CSF.126 Together, these qualities allow for rapid
turnover of CSF, while still maintaining the blood-CSF barrier.
Importantly, the transport of water within the CP takes place by distinct transcellular
and paracellular pathways. In both cases, these processes are driven by favorable ion
gradients that are primarily driven by the continuous activity of Na-K-ATPase, which enable
the osmotic transport of water.131,132 Transcellular diffusion occurs through the epithelial
cells, and is enabled by the membrane expression of aquaporin-1 (AQP1).133–137 In contrast,
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in paracellular transport, claudin-2 allows for the movement of water moves through
selectively permeable extracellular pores.138,139 This continuous production of CSF provides
a driving force for the bulk flow of CSF through the brain ventricular system, displacing the
existing fluid from the ventricular system to the subarachnoid space surrounding the brain.140
Upon exiting the ventricular system, CSF then flows along the surface of the brain
through the cisterns, which are a series of hollow chambers that generally contain the major
arteries within the subarachnoid space. The majority of the CSF drains into the bloodstream
via the subarachnoid granulations,141,142 dural lymphatic vessels,143,144 the nasal cribriform
plate145 and along cranial/spinal nerve sheaths.146 This process of CSF drainage allows for
homeostatic waste clearance to occur.147 The relative contribution of these various pathways,
and how they may be modulated by aging, stroke and neurodegenerative disease remain an
area of highly active investigation.148 The CSF contains a variety of waste products,
including Aβ1-40, which are derived from its function in clearing waste products from the
brain parenchyma. Previous work has shown that, in patients with AD and CAA, this
homeostatic balance abnormally shifts over the course of disease, leading to predictable
fluctuations in CSF Aβ1-40 concentration.149 Most importantly, increases in CSF Aβ1-40 are a
pathological hallmark of early CAA,150 and may actively contribute to disease by crossing a
critical threshold to favor the aggregation and deposition within the cerebrovascular
basement membrane.
While it is clear that CSF Aβ1-40 levels rise during the early stages of CAA, it is not
clear whether this is simply a biomarker of disease, or if this increase contributes to the
formation of the initial basement membrane amyloid deposits. The precise perivascular
routes, and the potential regulators of this process are not known. In addition to changes in
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the total amount of CSF Aβ1-40, increased affinity of the basement membrane for circulating
CSF Aβ1-40 could further accelerate the formation of CAA plaques in aging and after stroke.

1.6: Basement membrane fibronectin may promote the formation of CAA pathology.
In healthy adults, the vascular basement membrane is predominantly comprised of
heparan sulfate proteoglycans (HSPGs), collagen, laminin and integrins.151 Together, these
proteins create a porous, flexible structure that permits the flow of CSF in the healthy brain.
However, aging and stroke-induced basement membrane fibrosis could sequester Aβ1-40 and
lead to CAA. Therefore, I hypothesize that stroke abnormally increases basement membrane
fibronectin expression, which worsens with aging and contributes to the development of
CAA pathology.
Fibronectin is a modular glycoprotein that is composed of two 230 kD – 270 kD
subunits.152 It plays a central role in organizing the molecular structure of the basement
membrane during development, anchoring cellular components to the HSPG matrix, and is
also upregulated during the response to injury.90,153–155 Fibronectin is a highly modular
protein that is predominantly composed of three different repeats, termed Type I – III.156 The
Type I region is involved in the polymerization of fibronectin into large insoluble aggregates,
a process called fibrillogenesis, which occurs during wound repair.156 The Type II region
binds collagen, and the Type III region binds integrins and HSPGs.156 Together, each of
these domains plays an important role in linking the protein components of the basement
membrane to each other, as well as anchoring the cellular components via integrin receptors.
Fibronectin plays an important role in organizing the HSPG matrix within the
basement membrane. HSPGs are very large (> 1000 kD) proteoglycans that are formed by
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numerous, negatively charged heparan-sulfated glycosaminoglycans (GAG) side-chains that
surround a relatively small, positively charged protein core.157 HSPGs are the major
component of the cerebrovascular basement membrane, which expresses several subtypes,
including perlecan,158 agrin,159–161 collagen XVIII162 and syndecan-4.163 In particular,
syndecan-4 binds fibronectin with high affinity via the Type III domain.164 In addition to
providing structural integrity, HSPGs are involved in a number of processes, including
support of vascular development, maintenance of blood-brain barrier (BBB) integrity, and
angiogenic responses to focal injuries, such as stroke.157,165 They also may be important in
maintaining CSF flow in the healthy brain.
Integrins are a family of cell membrane receptors which contain both α and β
subunits, and play a major role in anchoring cells to the basement membrane and enabling
cell motility. Different classes of β1 integrin are expressed by endothelial cells (α1β1, α3β,
α6β1, αvβ1),166–169 pericytes (α4β1)170 and astrocytes (α1β1, α5β1, α6β1).169 Importantly, the
major receptor for fibronectin in the brain is α5β1 integrin, which is expressed on the outer
surface of astrocytic endfeet.171–173 The β1 subunit contains a binding site for fibronectin,
while the α5 subunit plays a role in modulating the binding affinity.174–177 Integrins also
provide the major anchor points for attaching the astrocytic endfeet to the endothelium via
binding to β-dystrophoglycan, another protein expressed within the basement
membrane.178,179 This anchoring to the basement membrane creates the ‘double-barreled’
structure of the PVS, which supports normal CSF transport.
CAA is associated with major changes in the basement membrane, including a
‘thickened’ morphology as well as well as altered protein composition. Studies of AD
patients have found that the outer basement membrane layer, which is normally produced by
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astrocytes, is selectively thickened.180 Further studies found that these alterations occur in
areas with increased amyloid pathology,181,182 and that these changes can occur prior to
development of amyloid pathology.183 Specific basement membrane proteins, including
collagen IV, laminins and nidogen are downregulated in amyloid plaques and have been
shown to prevent amyloid deposition in the healthy brain.184,185 However, both fibronectin
and perlecan increase in mouse models of AD.181,182,186 While both perlecan and fibronectin
have been shown to bind Aβ aggregates in vitro,187 the physiological relevance of this
phenomenon has never been examined in vivo. Overall, a better understanding of how
alterations in basement membrane composition contribute to the development of CAA is
needed, and may help to better understand how aging and stroke induce the formation of
CAA plaque pathology.
There is limited data available on the impact of aging on basement membrane
morphology and composition. Aging induces thinning of the basement membrane in the
cortex, hippocampus and thalamus, but not the striatum.181 Additionally, aging reduces
collagen IV, laminin and nidogen 2 expression, but upregulates fibronectin and perlecan
expression in the cortex.181 While similar increases in total fibronectin expression is
observed in other brain regions, this is not associated with reductions in other basement
membrane proteins, suggesting that the relative amount of fibronectin may be most important
in determining the cortical location of sporadic CAA pathology.181
In contrast with normal aging, stroke induces a ‘biphasic’ effect on basement
membrane thickness and composition. During the acute phase of injury, stroke increases
BBB permeability, allowing for the influx of serum and cellular factors into the brain
parenchyma that degrade the basement membrane via increased exposure to proteases and
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inflammatory cytokines.188–191 In particular, upregulation of matrix metalloproteinases
(MMP’s) leads to a general loss of basement membrane proteins during the acute phases of
ischemia, including reductions in collagen IV, laminin, agrin, perlecan and fibronectin.188,191–
193

However, few studies have examined the chronic effects of stroke on the basement

membrane. It is known that newly forming vessels upregulate both fibronectin and perlecan
during the chronic angiogenic response after stroke.165,194 These changes are similar to what
is seen in the aging brain at baseline, and may further exacerbate age-related changes in
basement membrane proteins. However, it is not known whether these changes accelerate
the formation of CAA pathology.
In conclusion, it is clear from the literature that CAA is associated with changes in
basement membrane composition, which are similar to what has been observed in both
normal aging and the chronic phase of stroke. Pathological upregulation of basement
membrane proteins, including various integrin receptors or fibronectin could favor the
development of CAA. This may occur by altering the transport of CSF-derived Aβ1-40
through the basement membrane, which could favor the initial formation of CAA pathology
in elderly stroke patients.

1.7: CSF bulk flow transports Aβ1-40 through the vascular basement membrane.
The cortical distribution of CAA pathology gives clues to its pathophysiological
mechanism. As described in earlier sections, CAA is initiated in the leptomeningeal arteries,
and ‘descends’ along cerebral arteries, arterioles and eventually capillary beds, sparing the
venous system almost entirely. Previous studies have shown that CSF Aβ1-40 levels rise in
the early stages of CAA,149,150 providing a potential source for the ‘outside to inside’
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distribution of CAA pathology within the surface cortex.19 Both classical studies of
perivascular anatomy, and the physiology of perivascular flow of CSF explain how and why
amyloid pathology spreads through the cortex in this distinctive pattern. Therefore, I
hypothesize that the transport of CSF Aβ1-40 along perivascular routes is a major driver of
CAA pathology in aging and after stroke.
Importantly, both the macroscopic and microscopic anatomy of the Virchow-Robin
space allow for a route of CSF flow along perivascular routes.195 A merging of the innermost
meningeal membrane (pia mater) with the outermost layer of cortex (glia limitans) produces
this small, but important anatomical space, allowing for the subarachnoid space to involute
and extend into the brain alongside each individual penetrating artery.196 Distal to this region
of pial involution, the glia limitans then fully envelopes each penetrating artery in a
monolayer of astrocytic endfeet.197 Components of the vessel wall, primarily smooth muscle
cells in the arteries, and eventually endothelial cells and pericytes in the capillary beds
secrete a glycosylated matrix of proteins, termed the ‘inner’ basement membrane.81,151
Similarly, the astrocytic endfeet also secrete their own distinct ‘outer’ basement membrane
along their edges.196 Therefore, as the Virchow-Robin space narrows, the astrocytic endfeet
and vessel wall are brought closer together, and eventually merge to form a single basement
membrane with 2 - 4 layers.196 This multilayered, largely acellular basement membrane
structure provides a unique avenue for CSF, and the solutes contained therein, to flow into
the brain with minimal resistance. This may allow for efficient CSF-ISF exchange.125,196
In addition to this anatomical evidence, numerous studies of brain solute exchange,
diffusion and bulk flow provide physiological evidence for the existence of a perivascular
circulation of CSF. Beginning in the 1970s, pioneering work showed that when various sized
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tracers, including polyethylene glycol and albumin, were infused into the brains of rats, they
all cleared from the interstitial fluid (ISF) at the same rate, regardless of molecular
weight.198–201 These findings suggest that solute movement within the PVS is primarily
driven by convective bulk flow, rather than purely by osmotic diffusion, which would predict
that solutes of different sizes would clear from the brain at different rates.202 Additional
work showed that the ISF moves at a rate of 10.5 µm/min, and that this ISF is a major source
of ‘extra-choroidal’ CSF.203 Interestingly, Rennels et al. (1985) subsequently found that
proteins infused into the cisterna magna, a major CSF compartment on the surface of the
brain, rapidly penetrated into the brain within minutes.204 Taken together, these studies
indicate that bulk flow is the major transport mechanism of CSF flow, completing the
physiologic ‘circuit’ for perivascular solute transport.
Nearly 30 years later, this perivascular exchange was later ‘re-discovered’ using twophoton microscopy, and shown to be important for the clearance of Aβ1-40 in a process
termed glial-lymphatic (‘glymphatic’) flow. Since then, the importance of glymphatic flow
has been further supported by a series of recent papers, confirming that CSF drives the bulk
flow of ISF within the PVS.82,125,205–209 In this initial model, the arterial beds act as a positive
‘source’ of bulk influx of CSF, and the venous system acting as a negative ‘sink’ for the bulk
clearance of ISF. Further work newly showed that aquaporin-4 (AQP4), expressed on
astrocytic endfeet, provides a semipermeable barrier for the exchange of CSF and ISF, which
is required for the clearance of intraparenchymally injected Aβ1-40.125 More recent studies
have updated this model, and have subsequently found that the perivascular influx of CSF
occurs within the outer basement membrane (associated with the glia limitans astrocyes), and
that the clearance of ISF can simultaneously occur in the opposite direction along the inner
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basement membrane of cerebral arteries.196 However, more work is needed to clarify how
CSF and ISF are exchanged within the perivascular microenvironment, and the role of the
basement membrane in regulating this process in health and disease.
Overall, given that (1) high levels of CSF Aβ1-40 predispose individuals to the
development of CAA, (2) CSF is in continuous contact with the basement membrane, (3) that
CSF drives the clearance of Aβ1-40 from the brain, and (4) the basement membrane is the
initial site of amyloid pathology in CAA, it is highly likely that this physiological route is
involved in the early stages of CAA development. However, the specific molecular and
cellular factors within the basement membrane that regulate CSF flow, and Aβ1-40 deposition,
have yet to be identified. A better understanding of how aging and stroke impact the
molecular composition of the basement membrane could shed important light on the
pathogenesis of CAA. Furthermore, this work could help to identify novel molecular targets
that could help to shield the basement membrane from Aβ1-40 deposition, allowing for new
disease-modifying therapies to be developed.

1.8: Theoretical considerations for CSF Aβ1-40 distribution in the basement membrane.
The vascular basement membrane is essential to maintaining the structural
organization of the PVS. In addition to providing structural integrity, disease-associated
basement membrane proteins, like fibronectin, may induce the deposition of CSF Aβ1-40 by
impairing the free diffusion of molecules. As CSF solutes are delivered to the PVS by bulk
flow, solutes must diffuse through the basement membrane, which could modulate regional
transport of solutes. Diffusion within the PVS is thermodynamically governed by Brownian
movement, which is described by the Stokes-Einstein equation, given as:
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Where D = free diffusion coefficient (cm2/s), kB = Boltzmann’s constant (1.38065 x 10-23), η
= viscosity (Pa x S) and dH = hydrodynamic diameter of the molecule (nm).202 This equation
indicates that the rate that a molecule diffuses through the PVS is directly related to
temperature, and inversely related to the diameter of the molecule and viscosity of the
diffusing medium (in this case, CSF within the basement membrane). For a given molecule
under physiological conditions (37°C), this equation predicts that the major determinant of
solute diffusion will be the viscosity (or “stickiness”) of the basement membrane, as well as
the hydrodynamic radius of the diffusing molecule.
Several basement membrane properties may impair the diffusion of CSF solutes
following injury. These include increased geometric path length around cells, increased dead
spaces between cells, alterations in the electrical charge of the basement membrane, general
increases in viscosity due to weak interactions, as well as upregulation of specific receptors
for the diffusing molecule of interest.202 The simplest way to describe impairment of
diffusion in biological systems, such as the basement membrane, is an experimentally
defined measurement called tortuosity (λ). Using tortuosity, it is possible to describe the
relative diffusion rate of molecules between two different experimental conditions (such as
aging or ischemia), making it a simple, yet powerful tool to get an overall picture of diffusion
rates within living brain tissue. Tortuosity is given by the following equation:
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Where λ = tortuosity, D = diffusion in the control condition, and D* = diffusion in the
experimental condition.202 In this equation, the subscripts denote the contribution of
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individual factors. For example, λg and Dg would correspond to the tortuosity and rate of
diffusion attributable to geometric path length, respectively, with other numbers representing
the contribution of other hypothetical factors. However, the individual factors can be
“cancelled out” by measuring the diffusion rate as a whole, dramatically simplifying
quantification under experimental settings. Diffusion can be experimentally measured in
several ways, including tetramethylammonium (TMA) iontophoresis, radioligand injection as
well as the tracking of fluorophores.202 Regardless of the technique that is used, tortuosity
can be determined simply by comparing the rate of diffusion between two states.
As a final point, tortuosity is also related to the volume fraction (α) of the
extracellular space (ECS), given by the following equation:
𝛼=
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Where α = volume fraction, VECS = volume of the ECS, and Vtissue = total volume of tissue.202
While tortuosity and volume fraction intuitively should co-vary (all things being equal,
increased free space for diffusion should result in faster diffusion, measured as reduced
tortuosity), they do not always correlate well under biological conditions. This is most likely
due to the contribution of some of the other factors outlined in the preceding paragraphs,
which are all taken into account by the tortuosity equation.
Both human and murine cortex exhibit relatively high tortuosity, with diffusion
occuring approximately ~2.5 times more slowly than what is observed in a free medium.210–
212

In pathological states, changes in basement membrane composition may further increase

tortuosity, restricting diffusion and favoring the deposition of CSF Aβ1-40. There is limited
data available that suggests both aging and ischemia further increase the tortuosity of whole
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brain tissue,213,214 however, more specific studies are needed to determine the impact of aging
on tortuosity of the vascular basement membrane, specifically.
While the in vivo impact of focal stroke on brain parenchymal tortuosity and volume
fraction is not known, the acute impacts of global hypoxia or ischemia on these parameters of
brain diffusion are well described, largely using in vitro slice physiology. One study found
that hypoxia dramatically reduced volume fraction and increased tortuosity in adult rat
cortex,215 with an additional study finding that hypoxia alone induced more modest increases
in tortuosity in adult rat cortex.216 While this work supports the notion that aging and hypoxia
may broadly reduce the diffusion of solutes through the extracellular space, one major caveat
is that these techniques do not specifically assess basement membrane tortuosity, rather, they
rely on measurements of whole brain slices in an ex vivo setting.
In my experimental setting, increased fibronectin expression may be a major driver of
increased tortuosity of the basement membrane after stroke, which could have major
consequences in vivo. This could occur due to its activity as a nonspecific ‘obstacle’ to
diffusion, as it may increase the viscosity and complexity of the structure for molecules to
diffuse through. Additionally, fibronectin may have selective effects on the diffusion of Aβ140,

as one study found that fibronectin binds amyloid aggregates via the type I domain.217

However, it is not known if fibronectin can bind soluble Aβ1-40 within the perivascular
microenvironment. Increased expression of basement membrane fibronectin could lead to
the specific trapping of CSF Aβ1-40 within the PVS, in addition to the nonspecific reductions
in diffusibility due to changes in basement membrane composition or structure.
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1.9: Astrocytic TGF-β signaling may mediate basement membrane fibrosis and CAA.
Previous work indicates that transforming growth factor-β (TGF-β) levels are
elevated in mouse models of CAA,218 and that overexpression of TGF-β in wild-type mice
leads to astrogliosis, fibronectin expression and microvascular damage.219,220 However, it is
not known whether TGF-β mediates post-stroke basement membrane fibrosis. This section
will first review the potential TGF-β signaling mechanisms involved in post-stroke
fibronectin expression. Then, the impact of aging and stroke on TGF-β expression and
astrocyte phenotypes will be examined.
TGF-β is a member of the TGF-β cytokine superfamily, which also contains glial
derived neurotrophic factor, activin, 8-vinyl reductase (DVR), and growth differentiation
factor subfamilies.221 The TGF-β subfamily contains 3 different isoforms: TGF-β1, TGF-β2
and TGF-β3, which are differentially expressed during development of the central nervous
system (CNS), and nearly absent from the adult brain under homeostatic conditions.222
However, following stroke, activated microglia secrete high levels of TGF-β1 during the
acute phase of injury.223 Previous work has shown that TGF-β activates TGF-β receptor-1
and receptor-2 (TGF-βR1/R2), which dimerize upon TGF-β binding within the cell
membrane.224 Following dimerization, TGF-βR1 phosphorylates Smad proteins, including
Smad2 and Smad3, which then complex with other Smad proteins and translocate to the
nucleus.225 These complexes subsequently influence gene expression by binding to
enhancer/repressor sites within the genome, influencing cell differentiation and the
expression of ECM proteins in astrocytes during development and after brain injury.226
TGF-β signaling after stroke has several beneficial pro-survival effects, including
expression of anti-apoptotic proteins Bcl-2 and Bcl-x1, leading to reduced neuronal death
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during the acute phase of injury.227 These early beneficial effects, which have only been
studied in young animals, have led to TGF-β being labeled as an anti-inflammatory molecule
in the context of acute brain injury.228,229 However, TGF-β is a highly pleiotropic cytokine,
and also induces astrogliosis and ECM deposition, which have well-documented detrimental
impacts, including inhibition of axonal regrowth230,231 and angiogenesis232 due to the
abnormal production of ECM proteins. Furthermore, other work has shown that TGF-β
expression is disproportionately increased in aged animals after stroke, which may increase
the likelihood of detrimental affects in the chronic phase of injury.223 Along these lines,
previous studies by our laboratory have shown that aged animals exhibit increased glial
scarring in the ischemic penumbra after MCAO, which is associated with delayed behavioral
recovery.233 Even in young animals, inhibition of TGF-β signaling may reduce astrogliosis
within the glial scar, however, the impact of this treatment on long-term cognitive function is
not known.229 Overall, the role of TGF-β during brain injury remains controversial, and the
few studies performed in aged animals suggest a detrimental effect of TGF-β signaling on
functional recovery, which could be due to abnormally high levels of astrogliosis.
Astrocytes are a major type of glial cell in the brain that, under normal conditions,
perform numerous homeostatic functions including support of BBB integrity,234
metabolism234 and waste clearance.125 Astrocytes interface with the perivascular niche via
numerous small endfeet, and regulate the composition of the outermost basement membrane
layer, which is involved early in the pathogenesis of CAA.181,196 Furthermore, reactive
astrocytes are associated with impaired CSF flow during normal aging,235 multiple
microinfarction,236,237 traumatic brain injury235 and Alzheimer’s disease.209,238 However, the
role of reactive astrocytes in basement membrane remodeling is understudied, and it is not
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known whether inhibiting TGF-β signaling in astrocytes can restore CSF flow under
pathological conditions.
Recent work has shown that reactive astrocytes generally exhibit two major
phenotypes, defined by their gene expression pattern – A1 (modeled by peripheral
stimulation with LPS) and A2 (modeled by MCAO).239 While A1 astrocytes have been
recently shown to induce inflammation, downregulate AQP4 and secrete toxic products that
are detrimental to neuronal survival,240 the functions and phenotypes of A2 astrocytes are not
known. Furthermore, excess TGF-β signaling, as occurs after stroke in the aged brain,223
could further impact A2 astrocyte responses to ischemic injury and induce the abnormal
production of ECM proteins. If true, astrocytes may hold the key to preventing CAA after
stroke.
Overall, previous work has shown that TGF-β increases in aging and stroke, and may
also contribute to the formation of CAA pathology. However, it is not known whether TGFβ mediates basement membrane fibrosis after stroke, or if inhibiting astrocytic TGF-β
signaling is sufficient to improve CSF flow and prevent the perivascular deposition of CSF
Aβ1-40 within the basement membrane. Elucidating the role of TGF-β would significantly
improve our understanding of the molecular and cellular regulation of basement membrane
composition in pathological states. Furthermore, modulating the function of A2 astrocytes
with TGF-β inhibitors could also lead to new therapeutic targets for post-stroke CAA in aged
populations.
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CHAPTER 2
Specific Aims of Dissertation Research

2.1: Overview.
CAA may be caused, in part, by a
failure of Aβ1-40 transport through the vascular
basement membrane of cerebral blood vessels
after stroke. The basement membrane
transports Aβ1-40 via facilitating CSF flow
within the PVS. Therefore, impairment of CSF
flow may contribute to CAA after stroke. I
propose that TGF-β signaling pathologically
increases the expression of fibronectin within
the basement membrane, reducing CSF flow
through the cortex. I further propose that

Figure 2-1: Reactive astrocytes may

increases in fibronectin selectively favors the

secrete fibronectin and impair the

binding of CSF Aβ1-40 to the basement

perivascular transport of CSF-

membrane, accelerating the formation of

derived Aβ1-40 after stroke.

amyloid pathology in the proximal regions of
cortical vessels after stroke (Fig. 2-1). Therefore, my overall hypothesis is that TGF-βdriven increases in basement membrane fibronectin leads to increased perivascular
deposition of Aβ1-40 after stroke, contributing to increased CAA burden and accelerated
cognitive decline. To test this hypothesis, I propose the following specific aims:
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2.2: Specific Aims.
Aim 1. To determine whether aging and stroke induce the deposition of CSF Aβ1-40
within the vascular basement membrane. While the clinical literature suggests that focal
stroke may be a risk factor for CAA, there is a lack of studies examining whether stroke
induces CAA in mouse models of focal stroke. Additionally, the potential
pathophysiological sources of basement membrane Aβ1-40 deposits are not known. I
hypothesize that aging and stroke impair perivascular CSF flow and induce the trapping of
CSF Aβ1-40, which contributes to increased CAA pathology and cognitive decline. To test
this hypothesis, I propose the following sub-aims:
•

Sub-Aim 1A: To assess how aging and stroke impact perivascular CSF flow.

•

Sub-Aim 1B: To characterize how aging and stroke modulate the perivascular
transport of CSF Aβ1-40 through the basement membrane.

Aim 2. To determine if astrocytic TGF-β signaling mediates basement membrane
fibrosis and Aβ1-40 deposition in aging and after stroke. While previous work has shown
that stroke induces basement membrane fibrosis in young animals, characterized by increased
expression of fibronectin, it is not known whether aging worsens post-stroke basement
membrane fibrosis. Furthermore, it is not known whether these changes in protein
composition mediate the initial trapping of CSF Aβ1-40 or the eventual formation of CAA
plaques. Finally, the impact of aging and TGF-β on perivascular astrocyte phenotype and
function are understudied, or if blocking TGF-β can reduce basement membrane fibrosis
after stroke. Therefore, I hypothesize that stroke induces basement membrane fibrosis in a
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TGF-β-dependent manner, which worsens with aging. To test this hypothesis, I propose the
following sub-aims:
•

Sub-Aim 2A: To characterize how aging and stroke impact the structure and
composition of the cerebrovascular basement membrane.

•

Sub-Aim 2B: To examine whether fibronectin mediates post-stroke Aβ1-40
deposition, and if this worsens with aging in mice.

•

Sub-Aim 2C: To evaluate whether TGF-β activates A2 astrocytes to produce
fibronectin using both in vitro and in vivo systems.

•

Sub-Aim 2D: To explore whether blocking TGF-β signaling reduces perivascular
gliosis and basement membrane fibrosis in young and aged mice with stroke.

Aim 3. To explore whether peripheral markers of small vessel fibrosis predict CAA
diagnosis and disease progression. Previous work has shown that CAA can be diagnosed
using cortical biopsy or a set of imaging guidelines, termed the “Boston criteria.” However,
CAA diagnosis and management has been hampered by a lack of blood biomarkers that can
easily and reliably predict the presence of pathology or correlate with long-term functional
outcomes. Therefore, I hypothesize that serum markers of basement membrane fibrosis
(soluble fibronectin, TGF-β and MMPs) may predict CAA diagnosis and functional recovery
in human ICH patients. To test this hypothesis, I propose the following sub-aims:
•

Sub-Aim 3A: To test the clinical utility of biomarkers of fibrosis in diagnosing CAA
pathology after ICH.

•

Sub-Aim 3B: To evaluate whether biomarkers of fibrosis are predictive of long-term
functional outcomes after ICH.
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2.3: Translational statement.
This research is significant because it impacts our understanding of a new potential
mechanism by which stroke induces cognitive decline. Additionally, these findings shed
light on a new physiological route by which Aβ1-40 becomes deposited in the basement
membrane of aged mice with stroke, which may have relevance for human stroke patients, as
well as elderly patients with sporadic CAA. Fibronectin may be a major mediator of
perivascular CSF Aβ1-40 deposition in aging and after stroke, which could be secreted by
astrocytes in response to TGF-β signaling. Furthermore, blocking TGF-β signaling to
astrocytes by peripheral pharmacological treatment may reverse basement membrane
fibrosis, which could lead to new therapies for CAA in stroke survivors. Finally, this
preclinical research could be used to develop new biomarkers for CAA in human ICH
patients, which could be translated to the clinic as a diagnostic panel, potentially improving
CAA diagnosis and management.
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CHAPTER 3
Early Validation of Perivascular CSF Flow
in the Murine Brain

3.1: Introduction
3.1.1: Overview.
Previous studies showed that brain ISF solutes are cleared by bulk flow,200 despite the
fact that the BBB tight junction proteins preclude significant bulk influx of plasma.241 One
potential explanation for these disparate findings is that CSF, contained within the cisterns,
exchanges with brain ISF via the PVS.204 More recent work has shown that this process of
perivascular CSF flow drives the bulk flow of ISF,125 and is required for the clearance of
Aβ1-40 via the meningeal lymphatic system.143 This process is thought to be critical to
maintaining brain homeostasis, and may help to prevent CAA in healthy individuals.

3.1.2: Significance.
We hypothesized that CSF flow occurs along perivascular routes, and that diffusion
through the basement membrane is dependent on the size of the injected tracer. While these
findings have been previously shown in the literature, given that these techniques are largely
new to our laboratory, it was important for us to internally validate our techniques.
Therefore, prior to undertaking our studies in mouse models of stroke, we wished to replicate
previous physiological studies in our own laboratory using naive young animals. This also
afforded us a chance to develop and troubleshoot our own techniques to study CSF flow,
helping to ensure the success of our future experiments. While many of our findings were in
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agreement with the existing literature, we found an interesting phenomenon of size exclusion
within basement membrane sublayers that deserves further study.

3.1.3: Experimental design.
We sought to replicate previous work using intracisternal injection of tracers in
anesthetized mice, which have been used previously as an experimental model of
perivascular CSF flow. To accomplish this, we developed a custom injection apparatus and
used it to infuse a variety of tracers, starting with Evans blue dye, which is visible to the
naked eye and allows for quick confirmation of successful injection. We then progressed to
using simultaneous injection of dyes into the vasculature and cisterna magna, which allowed
us to assess the perivascular localization of CSF dye by conventional fluorescence
microscopy in fixed brain tissue. Next, we tested multiple dextran particles of different
molecular weights, and assessed their transport through the basement membrane by in vivo
two-photon microscopy. We also confirmed our findings by intracisternal injection of
radiolabeled 14C-Inulin and 3H2O, which allowed us to easily quantify the amount of tracer
taken up into the brain ISF and facilitated the creation of optimal time-courses for our later
experiments. Finally, we also compared the clearance rate of 125I-Aβ1-40 to 125I-Αlbumin to
evaluate whether it is removed solely via bulk flow, or if other clearance mechanisms are
involved.
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3.2: Methods
3.2.1: Animals.
Wild-type young (2 – 3 month-old) male C57BL/6 mice were obtained from Charles
River. Mice were kept on a 12-hour light-dark cycle, and fed standard dry chow with ad
libitum access to food and water. Mice were examined regularly by trained members of the
lab and the veterinary staff for any signs of illness, as well as gross pathology at the time of
sacrifice. Importantly, all studies were carried out in accordance with the recommendations
in the guide for the Care and Use of Laboratory Animals of the National Institutes of Health.
The protocols were approved by the UTHealth Institutional Animal Care and Use Committee
(IACUC) and carried out in a facility approved by the Association for Assessment and
Accreditation of Laboratory Animal Care (AAALAC). Animals were randomized to
experimental conditions, and investigators were blinded to treatment.

3.2.2: Preparation of fluorescent tracers.
Artificial CSF (aCSF) containing Na+ (150 mM), K+ (3 mM), Ca2+ (1.4 mM), Mg
(0.8 mM), P (1.0 mM) and HCO3 (24.1 mM) was freshly prepared in sterile distilled water
prior to the experiment. First, on the day of the experiment, a 2% solution of Evans blue dye
(Sigma) was created in aCSF and mixed 1:1 with aCSF alone or aCSF containing 10%
bovine serum albumin (BSA, Sigma) in aCSF, then filtered using a molecular-weight cutoff
filter (MW cutoff = 50 kD) to create 1% working stocks of Evans blue dye (EBD) or Evans
blue albumin (EBA) conjugate. Additionally, for subsequent multi-color experiments,
various lyophilized dextran conjugates were first obtained from Thermo Fisher and then
reconstituted separately in aCSF. Then, 4% stock solutions of 2000 kD fluorescein
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isothiocyanate dextran (FITC-d2000), lysine-fixable 70 kD FITC dextran (FITC-d70) and
lysine-fixable 3 kD tetramethylrhodamine dextran (TR-d3) were prepared and stored at 20°C prior to the experiments. Then, on the day of the experiment, fluorescent tracers were
then further diluted/combined in aCSF to a working concentration of 1%. To measure
fluorescent background signal, aCSF with no tracers was also retained for injection into
control animals. Tracer mixtures were kept on ice for up to 4 hours prior to use, and vortexed
for 5 seconds immediately before infusion.

3.2.3: Preparation of 125I-radiolabeled tracers.
Recombinant human Aβ1-40 (Anaspec, Fremont, CA) or BSA (Sigma) was first
dissolved to a concentration of 1 µg/µL in sterile, chloride-free 250 mM sodium phosphate
buffer (pH = 7.4). Then, peptides were conjugated to Iodine-125 (125I) with chloramine T as
previously described.242 125I-peptide was separated from free 125I by washing the mixture
through a Sephadex G-10 column. Successful conjugation was measured by TCA
precipitation, and fractions retaining > 95% counts per minute (CPM) values in the solid
phase were then combined and lyophilized overnight for later use.

3.2.4: Preparation of 14C-Inulin/3H2O tracer cocktails.
14

C-Inulin and 3H2O were purchased directly from Perkin-Elmer, and stock solutions

of 14C-Inulin (Perkin-Elmer, ~2 x 105 disintegrations/minute/microliter [DPM/uL]) and 3H2O
(Perkin-Elmer, ~2 x 106 DPM/uL) were dissolved in aCSF and radioactivity normalized via
liquid scintillation counting. Then, stock solutions were combined to a final concentration of
1 x 105 DPM/uL 14C-Inulin and 1 x 106 DPM/uL 3H2O in aCSF.
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3.2.5: Intracisternal injection.
Mice were deeply anesthetized with an intraperitoneal injection of KetamineXylazine dissolved in 0.9% saline (120 mg/kg Ketamine, 10 mg/kg Xylazine), then placed in
a stereotaxic frame. The hair over the cervical spine was then shaved, and then the skin was
aseptically prepared and incised. Following this, a 30 gauge needle attached to catheter
tubing was inserted through the superficial neck musculature and into the cisterna magna as
previously described.125 Tracer was slowly infused into the cisterna magna (1 µL/min) over
10 minutes, after which mice were transferred to a warmed cage. Then, 15, 30 or 60 minutes
after the initiation of the injection, mice were sacrificed by Avertin overdose (250 mg/kg),
followed by transcardial perfusion with phosphate buffered saline (PBS) supplemented with
0.2% heparin, then 4% paraformaldehyde (PFA) in PBS for histological experiments.
Tissues (brain and skull) were dissected and stored at 4% PFA for histology, or snap frozen
and stored at -80°C for radiouptake measurements.

3.2.6: Intravenous injection.
Mice were deeply anesthetized with an intraperitoneal injection of KetamineXylazine dissolved in 0.9% saline (120 mg/kg Ketamine, 10 mg/kg Xylazine). Two minutes
prior to sacrifice, a 2 cm midline incision was made on the skin covering the ventral neck
musculature, and the jugular vein visualized. Then, a 100 µL bolus of 5% EBA was injected
into the jugular vein, and allowed to circulate for 30 seconds. Successful injection was
confirmed via inspection of the mucous membranes for gross darkening. Mice were
sacrificed by Avertin overdose (250 mg/kg), followed by cervical dislocation. Then, tissues
were dissected and post-fixed in 4% PFA until later use.
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3.2.7: Intraparenchymal injection.
Mice were deeply anesthetized with an intraperitoneal injection of KetamineXylazine dissolved in 0.9% saline (120 mg/kg Ketamine, 10 mg/kg Xylazine), then placed in
a stereotaxic frame. A craniotomy was performed and a Hamilton syringe was then
advanced into the striatum (0.4 mm anterior to Bregma, lateral 2.2 mm, ventral 3.5 mm).
Then, 2 µL dH2O containing 1 x 106 CPM of reconstituted tracer solution was then infused at
a rate of 1 µL/min. To reduce inflammation, the needle was left in place for the duration of
the experiment. Mice were sacrificed by Avertin overdose (250 mg/kg) after 60 minutes, and
successful injections confirmed by inspection of the needle tract. Finally, brains were snap
frozen and stored at -80°C prior to gamma counting.

3.2.8: Brain sectioning.
Following perfusion, brains were extracted and post-fixed for 24 hours in 4% PFA.
Then, brains were dehydrated in 30% sucrose, frozen to -20°C and sectioned to 24 µm
(immunohistochemistry [IHC]/cresyl violet staining) or 100 µm (tracer quantification)
sections. Sections were then mounted onto slides and coverslipped with Fluoromount G or
Vectashield + DAPI (4',6-diamidino-2-phenylindole, Vector Laboratories).

3.2.9: Fluorescence microscopy.
Sections were imaged under fluorescence with a Leica DMi8 microscope at 10X
magnification. A blinded investigator imaged the lateral cortex (0.38 mm anterior to
Bregma, 2.5 mm lateral, 1.5 mm deep). Then, 100 µm Z stack images were obtained, and
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maximum intensity projections performed with LAS X software. Single-plane mosaic images
were also obtained at 10X magnification with autofocus.

3.2.10: Two-photon microscopy.
Mice were deeply anesthetized with an intraperitoneal injection of KetamineXylazine dissolved in 0.9% saline (120 mg/kg Ketamine, 10 mg/kg Xylazine), then placed in
a stereotaxic frame. Immediately following acute installation of a glass coverslipped cranial
window over the right dorsal forebrain, tracer was infused into the cisterna magna, and cortex
was imaged through the window. Briefly, animals were imaged using a custom-built twophoton microscope (Bruker Nano, WI) with femto-second pulse lasers (Spectra physics).
Fluorophore was excited at 810 nm and emission of photon was collected by two-channel
top-mounter GaAsp detectors equipped with dual emission filters (525/70m-2P and 595/50m2P). Two-photon image acquisition was performed with a imaging software Prairie View. A
water immersion objective lens (Nikon CFI 16x/0.80) was used throughout the imaging
session. Upon completion of imaging experiments, mice were sacrificed by Avertin
overdose (250 mg/kg) and then cervically dislocated.

3.2.11: Gamma counting.
Frozen brain samples were thawed on ice, then manually homogenized in 30% TCA
in glass test tubes. Then, whole homogenates were centrifuged at 5000 x g for 15 minutes,
and the supernatant removed to a separate tube. Then, the amount of peptide-bound (pellet)
and free iodine (supernatant) were quantified using a gamma counter (Packard Cobra II),
courtesy of Dr. Claudio Soto.
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3.2.12: Liquid scintillation counting.
Samples were thawed on ice, then placed in 5 mL glass vials and dissolved in 1 mL
Solvable (Perkin Elmer) overnight at 37°C. Then, homogenates were vortexed and mixed
with 4 mL Hionic-Fluor scintillation cocktail (Perkin Elmer). Following this, β-emissions
were measured using a Tri-Carb T2900 Liquid Scintillation Counter (LSC) (Perkin Elmer),
with 3H2O emissions counted at less than 20 keV, and 14C-Inulin measured counted between
20 and 150 KeV. Control vials containing aCSF alone, aCSF + 14C-Inulin and aCSF + 3H2O
were used to account for background radiation, as well as to normalize emission signals from
samples for subsequent analyses.

3.2.13: Statistics. All data are presented as mean (+/-) SEM, with the number of animals per
experimental group (n). Statistically significant changes over time were determined by oneway analysis of variance (ANOVA). Statistical significance in total clearance was calculated
by Student’s t-test. Significance is denoted as *p < 0.05, **p < 0.01, ***p < 0.001.
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3.3: Results
3.3.1: CSF traveled through the brain along perivascular routes.
First, to test the hypothesis that CSF solute exchange occurs within the PVS in a sizedependent manner, I compared the distribution of intracisternally injected Evans blue (EBD,
~500 Da) to Evans blue albumin (EBA, 70 kD) at 60 minutes post-injection. Upon gross
examination, I found that EBD spread from the circle of Willis and diffused bilaterally across
the dorsal surface of the brain along vascular tracts, including the MCA, as well as the
posterior cerebral artery (PCA) and the anterior cerebral artery (ACA) (Fig. 3-1A). The dye
formed a visible diffusion gradient, appearing to spread from the arterial structure to the
surrounding parenchymal tissue (Fig. 3-1A). Unexpectedly, EBA, the larger molecule, was
more tightly associated with surface vessels than EBD (Fig. 3-1B). Examination under
fluorescence revealed that this vascular association continued within the PVS of deep brain
vessels, and appeared more strongly with EBA injection (Fig. 3-1C). These studies confirm
that CSF flow occurs along the surface of the brain, and follows perivascular routes, rather
than simply diffusing randomly throughout the brain. They also suggest a size-exclusion
property of the pial membrane, which allows for the rapid diffusion of EBD, but not EBA,
away from the major vessels and into surface capillaries and interstitial spaces.
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Figure 3-1: Visualization of CSF influx by intracisternal dye injection. (A.) Photograph
of (i.) dorsolateral and (ii.) ventral mouse brain 30 minutes after intracisternal injection with
Evans blue dye (EBD, 500 Da). (iii. – vi.) Light micrograph showing intraparenchymal EBD
distribution within coronal sections. (vii. – viii.) Fluorescent mosaic micrographs from two
mice showing EBD influx along the superficial surfaces of the brain. (B.) Photograph of (i.)
dorsolateral mouse brain 30 minutes after intracisternal injection with Evans blue albumin
(EBA, 70 kD). (ii. – iii..) Light micrograph showing perivascular EBA distribution within
coronal sections. (iv.) Representative fluorescent mosaic image showing EBA influx along
the superficial surfaces of the brain. (C.) Fluorescent micrographs showing how (ii.) EBA
exhibits stronger perivascular localization than (i.) EBD. Scale bar (black, white) = 50 µm.
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Then, to confirm that CSF influxes into the deeper structures of the brain along penetrating
arterial beds, I double-labeled CSF and plasma by injecting FITC-dextran (70 kD, FITC-d70)
into the cisterna magna, and then injecting EBD into the jugular vein immediately prior to
sacrifice (Fig. 3-2A). I found that the injected CSF FITC-d70 tracer strongly localized to the
injected plasma EBD tracer, and distributed along arteries, arterioles and capillary beds,
extending into the deepest structures of the brain (Fig. 3-2B). These findings were later
confirmed with two-photon microscopy, where CSF flow was observed to occur within the
PVS of young mice in real-time. When different size tracers were simultaneously injected
(2000 kD, FITC-d2000; 4 kD, 594-d3), we found that the smaller tracer traveled more
closely to the vessel wall, while the larger tracer was excluded from this region and diffused
along the outer surface (Fig. 3-2C). This intriguing finding suggests that the basement
membrane layers exhibit size-exclusion properties, potentially filtering larger particles out of
the inner basement membrane layers. In addition to being interesting from a biophysical
perspective, this could have significance for the ability of to efficiently transport smaller
monomeric vs larger oligomeric amyloid species.
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Figure 3-2.

CSF influx occurs along perivascular routes. (A.) (i.) Representative

fluorescent mosaic micrograph showing (ii.) plasma (red) colocalizing with (iii.) CSF. (iv.)
Nuclei were counterstained with DAPI. (B.) (i.) High-resolution confocal micrograph
showing CSF influx along perivascular routes. (ii.) 3-dimensional reconstruction of CSF
influx showing diffusion away from the perivascular regions. (C.) Representative in vivo
two-photon image showing differential distribution of FITC-d2000 and TR-d3. Scale bar
(black, white) = 100 µm.

Note: Panel C was used with permission from Dr. Akihiko

Urayama (unpublished data).
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Figure 3-3. Kinetics of influx and efflux of injected tracers. (A.) Intracisternally injected
14

	
  

C-Inulin levels increase within the brain interstitial fluid over time and equilibrates by 30

minutes. n = 5 – 8 per time-point. (B.) Intracisternally injected 3H2O reduces and equilibrates
with the brain by 30 minutes. n = 5 – 8 per time-point. (C.) Intraparenchymally injected 125IAlbumin (70 kD) clears more slowly from the brain than

125

I-Aβ1-40 (4.5 kD) over 60

minutes. n = 5 per group. Data are analyzed by Student’s t-test, *** p < 0.001.

3.3.2: CSF solutes rapidly achieve equilibrium with the brain interstitial fluid. Next, to
assess the time-course of diffusion of CSF solutes, we performed intracisternal injections of
14

C-Inulin and 3H2O.

14

C-Inulin was selected as a marker for extracellular diffusion of CSF,

due to the fact that it is soluble in water but cannot cross lipid bilayers. 3H2O was used to
measure the intracellular uptake of CSF, which largely occurs in astrocytes via AQP4. I
found that 14C-Inulin levels gradually increased over time (F[3, 34] = 9.87, p < 0.001). In
contrast, I found that 3H2O levels rapidly increased, and then plateaued (F[3, 36] = 230.6, p <
0.001). These findings indicate that both intracellular and extracellular uptake occur over
different time courses, and provide support for choosing a 30-minute duration for subsequent
studies, as injected extracellular tracers will have reached equilibrium.
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In a separate experiment, we measured the clearance rate of solutes within the
interstitial fluid by performing intraparenchymal injection of 125I-Albumin or 125I-Aβ1-40.
Unlike previous studies that have found that intraparenchymally injected solutes all move at
the same rate, regardless of molecular weight, I found that 125I-Aβ1-40 (4 kD) cleared much
more rapidly than 125I-Albumin (70 kD) (t[7] = 14.9, p < 0.001), being removed almost
entirely from the brain by 60 minutes post-injection. This may be due to additional clearance
mechanisms for interstitial Aβ1-40.
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3.4: Discussion
Even after 30 years of extensive research,202 the existence of physiologically
meaningful perivascular CSF flow remains controversial.243,244 However, newer studies with
two-photon microscopy125 have helped this concept gain wider acceptance within the
scientific community. Importantly, our work provides further evidence for the perivascular
flow of CSF within the healthy brain using multiple types of measurements, including ex vivo
fluorescence imaging, brain radiouptake measurements as well as in vivo two-photon
imaging.
Unlike previous studies of interstitial clearance,200 we newly found that the influx of
CSF solutes through the basement membrane is size-dependent, with the transport of large
solutes (2000 kD) occurring in a separate layer of basement membrane than smaller solutes
(70 kD). This may have disease relevance to CAA, as monomeric Aβ1-40 is small (~4.5 kD),
but can form larger oligomers and eventually enormous, insoluble plaques,245 potentially
affecting different layers of the basement membrane at different disease stages. Alterations
in the composition or communication between these layers could further reduce the transport
rate of CSF solutes, which could further worsen deposition of Aβ1-40 within the basement
membrane. Similar to CSF influx, we additionally found that that intraparenchymally
injected albumin cleared more slowly from the brain than Aβ1-40 in naïve animals, measured
at 60 minutes post-striatal injection. While this could be due to size differences (molecular
weight of albumin is 70 kD), more likely, our observed differences are due to the existence of
specific BBB transporters that are involved with the active clearance of Aβ1-40, which could
increase the rate of Aβ1-40 clearance from the brain compared to other compounds, such as
albumin.246,247 Further work is needed to determine how aging and stroke alter the ability of
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these active transport mechanisms in clearing Aβ1-40 across the BBB, which could protect the
brain from CAA even under conditions that would otherwise favor the deposition of Aβ1-40
within the basement membrane.
In summary, these initial studies confirm that CSF flows from the cisterns into the
brain parenchyma, and that this transport occurs within the PVS. They further indicate that
the transport of solutes is segregated by molecular weight, with larger molecules excluded
from the inner regions of the PVS. They also suggest that microstructural differences within
the basement membrane sub-layers, which may produce the size-exclusion properties to
different CSF solutes, becomes altered with disease and could sensitize the brain to CAA in
pathological states.
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CHAPTER 4
Fibronectin Induces the Perivascular Deposition of
CSF-derived Aβ in Aging and After Stroke
4.1: Introduction
4.1.1: Significance.
While CAA is a pervasive finding in stroke survivors, the pathophysiological
mechanisms underlying progressive vascular Aβ1-40 accumulation remain understudied.
Recent studies suggest that the clearance of Aβ1-40 from blood vessels is mediated via a
perivascular route of CSF flow, termed the glymphatic system.125 During glymphatic flow,
the pulsation of arteries pushes CSF from the meningeal cisterns along penetrating arterioles
and eventually capillary beds through the PVS,248 which is bordered on either side by the
vascular basement membrane and astrocytic endfeet.181,249 Interestingly, Peng et al. (2016)
showed that in addition to clearing Aβ1-40 from the brain, the glymphatic system can also
redistribute CSF Aβ1-40 back into the brain along perivascular routes. This process can be
exacerbated by brain pathology, as they further showed that CSF-derived Aβ1-40 selectively
accumulates in the brains of aged APP/PS1 mice, and colocalizes with pre-existing cortical
Aβ plaques. Taken together with clinical data showing that CSF Aβ1-40 levels fluctuate over
the course of disease in dementia patients,250 these findings suggest that CSF Aβ1-40 may
deposit within perivascular regions involved in glymphatic flow. While increased
perivascular redistribution of CSF Aβ1-40 could lead to CAA, the molecular and cellular
factors that induce Aβ1-40 deposition in CAA, especially in the context of ischemic stroke,
remain understudied.
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The perivascular flow of CSF may be dependent on the vascular basement membrane
which consists of a glycosylated protein matrix that can be stained with tomato lectin. This
protein matrix may act as a filtration path that could restrict, in part, the redistribution of
solutes dissolved in the CSF. We postulate that this novel basement membrane function may
become dysregulated after ischemic stroke, which stimulates the overexpression of
fibronectin and its receptor, α5β1 integrin. Cellular fibronectin is a dimeric 440 kD basement
membrane glycoprotein that links cell membrane integrins to HSPGs.171–173 Importantly,
fibronectin is also expressed in CAA plaques251 and may exhibit affinity for aggregated
Aβ.217,252 Therefore, we hypothesize that stroke-induced increases in basement membrane
fibronectin leads to perivascular deposition of soluble, CSF-derived Aβ1-40 by direct binding.

4.1.2: Experimental Design.
We show that both aging and focal stroke inhibit the bulk flow of CSF along
perivascular routes within the brain, which is associated with impairment of cognitive
function. Furthermore, we also demonstrate that CSF Aβ1-40 is abnormally deposited within
the basement membrane after stroke in aged animals, and that this deposition strongly
correlates with the peri-infarct basement membrane labeled by lectin. We identified that
fibronectin and the integrin-α5 receptor subunit are upregulated basement membrane proteins
in aged animals with stroke, which enhanced the deposition of CSF Aβ1-40. Based on our
findings, we propose targeting fibronectin as a strategy to treat age and stroke-related CAA.
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4.2: Methods
4.2.1: Animals.
Wild-type young (2 – 3 month-old) and aged (18 – 20 month-old) male C57BL/6
mice were obtained from Charles River and the National Institute of Aging, respectively.
Mice were kept on a 12-hour light-dark cycle, and fed standard dry chow with ad libitum
access to food and water. Mice were examined regularly by trained members of the lab and
the veterinary staff for any signs of illness, as well as gross pathology at the time of sacrifice.
The protocols were approved by the UTHealth IACUC and carried out in an AAALACapproved facility, as described in the preceding chapter. Animals were randomized to
experimental conditions, and investigators were blinded to treatment.

4.2.2: Permanent distal middle cerebral artery occlusion.
Mice were subjected to permanent distal middle cerebral artery occlusion (DMCAO)
as previously described.253 Briefly, mice under isoflurane anesthesia were placed in a prone
position inside a sterile surgical field, and body temperature maintained at 37°C. Following
this, the right dorsolateral cranium was shaved and aseptically prepared. Then, local
anesthetic was injected (Marcaine, 0.05 mL), the skin and underlying temporalis muscle were
incised, and a 2 mm burr hole was drilled to expose the MCA, which was then cauterized to
induce ischemia. After successful cauterization, the burr hole was closed with dental cement,
the temporalis muscle repaired with Vetbond and the skin incision closed with Vicryl 5-0
nylon sutures. Sham surgeries were performed following an identical procedure, except that
no cauterization was performed. Ischemia was confirmed by Laser Doppler flow
measurement immediately following MCA cauterization.
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4.2.3: Behavioral tests
•

DigiGait. The impact of aging and stroke on motor function was assessed using
DigiGait (Mouse Specifics) at 3 and 7 days post-injury (DPI) in a double-blinded
manner. Mice were first acclimated to the system, and then the speed was gradually
increased to 15 centimeters/second. Gait was recorded for 60 seconds, and the degree
of left forepaw rotation was measured using automated DigiGait analysis software
over 10 steps by a separate blinded investigator.

•

Barnes Maze. Hippocampal-dependent spatial reference memory was assessed at 28
DPI using a one day training-testing paradigm, modified from previously described
work 254. Following habituation, mice were trained to find the escape hole in an
illuminated, elevated Barnes maze (Mouse Specifics). This training was repeated 4
times, and then tested 4 hours later in a 3 minute probe trial. The latency to find the
escape hole, number of errors and total distance moved were quantified using
EthoVision XT software in a blinded manner.

•

Open Field. Spontaneous exploratory behavior was assessed at 28 DPI by open field
testing. Mice were allowed to explore a 40 cm2 opaque chamber for 5 minutes.
Absolute distance traveled (centimeters) was recorded and quantified using
EthoVision XT software in a blinded manner.
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4.2.4: Preparation of fluorescent tracers.
aCSF containing Na+ (150 mM), K+ (3 mM), Ca2+ (1.4 mM), Mg (0.8 mM), P (1.0
mM) and HCO3 (24.1 mM) was prepared in sterile distilled water on the day of the
experiment. Stock solutions of lysine-fixable 3 kD cascade blue dextran (CB-d3, 3,000 MW,
anionic, 4% stock, Thermo Fisher) and 2000 kD FITC dextran (FITC-d2000, 2,000,000 MW,
anionic, 4% stock, Thermo Fisher) were prepared in aCSF. Additionally, AlexaFluor-647conjugated human amyloid-β1-40 (647-Aβ1-40, 100 µM stock, Anaspec), FITC-conjugated
recombinant human amyloid-β1-40 (FITC-Aβ1-40, 100 µM stock, Anaspec), and FITCconjugated recombinant human amyloid-β1-42 (FITC-Aβ1-42, 100 µM stock, Anaspec) were
also prepared in aCSF. Tracers were then combined to a solution 1 (2% CB-d3, 1% FITCd2000 and 10 µM 647-Aβ1-40), solution 2 (10 µM FITC-Aβ1-42 and 10 µM 647-Aβ1-40) or
solution 3 (10 µM FITC-Aβ1-40 alone). In other experiments, recombinant human fibronectin
(R&D Systems, cat. 4305-FN) or aCSF was added to the tracer mixture to a concentration of
500 nM and incubated for 1 hour at room temperature prior to infusion. Tracer mixtures
were kept on ice for up to 4 hours prior to use, and vortexed for 5 seconds immediately
before infusion. To measure fluorescent background signal, zero control animals received
aCSF with no tracers.

4.2.5: Tracer injection.
Mice were deeply anesthetized with an intraperitoneal injection of KetamineXylazine dissolved in 0.9% NaCl (120 mg/kg Ketamine, 10 mg/kg Xylazine), then placed in
a stereotaxic frame. The skin over the cervical spine was then shaved, aseptically prepared
and incised. Following this, the needle was inserted through the superficial neck musculature
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and into the cisterna magna as previously described.125 Tracer was slowly infused into the
cisterna magna (1 µL/min) over 10 minutes, after which mice were transferred to a warmed
cage. Then, 30 minutes after the initiation of the injection, mice were sacrificed by Avertin
overdose (250 mg/kg), followed by transcardial perfusion with 0.2% heparin-PBS, then 4%
PFA. Tissues were dissected and stored in 4% PFA until later use.

4.2.6: Fluorescent microscopy and tracer imaging.
Following perfusion, brains were extracted and post-fixed for 24 hours in 4% PFA.
Then, brains were dehydrated in 30% sucrose, frozen to -20°C and sectioned to 24 µm
(IHC/cresyl violet staining) or 100 µm (tracer quantification) sections. Sections were then
mounted onto slides and coverslipped. For experiments involving colocalization with lectin,
sections were first stained with Lycopersicon esculentum (Tomato) lectin (see
Immunohistochemistry). Sections were imaged under fluorescence with a Leica DMi8
microscope at 10X magnification. A blinded investigator imaged the lateral cortex (0.38 mm
anterior to Bregma, 2.5 mm lateral, 1.5 mm deep). Then, 100 µm Z stack images were
obtained, and maximum intensity projections performed with LAS X software. Images were
then quantified in ImageJ (see Data Analysis).

4.2.7: Immunohistochemistry.
IHC was performed on fixed brain sections (24 µm) that were mounted onto slides
and incubated with Lycopersicon esculentum lectin (1:100, λ = 594, Vector Laboratories, cat.
DL-1177), anti-fibronectin (Rabbit, 1:100, abcam, cat. ab2413), anti-integrin-α5 (Rabbit,
1:100, abcam, cat. EPR7854) or anti-glial fibrillary acid protein [GFAP]-Cy3 (Mouse,
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1:1000, Millipore Sigma, cat. C9205,) antibodies. Then, sections were incubated with
secondary antibodies (Goat anti-Rabbit (Abcam, Alexa-Fluor, 1:500, λ = 488, 594 or 647
nm). Finally, sections were cover-slipped with Vectashield containing DAPI (Vector
Laboratories, H-1200).

4.2.8: Protein isolation, SDS-PAGE and western blotting.
The right cortex was perfused with heparinized PBS, homogenized and lysed in
buffer containing 1% NP-40, 1 mM phenylmethylsulfonyl fluoride (PMSF), cOmplete
(Roche) and PhosSTOP (Roche). Following centrifugation, the supernatant was removed
and diluted to 4 mg/mL in 4x Laemmli Sample Buffer (Bio-Rad, 161-0737) supplemented
with 4% β-mercaptoethanol, then heated to 95°C for 5 minutes. Following sample
preparation, 10 µL of each lysate was run on a 4-15% Criterion TGX 26-well gels (Bio-Rad,
cat. 5671085), and SDS-Page performed at 120V for 60 minutes in Tris-Glycine-SDS buffer
(Bio-Rad). Protein bands were subsequently transferred to a polyvinylidene fluoride (PVDF)
membrane and probed with anti-fibronectin (Rabbit, 1:1000, abcam, cat. ab2413), anti-α5
Integrin (Rabbit, 1:1000, abcam, cat. EPR7854) or anti-vinculin antibody (Rabbit, 1:10,000,
abcam, cat. EPR8185). Blots were then probed with HRP-conjugated goat anti-rabbit
secondary antibody (1:10,000, Vector Laboratories, cat. PI-1000) and imaged using a BioRad ChemiDoc Imager.

4.2.9: Generation of radiolabeled amyloid-β.
Recombinant human Aβ1-40 (Anaspec, Fremont, CA) was first dissolved to a
concentration of 1 µg/µL in sterile, chloride-free 250 mM sodium phosphate buffer (pH =
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7.4). Then, Aβ1-40 was conjugated to 2 mCi Iodine-125 (125I) with chloramine T (1 µg/µL) as
previously described.242 The labeling reaction was terminated by adding sodium
metabisulfate (10 µg/µL) to the reaction.

125

I-Aβ1-40 was separated from free 125I by washing

the mixture through a Sephadex G-10 column. Successful conjugation was measured by TCA
precipitation ratio, calculated as % precipitation = CPM (pellet) / (CPM [pellet] +
CPM[supernatant]). Fractions retaining > 95% CPM values in the solid phase were then
combined and lyophilized overnight for later use.

4.2.10: Fibronectin-125I-Aβ1-40 binding assay.
To measure the binding affinity of radiolabeled 125I-Aβ1-40 for fibronectin, an in vitro
assay was developed that relies on separation of free 125I-Aβ1-40 (4.2 kD) from fibronectin125

I-Aβ1-40 conjugates (> 220 kD) based on molecular weight. First, serially diluted

recombinant human fibronectin (1 x 103 to 1 x 108 ng/ml) (R&D Systems, cat. 4305-FN) was
incubated with 125I-Aβ1-40 (1 x 105 CPM) at room temperature for 1 hour. Reaction mixtures
were then centrifuged in a molecular weight cutoff spin column (> 50 kD, Amicon Ultra,
Millipore-Sigma). The columns were washed with 400 µL of sterile PBS and centrifuged 3
times for 5 minutes at 5,000 x g. Finally, the remaining 125I-Aβ-fibronectin conjugates were
resuspended in sterile PBS and the amount of fibronectin-bound 125I-Aβ quantified by a
gamma counter (Packard Cobra II). See Data Analysis for the calculation of the standard
curve.
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4.2.11: Data Analysis.
•

Atrophy quantification. High resolution images of cresyl violet-stained coronal brain
sections (24 µm) were obtained (Fig. 4-1). Then, ventricular volume and hemisphere
size were quantified as previously described (Harris et al., 2016; Verma et al., 2014).
Tissue atrophy percentage was calculated by the formula: % tissue loss = 100 - ([total
ipsilateral tissue/total contralateral tissue] × 100).

•

Tracer intensity. Tracer influx was quantified by measuring intensity as a function of
tissue depth using ImageJ (Fig. 4-1). Then, average intensity values were imported
into Excel, and integrated into 50 µm bins. Absolute binned intensity values were
then plotted as raw intensity (arbitrary units, [A.U.]). To normalize potential ageinduced differences in background intensity, the relative tracer intensity was
calculated by subtracting each binned value from intensity values obtained from agematched control mice that did not receive tracer injections (Δ Intensity [A.U.]).

•

Immunohistochemical quantification. IHC images were acquired and quantified in
a double-blinded manner. Based on lectin staining, regions of interest (ROI’s) were
drawn around 3 peri-infarct vessels/image across 3 brain sections for a total of 27
vessels/brain. Threshold was held constant between brains, and the area and average
pixel intensity of fibronectin was measured relative to the ROI.

•

Calculation of 50% Effective Concentration (EC50). The EC50 was quantified using
a sigmoidal EMax model by plotting the log [Fibronectin] against the %Aβ binding
(calculated as CPM [X]/CPM [Max]). A sigmoidal regression line was fit with Prism,
and the EC50 was interpolated from the curve. Each measurment at each
concentration was replicated 3 times.
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4.2.12: Statistics.
Data are expressed as mean (+/-) SEM with the number of animals per group (n).
The physiology data measured at different depths was analyzed by repeated measures twoway ANOVA, with factors of aging and DMCAO. Repeated measures one-way ANOVA
was used for repeated measures with only one factor. For immunohistochemical
quantification of area or intensity, as well as for analysis of band intensity of western blots,
two-way ANOVA was used, examining the effects of aging and DMCAO on the dependent
variable. All of the above analyses were followed by Sidak’s post-hoc test. Scatter plots were
provided and linear mixed-effects models were used to study the association between the
dextran intensity and and Aβ1-40 intensity, and between the lectin intensity and the tracer
intensity. Statistical significance is denoted as *p < 0.05, **p < 0.01, ***p < 0.001, ns, no
significance.
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4.3: Results
4.3.1: Aging and DMCAO impaired the perivascular flow of CSF.
Previous work has shown that aging impairs glymphatic flow,235 and that multiple
microinfarction disrupts CSF flow in middle-aged mice (12 months-old).208 However, it was
not known whether a single focal stroke, modeled by DMCAO, induces glymphatic
impairment, or if this would further worsen underlying impairments in aged mice (generally
considered to be > 18 months of age). Therefore, to assess the impact of aging and DMCAO
on overall perivascular CSF flow, we injected fluorescent tracer into the cisterna magna at 30
days post-DMCAO, and quantified the uptake 30 minutes later (Fig. 4-1, Fig. 4-2). We
found that CSF influx, measured as the distribution of dextran-derived fluid space markers,
occurred along the superficial surfaces of the brain (Fig. 4-2). Furthermore, we found that
the distribution of both low (CB-d3, 3 kD) and high (FITC-d2000, 2000 kD) molecular
weight dextran colocalized with lectin-stained vessels, supporting a perivascular route for
CSF influx (Fig. 4-1A). When raw CB-d3 uptake values were examined, we found reduced
CSF flow occurred in aged animals at baseline (Fig. 4-2D, iii, Main Effect: Age, [F(1, 19) =
6.2, p = 0.022]). We then measured how CSF influx changed in the injured cortex, relative to
the contralateral hemisphere, and found the distribution of CB-d3 was inhibited by DMCAO
in both young and aged animals (Fig. 4-1C, i., [F(1, 18) = 52.3, p < 0.001]). Taken together,
these data indicate that DMCAO produced a unilateral impairment of bulk CSF influx
through the lectin-stained basement membrane, even in aged mice, which exhibit baseline
reductions in CSF flow.
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Figure 4-1. Aging and DMCAO disrupted the transport of CSF and enhanced Aβ1-40
distribution in the superficial cortex. (A.) Representative images of tracer uptake (CB-d3,
647-Aβ1-40, FITC-d2000) and colocalization with lectin+ basement membrane. (B.) (i.)
Representative 10X magnification images from young sham and DMCAO animals showing
axis of tracer quantification, (ii.) Comparison of intensity tracings from young sham and
DMCAO animals. (C.) Quantification of (i.) CB-d3 tracer uptake and (ii.) 647-Aβ1-40 from
ipsilateral (injured/sham) cortex, 1 – 250 µm depth. Data are normalized to contralateral
hemisphere. All experiments, n = 5 – 8 per group. Data are analyzed by two-way ANOVA
with Sidak’s post-hoc test. *p < 0.05, **p < 0.01, ***p < 0.001. Scale bar = 50 µm.
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Figure 4-2. Infusion technique, representative images and raw tracer uptake
values. (A.) Measurement of glymphatic flow by tracer uptake. (B.) Representative images
of tracer uptake (CB-d3, FITC-d2000) changes with aging any stroke. (C.) Representative
raw tracing of dextran uptake in a tracer infused and non-tracer infused mouse
brain. (D.) Aging and stroke both reduced glymphatic flow compared to young sham
animals in the injured cortex. Data are analyzed by repeated measures two-way ANOVA
with Tukey’s post-hoc test. *young sham vs. young stroke, #aged sham vs aged stroke, †young
sham vs. aged sham, ‡young stroke vs. aged stroke. *p < 0.05, **p < 0.01, ***p <
0.001. Scale bar = 50 µm.
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4.3.2: DMCAO increased the perivascular distribution of CSF Aβ1-40, which worsens with
aging.
Previous work has shown that the glymphatic system provides a perivascular route for
the deposition of CSF Aβ1-40 in mouse models of Alzheimer’s disease with pre-existing Aβ
pathology,209 but it was not known whether stroke would induce de novo Aβ1-40 deposition,
given the absence of pre-existing Aβ plaques in wild-type mice. Therefore, to determine
whether stroke selectively induced the ‘trapping’ of CSF Aβ1-40, we first examined whether
DMCAO increased the total amount of Aβ1-40 deposition within the brains of young and aged
wild-type mice by quantification of 647-Aβ1-40 distribution. While we did not observe an
impact on aged animals at baseline, we found an interesting interaction effect, which showed
a paradoxical increase in 647-Aβ1-40 distribution in aged animals with DMCAO (Fig. 4-1C,
ii., F[1, 18] = 21.7, p < 0.001). Importantly, these differences between young and aged mice
with DMCAO were not associated with significant differences in tissue atrophy ipsilateral to
the injury (Fig. 4-3B, p = 0.96]), suggesting that other mechanisms, aside from infarct
volume, could play an important role in determining the fate of CSF Aβ1-40. Taken together,
these data indicate that both aging and DMCAO induced the abnormal deposition of CSF
Aβ1-40, with a major effect of DMCAO on the injured hemisphere, and a major effect of
aging on the contralateral hemisphere.
Then, to determine whether this effect was truly specific to Aβ1-40, we compared the
distribution of 647-Aβ1-40 to FITC-Aβ1-42 in aged animals with sham and DMCAO in a
separate cohort (Fig. 4-4A). This analysis confirmed that 647-Aβ1-40 was increased in aged
animals with DMCAO (Fig. 4-4B, i., p = 0.015), with no significant impact on FITC-Aβ1-42
distribution (Fig. 4-4B, ii., p = 0.596). Normalization of these values confirmed that 647-
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Aβ1-40/ FITC-Aβ1-42 ratio was significantly increased with DMCAO (Fig. 4-4B, iii., p =
0.045). Given that the same amount of Aβ1-40 and Aβ1-42 were infused into the brain, and that
the proteins are similar in molecular weight, these data indicate a specific effect of DMCAO
on the transport of CSF Aβ1-40 through the aged basement membrane after DMCAO, which
we next explored by correlation analysis.
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Figure 4-3. Comparison of cortical atrophy, motor and cognitive impairments in young
and aged mice with DMCAO. (A.) Timeline of stroke surgery and behavioral tests. (B.) (i.)
Cresyl violet staining of DMCAO brains revealed focal damage to the lateral cortex in both
young and aged mice at 30 DPI. (ii.) DMCAO induced similar degrees of atrophy in young
and aged mice at 30 DPI (Data are analyzed by Student’s t-test, n = 10 per group). (C.)
DMCAO induced alterations in forepaw rotation at day 3, which recovered by day 7 as
measured by Digigait. n = 5 - 12 per group (D.) (i.) Aging and stroke impaired performance
on the Barnes maze. (ii.) Aging reduced exploratory behavior on the open field test. n = 7 –
8 per group. Data from panels C and D are analyzed by two-way ANOVA with Sidak’s posthoc test. *p < 0.05, **p < 0.01. ns, no significance.
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Figure 4-4. DMCAO selectively increased the uptake of Aβ1-40 in the injured cortex of
aged animals. (A.) Representative images comparing the distribution of 647-Aβ1-40 to
FITC-Aβ1-42 in aged animals treated with sham or DMCAO at 30 DPI. (B.) Quantification of
(i.) 647-Aβ1-40 uptake, (ii.) FITC-Aβ1-42 uptake and (iii.) 647-Aβ1-40/FITC-Aβ1-42 ratio. All
data are acquired from 1 – 250 µm depth of superficial cortex, and normalized to the
contralateral hemisphere. n = 5 per group. Data are analyzed by Student’s t-test, *p <
0.05.
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4.3.3: Aging decoupled Aβ1-40 transport from CSF flow.
To examine whether abnormal Aβ1-40 deposition is related to the bulk flow of CSF,
the average intensity of 647-Aβ1-40 and CB-d3 (CSF fluid space marker) were compared
within each 50 µm bin for the ipsilateral hemisphere (5 bins/animal) (Fig. 4-5, A-B).
Comparison of CB-d3 and 647-Aβ1-40 influx curves revealed similar distribution kinetics as a
function of tissue depth in young sham animals (Fig. 4-5A). Furthermore, linear regression
revealed a positive correlation (non-zero slope) of CB-d3 and 647-Aβ1-40 uptake in young
sham (Fig. 4-5C, i., [t(21) = 5.89, p < 0.001]) and young stroke animals (Fig. 4-5C, ii., [t(25)
= 3.25, p = 0.003]). However, CB-d3 uptake did not predict Aβ1-40 uptake in aged sham
[t(17) = 0.9, p = 0.379] or aged stroke animals [t(17) = 1.89, p = 0.076]. These findings
indicate that age-induced disruption of bulk CSF influx did not predict the behavior of Aβ1-40,
implying that other mechanisms, such as altered diffusion of Aβ1-40 through the basement
membrane, may have played a more important role in determining CSF Aβ1-40 deposition
with aging, which may be further changed by DMCAO.
Since bulk flow did not significantly predict CSF Aβ1-40 deposition in disease states,
we then broadly assessed whether components of the basement membrane are associated
with CSF Aβ1-40 accumulation in vivo. To accomplish this, the average intensity of 647-Aβ140

and CB-d3 were each compared to the expression of glycosylated basement membrane

matrix proteins, measured by the intensity of 594-lectin staining (Fig. 4-6). Interestingly,
linear regression of 594-lectin vs. 647-Aβ1-40 intensity revealed a highly significant positive
correlation in all experimental groups (Fig. 4-6C, i. – iv.; young sham, [F(1, 23) = 10.1, p < 0
.001]; young stroke, [F(1, 27) = 67.91, p < .0001]; aged sham, [F(1, 19) = 26.4, p < 0.001];
aged stroke, [F(1, 19) = 17.61, p < 0.001]). In contrast, linear regression of 594-lectin vs.
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CB-d3 intensity (used as a fluid space marker and to control for potential non-specific
trapping within the extracellular space) revealed a positive relationship in young sham
animals (sham, Fig. 4-6B, i., t(23) = 3.7, p = 0.001], but not in young DMCAO animals (Fig.
4-6B, ii., [t(27) = 0.4, p = 0.685]). Additionally, in aged animals, 594-lectin intensity did not
correlate with CB-d3 intensity in sham (Fig. 4-6B, iii., [t(19) = 0.9, p = 0.384]) or DMCAO
mice (Fig. 4-6B, iv., [t(19) = 0.5, p = 0.619]). Overall, these data showed that basement
membrane proteins were more strongly associated with 647-Aβ1-40 than CB-d3 controls,
indicating an association of lectin-stained basement membrane proteins on Aβ1-40 levels. This
difference was further exacerbated by aging and DMCAO.
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Figure 4-5. Distribution of dextran did not predict Aβ1-40 distribution in disease
conditions. (A.) Distribution of Aβ1-40 and dextran by tissue depth in young sham animals,
(B.) Correlation plot of dextran and Aβ40 uptake in all experimental groups. (C.) (i. - iv.)
Linear regression of dextran vs. Aβ1-40 uptake. A - C, n = 5 - 7, 5 bins/animal. Data are
analyzed by a linear mixed effect model to control for within-subject correlations.
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Figure 4-6. Lectin staining predicted Aβ1-40 distribution in all experimental groups.
(A.) Correlation plot of lectin staining and Aβ1-40 uptake in all experimental groups. (B.)
Comparison of lectin-Aβ slopes across experimental groups. (C.) (i. - iv.) Linear regression
of lectin vs. Aβ40 uptake and lectin vs. dextran (3 kD) uptake. A - C, n = 5 - 7. Data are
analyzed by a linear mixed effect model to control for within-subject correlations.
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4.3.4: DMCAO increased fibronectin and integrin-α5 expression in young and aged
animals.
We next examined how the expression of fibronectin changes in the context of the
PVS, bordered by astrocytic endfeet and the lectin-stained basement membrane matrix. IHC
revealed increases in fibronectin expression at 7 DPI (Fig. 4-7A). To confirm these findings,
total protein levels of fibronectin and integrin-α5 were then assessed by western blot of the
peri-infarct cortex (Fig. 4-7B, Fig. 4-8). Stroke increased fibronectin expression (Fig. 4-7C,
i., [F(1, 19) = 63.8, p < 0.001]), with no additional effects of aging [F(1, 19) = 0.06, p = 0.81]
or interaction [F(1, 19) = 0.1, p = 0.733]. In contrast, integrin-α5 levels were increased by
both DMCAO (Fig. 4-7C, ii., [F(1, 19) = 34.6, p < 0.001]) and aging [F(1, 19) = 5, p =
0.038], with no significant interaction effect [F(1, 19) = 1.5, p = 0.232]. These data indicate
that perivascular fibronectin deposition occurred by 7 DPI, which was also accompanied by
further increases in integrin-α5 expression in aged animals with DMCAO. We also observed
acute reductions in LRP1 following DMCAO in aged animals (Fig. 4-9), which may further
impair the clearance of Aβ1-40 from the basement membrane across the BBB in the aged
brain.80
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Figure 4-7. DMCAO increased the expression of fibronectin and integrin-α5 at 7 DPI.
(A.) Representative images of fibronectin expression in young and aged animals, taken at 7
DPI (40X magnification). (B.) Representative blots and quantification of fibronectin,
integrin-α5 and vinculin (loading control) expression of these proteins at 7 DPI. Data are
analyzed by two-way ANOVA with Sidak’s post-hoc test, n = 5 – 7 per group, *p < 0.05, *
***p < 0.001. Scale bar = 50 µm.
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Figure 4-8. DMCAO upregulated the expression of fibronectin and integrin α5 in young
and aged mice. Western blot image showing upregulation of basement membrane proteins
at 3 and 7 DPI in both young and aged mice. Gels were run in parallel, cut at 100 kD, then
transferred to the same PVDF membrane. Proteins were identified by molecular weight
using Bio-Rad Precision Plus Dual Color standards.
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Figure 4-9. DMCAO reduced LRP1 expression in aged mice. (A.) Quantification of
LRP1 expression in young and aged mice at 7 DPI. (B.) Western blot showing reduced
expression of LRP1 in aged mice with DMCAO. n = 5 – 7. Data are analyzed by two-way
ANOVA with Sidak’s post-hoc test, *p < 0.05.

	
  

79

4.3.5: CSF-derived Aβ1-40 colocalized with fibronectin, the integrin-α5 subunit and lectinstained basement membrane components, which increased with DMCAO.
Based on our data showing that aging and DMCAO cause increased association of
CSF Aβ1-40 with the lectin-stained basement membrane, we next assessed the contribution of
fibronectin and the integrin family of receptors to this phenotype. In addition to fibronectin,
we selected integrin-α5 because previous work has shown that it is strongly expressed in the
basement membrane,257,258 regulates the binding of multiple beta subunits to fibronectin,259
and is associated with increased Aβ accumulation in disease states.260
Image quantification at 30 DPI revealed that DMCAO increased the expression of
FITC-lectin-stained basement membrane components (Fig. 4-10B, ii., [F(1, 19) = 5.756, p =
0.0269]). Aging also exhibited a trend for increased FITC-lectin staining, but it failed to
reach statistical significance [F(1, 19) = 3.252, p = 0.0872]. Additionally, we found that
perivascular fibronectin staining increased with DMCAO in both young and aged animals
(Fig. 4-10B, i., F[1, 12] = 19.5, p < 0.001) and colocalized with the lectin-stained basement
membrane (Fig. 4-10A). Furthermore, intracisternally injected FITC-Aβ1-40 colocalized with
fibronectin within the basement membrane across all conditions, and was most apparent in
aged animals with DMCAO (Fig. 4-10A). This indicates that fibronectin was a marker of
sites within the basement membrane that were predisposed to Aβ1-40 deposition, which
further increased with aging and DMCAO. This suggests a potential mechanism of Aβ1-40
deposition via its association with fibronectin.
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Figure 4-10. Fibronectin expression colocalized with sites of CSF Aβ1-40 deposition. (A.)
Colocalization of intracisternally injected FITC-Aβ1-40 with fibronectin occurs within the
lectin stained basement membrane at low levels in young sham mice, which worsens with
aging and DMCAO. Low-power images were acquired at 10X magnification, and high power
images were acquired at 40X magnification. (B.) Quantification of (i.) fibronectin and (ii.)
lectin staining at 30 DPI. n = 3 – 5 per group for all experiments. Data are analyzed by twoway ANOVA with Sidak’s post-hoc test. *p < 0.05, **p < 0.01. Scale bar = 200 µm.
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Despite observing colocalization with Aβ1-40, we did not observe consistent increases
in fibronectin expression in aged animals. Therefore, we next explored the impact of aging
and DMCAO on it’s major receptor, integrin-α5, to determine whether it could further
modulate Aβ1-40 distribution in the aged brain. We found that perivascular integrin-α5
staining in the aged brain further increased with DMCAO, and colocalized with the lectinstained basement membrane (Fig. 4-11A). Furthermore, intracisternally injected FITC-Aβ140

colocalized with integrin-α5 within the basement membrane across all conditions, and was,

again, most apparent in aged animals with DMCAO (Fig. 4-11A). Total expression of
vascular integrin-α5 was highest in aged animals with DMCAO (Fig. 4-11B), with main
effects of DMCAO (F[1, 12] = 344.6, p < 0.001) and aging (F[1, 12] = 15.1, p = 0.002) on
increased expression, with a significant interaction effect (F[1, 12] = 27.9, p < 0.001).
Increased expression of integrin-α5 could alter the affinity of the basement membrane by
complexing with its major ligand, fibronectin. Alternatively, it could possess additional
binding sites for Aβ1-40.
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Figure 4-11. Integrin-α5 expression colocalized with sites of CSF Aβ1-40 deposition. (A.)
Colocalization of intracisternally injected FITC-Aβ1-40 with integrin-α5 occurs within the
lectin stained basement membrane at low levels in young sham mice, which worsens with
aging and DMCAO. Low-power images were acquired at 10X magnification, and high power
images were acquired at 40X magnification. (B.) Quantification of integrin-α5 staining at 30
DPI. n = 3 – 5 per group for all experiments. Scale bar = 200 µm. Data are analyzed by
two-way ANOVA with Sidak’s post-hoc test. *p < 0.05, **p < 0.01. Scale bar = 200 µm.
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4.3.6: Fibronectin treatment increased the perivascular deposition of CSF Aβ1-40.
Previous work has suggested that plasma fibronectin may bind serum amyloid species
via the fibronectin type I domain,217 but there are a lack of studies examining its potential
affinity to the Aβ1-40 fragment, especially in the context of the brain microenvironment.
Therefore, to first assess the binding characteristics of fibronectin to Aβ1-40, recombinant
fibronectin was incubated with 125I-Aβ1-40 (Fig. 4-12A, i.). We found that fibronectin bound
Aβ1-40 in vitro with an EC50 of 216 nM (Fig. 4-12A, ii.). Then, to determine whether
fibronectin impacted CSF flow or Aβ1-40 deposition, fibronectin or vehicle control was
incubated with CB-d3 and 647-Aβ1-40, and then injected intracisternally (Fig. 4-12B).
Fibronectin treatment increased the 647-Aβ1-40/CB-d3 ratio (Fig. 4-12C, [F(1, 8) = 11.2, p =
0.01]), which decreased with tissue depth [F(4, 32) = 18.1, p < 0.001]. Furthermore, an
interaction between fibronectin treatment and tissue depth was also observed [F(4, 32) = 3.1,
p = 0.028]. Treatment did not affect total CB-d3 ([F(1, 8) = 0.05, p = 0.835]) or 647-Aβ1-40
influx ([F(1, 8) = 0.6, p = 0.468]). These data demonstrate that fibronectin-Aβ1-40 binding
occurred, and that this interaction was sufficient to induce the selective accumulation of Aβ140

	
  

within the superficial cortex, without impacting bulk CSF influx.
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Figure 4-12. Fibronectin conjugation altered the perivascular transport of Aβ1-40. (A.)
(i.) Experimental design of in vitro fibronectin binding assay. (ii.) Binding kinetics of
fibronectin and 125I-Aβ1-40. (B.) Representative images showing increased distribution of
fibronectin-Aβ1-40 conjugates compared to unconjugated Aβ1-40 following intracisternal
injection into naïve young mice. (C.) Comparison of (i.) CB-d3 uptake, (ii.) 647-Aβ1-40
uptake and (iii.) 647-Aβ1-40/CB-d3 ratio. n = 5 - 6 per group for all experiments. Data are
analyzed by Student’s t-test, *p < 0.05.
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4.3.6: Aging and DMCAO induced impairments in motor function, cognition, and
exploratory behavior.
Previous work has shown that young mice develop cognitive impairment after
DMCAO.11 To evaluate whether aging and DMCAO induced similar behavioral changes in
our animals, we tested mice on DigiGait, Barnes maze and open field (Fig. 4-3, C-D). We
found that stroke induced left forepaw rotation at 3 DPI (Fig. 4-3C, [F(1, 31) = 21.4, p <
0.0001]), which resolved by 7 DPI ([F(1, 21) = 1.6, p = 0.214). Aging also induced mild
forepaw rotation at 3 DPI [F(1, 31) = 4.7, p = 0.037) and 7 DPI [F(1, 21) = 5.6, p = 0.028].
No significant interaction of aging and DMCAO were observed at 3 DPI [F(1, 31) = 0.9, p =
0.35] or 7 DPI [F(1, 21) = 1, p = 0.333]. These data indicate that both aging and DMCAO
induce motor impairment, with DMCAO-induced motor deficits recovering by 7 DPI.
Aging increased the latency to find the escape hole on the Barnes maze (Fig. 4-3D,
[F(1, 26) = 8.3, p = 0.008). No major effect of DMCAO on latency was observed [F(1, 26) =
1.2, p = 0.287), likely due to a trending interaction between aging and DMCAO [F(1, 26) =
3.3, p = 0.082), as DMCAO worsened Barnes maze performance in young (Sidak test, p =
0.049), but not aged animals (p = 0.8784). Finally, aging reduced total movement on open
field testing (F(1, 26) = 12.6, p = 0.002), with no effect of DMCAO [F(1, 26) = 0.003, p =
0.96] or interaction observed [F(1, 26) = 0.06, p = 0.817]. Taken together, these data indicate
that cognitive deficits existed in conditions of reduced CSF flow, even when motor deficits
were no longer detectable by gait measurement.
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4.4: Discussion
4.4.1: Aging and stroke impair the perivascular flow of CSF through the basement
membrane.
Previous work has shown that aging82 and multiple types of brain injury, including
traumatic brain injury,261 multiple microinfarction208 and AD,209 all reduce the perivascular
bulk flow of CSF. However, it was not previously known whether focal ischemic stroke
impairs the perivascular flow of CSF. Furthermore, no study had examined whether normal
aging or stroke impact the deposition of CSF Aβ1-40 within the basement membrane.
In agreement with previous studies of CSF influx, we found that both aging and
stroke impaired the transport of CSF through the basement membrane. However, we newly
showed that these effects occured independently of each other: while stroke reduced CSF
influx in young animals, it showed minimal further reduction in aged animals, who were
already severely impaired at baseline. This is surprising, because recent work showed that
age-related glymphatic impairment significantly worsened with experimental induction of
multiple microinfarction.208 However, our study differed in several important respects:
1.

Injury model differences. We performed a single, focal stroke (modeled by
distal MCA occlusion), while their model relied on the induction of
multiple small infarctions via intravenous latex microbeadbead injection.
Differences in the pathophysiology of these two diseases could explain
disparate findings, and suggest that focal and repeated infarction may have
distinct effects on CSF flow in the aged brain.

2.

Age differences. Their study used 12-month-old mice as their aged
population, while we used much older 20 month-old mice that are more
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analagous to elderly stroke patients. Given that Kress et al. (2014) found
that CSF influx continues to decline between 12 and 18 months,82
indicating major differences in baseline CSF flow, these further reductions
could have made it more difficult to detect stroke-induced impairment in
our aged animals.
3.

Tracer differences. Third, their study used fluorescent ovalbumin (45 kD),
while ours used fluorescent dextrans (3 and 2000 kD). Given that our early
validation studies, detailed in Chapter 3, showed molecular size-dependent
distribution of CSF solutes in the basement membrane, it is possible that
their study measured CSF flow in a different layer of basement membrane
than where Aβ1-40 (~4.5 kD) is transported.

Overall, further work using multiple experimental stroke models and differently sized tracers
is required to definitively determine if stroke worsens age-related impairments in
perivascular CSF flow.
In addition to changes in total CSF flow, our study also examined whether aging and
stroke had specific impacts on the deposition of CSF Aβ1-40. One recent publication found
that Aβ1-40 can re-enter the brain from the CSF and associate with pre-existing amyloid
plaques within the brain parenchymal extracellular space.209 In this case, the distribution of
Aβ1-40 was altered by binding to these pre-existing plaques, which trapped them within the
brain tissue rather than allowing them to circulate back out to the cisterns. Based on these
data, CSF Aβ1-40 is ideally positioned to contribute to the perivascular Aβ deposits that are
characteristic of CAA.
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This novel source of Aβ1-40 could explain several interesting characteristics of CAA
pathophysiology, including the early involvement of leptomeningeal and penetrating arteries,
the initial deposition within the basement membrane, as well as the primarily ‘outside-in’
cortical distribution of plaques, with worse pathology being observed in the superficial
cortical layers. We newly discovered that aging and stroke selectively increase the
deposition of CSF Aβ1-40, which occurs independently of changes in bulk CSF flow. This
finding suggests that other factors, such as the diffusion of Aβ1-40 between glycosylated
extracellular basement membrane proteins (stained with lectin), play a major role in
determining the amount and location of Aβ1-40 deposition within the basement membrane,
particularly in aging and stroke. One potential implication of this finding is that the
movement of Aβ1-40 within the PVS cannot be approximated by dextran flux, which is
problematic for all but one209 of the previously discussed studies of glymphatic flow. Other
factors, including the degree of basement membrane glycosylation, play a more important
role in modulating the distribution of CSF Aβ1-40.
Overall, my work supports the notion that aging and brain injury both reduce the
perivascular flow of CSF. It also newly shows that stroke specifically disrupts the transport
of CSF-derived Aβ1-40, which correlates with upregulation of lectin-stained basement
membrane proteins, as well as fibronectin. This deposition of CSF Aβ1-40 occurs even in
wild-type mice that do not have pre-existing amyloid plaque pathology. These studies
provide a potential new mechanism by which aging and stroke sensitize cortical vessels to
the development of CAA pathology.
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4.4.2: Aging and stroke interact to remodel the vascular basement membrane.
My findings suggest multiple facets of a potential new mechanism of CAA
development, including both the physiological route of the initial perivascular Aβ deposition
after stroke, as well as the specific extracellular matrix components that pathologically
enhance this Aβ deposition after stroke. While previous studies have examined the
independent effects of aging and stroke on basement membrane composition,165,181,194 there is
a significant gap in the literature with respect to the impact of stroke on the aged basement
membrane. A better understanding of how aging and stroke impact the regulation of
basement membrane composition is critical to developing new and effective therapies to
combat CAA.
I first examined how aging and stroke impact the overall morphology of the vascular
network by staining the basement membrane with lectin. Similar to previous studies, I found
that stroke increased the density of microvessels. Following stroke, aged animals also
produced new vessels. However, many of these peri-infarct vessels appeared “string-like,”
which is a sign of nonperfused vasculature. Given the dependence of bulk flow on the
pulsation of arteriolar blood vessels, these likely do not contribute to effective CSF flow. As
such, these vessels may be the most prone to the development of CAA after stroke, given that
they exhibited reduced ability to transport CSF through the PVS.
I then hypothesized that post-stroke basement membrane fibrosis includes chronic
changes in both fibronectin and a subunit of its receptor, integrin-α5, which together ‘prime’
the basement membrane matrix for the binding of CSF-derived Aβ. Indeed, my findings
indicate that stroke induces the chronic deposition of extracellular fibronectin as well as
lectin+ matrix proteins (which are most likely enriched for HSPG) and integrin-α5.
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Surprisingly, while the total amount of fibronectin dramatically increased after stroke, this
response was not different between young and aged animals. However, I did detect increased
lectin+ matrix and integrin-α5 expression in aged animals with stroke. Both of these proteins
directly interact with fibronectin within the basement membrane. Given that fibronectin is a
highly modular protein that is subject to alternative splicing, post-translational modification
and fibrillogenesis, the “quality” of fibronectin, rather than the “quantity,” may change with
aging. Further work with targeted mass spectrometry is needed to sequence fibronectin and
determine if any of its domains are being altered with aging, and whether this can enhance its
affinity for Aβ1-40 in aged animals with stroke.
Overall, I found that stroke chronically alters basement membrane morphology and
composition in a way that strongly resembles CAA plaques. These changes are characterized
by increases in lectin+ matrix and fibronectin content, within foci of basement membrane
thickening. Targeting these early changes may help to reduce CAA in stroke survivors.

4.4.3: Fibronectin may trap Aβ1-40 within the basement membrane by multiple
mechanisms.
I found that CSF Aβ1-40 selectively deposited in regions of thickened basement
membrane, which displayed high levels of lectin+ matrix, fibronectin and integrin-α5.
Furthermore, I also found that treatment with fibronectin increases CSF Aβ1-40 deposition
within superficial cortical layers (Fig. 5). Finally, I confirmed these findings in a cell-free in
vitro assay, where I found that fibronectin binds Aβ1-40 with high affinity. Fibronectin may
impact multiple physiological factors that could play a role in determining the degree to
which CSF Aβ1-40 becomes deposited in the aged brain, which might be further altered with
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brain injury such as stroke. In particular, fibronectin may alter several distinct factors that
modulate the diffusion of Aβ1-40 through the extracellular space (Reviewed in Syková &
Nicholson, 2008).202
First, there is significant evidence that astrogliosis increases the geometric tortuosity
of brain tissue, which may also apply to the basement membrane.212,262,263 I found that areas
of increased fibronectin expression also exhibited increased numbers of GFAP+ perivascular
reactive astrocytes (see Chapter 5), which may act as a cellular barrier to the diffusion of Aβ,
effectively ‘trapping’ it within the PVS. Second, post-stroke angiogenesis, which also
involves fibronectin, may induce the focal trapping of CSF solutes by increasing the volume
of physiologic dead space within the PVS (i.e. regions that do not participate in CSF flow). I
found that stroke increased the thickness of the lectin-stained basement membrane, which
also exhibited increased branching and lacunarity. Third, fibronectin overexpression may
increase the viscosity of the basement membrane, which could trap CSF Aβ1-40. Previous
work has shown that cortical stab wound in rats leads to local astrogliosis and increased
deposition of numerous ECM proteins throughout the injured hemisphere, although
fibronectin levels were not examined.264 However, the above factors appear to play a minor
role in Aβ1-40 deposition due to the fact that we did not observe the same increases in sizematched dextran levels, as examined the preceding chapter. This points to a specific property
of Aβ1-40 that is independent of molecular weight, which we investigated in the present
experiments.
Rather than exploring these more nonspecific mechanisms, we evaluated whether
fibronectin was a novel ECM receptor for CSF Aβ1-40, which could explain the unique
pattern of deposition that we observed in the basement membrane. Increased fibronectin may
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positively charge the basement membrane,265 which could contribute to selective binding of
negatively charged CSF proteins, such as Aβ40 peptide (pI = 5.17). Under normal conditions,
the basement membrane retains a negative charge due to the high glycosaminoglycan
content.241 This protective effect may be lost following injury due to increases in positively
charged proteins, including fibronectin, although this may be balanced in some regions with
increases in HSPG content, although this would need to be verified by more specific staining.
Due to its charge, numerous potential binding sites and its central role in the assembly
of the basement membrane, increases in fibronectin may selectively mediate the deposition
of CSF Aβ1-40 by direct binding. Previous work has shown that plasma fibronectin binds
aggregated amyloid proteins via the Type 1 domain, and colocalizes with amyloid plaques in
human AD brain sections.217 I newly found that fibronectin bound soluble Aβ1-40 in vitro
with high affinity, and that these conjugates deposited more readily within the murine
basement membrane than free Aβ1-40. This suggested an additional binding partner, which Ι
identified as integrin-α5, which strongly colocalized with the distribution of Aβ1-40 in all
conditions. Overall, these data indicate that fibronectin binds soluble Aβ1-40, which then
becomes sequestered in the basement membrane by binding to integrin-α5. These
interactions most likely occur via Type I and Type III fibronectin domains, respectively.
However, more work with specific blocking antibodies or fibronectin mutants are required to
confirm the specific amino acid residues that are involved in this process.
This work clearly establishes the role of fibronectin and integrin-α5 in contributing to
the initial phases of post-stroke CSF Aβ1-40 deposition via direct binding to the Aβ1-40
peptide, especially in aged animals. While other factors such as increased cellularity, dead
space and viscosity generally impair the bulk flow of solutes deep into the brain, within the
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superficial layers of cortex, I found that even low levels of bulk flow supported abnormal
Aβ1-40 deposition within peri-infarct vessels.
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CHAPTER 5
TGF-β Stimulates A2 Astrocytes to Remodel the Basement Membrane
and Impair the Perivascular Flow of CSF After Stroke

5.1: Introduction
5.1.1: Overview.
The results outlined in the preceding chapters demonstrate that aging and stroke
simultaneously impair the bulk flow of CSF and induce the perivascular deposition of CSFderived Aβ1-40. They further indicate that fibronectin/integrin-α5 complexes contribute to
this phenomenon by sequestering soluble CSF Aβ1-40 within the basement membrane, and
that they may also act as a physical barrier to perivascular CSF flow. Importantly, these
complexes could be expressed by perivascular astrocytes, providing a link between reactive
astrogliosis, abnormal AQP4 expression and Aβ1-40 deposition. However, it is not known
how stroke and TGF-β alters the phenotype of perivascular astrocytes, or whether these
ubiquitous cells are the major source of fibronectin and integrin-α5 expression after stroke.

5.1.2: Significance.
Astrocytes are the most common glial cell in the brain,266 and are in direct
communication with neurons,267 oligodendrocytes,268 microglia240 and blood vessels.91 In
addition to maintaining homeostasis under normal conditions,269 astrocytes possess a preprogrammed response that becomes activated with neuroinflammatory insults,240 including
brain injuries such as stroke, termed ‘reactive astrogliosis.’239 When exposed to noxious
stimuli, astrocytes upregulate a set of ‘pan-reactive’ genes, including increased expression of
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intermediate filaments such as GFAP and vimentin,239 which allow the astrocytes to orient
towards the site of inflammation, hypertrophy and form a glial scar to contain the source of
the stimulus.270 These responses may become dysregulated with aging, necessitating the use
of aged animal models to develop therapies that reflect the average human stroke patient.
Exciting new research suggests that astrocytes can tune their responses to the specific
type of injury, generally falling into two broad polarization states, termed ‘A1’ and ‘A2’.239
The so-called ‘A1’ astrocytes are stimulated via microglial secretion of pro-inflammatory
cytokines, including interleukin-1β (IL-1β), interleukin-6 (IL-6) and tumor necrosis factor-α
(TNF-α), which induce a set of genes that impairs their ability to regulate synaptic function,
inhibits AQP4 polarization to astrocytic endfeet, alters their production of ECM products,
and causes the secretion of as-yet undiscovered products that cause direct neurotoxicity.240
In addition to these acute responses, baseline A1 activation also increases over the course of
normal aging, and could further impact the responses of the aged brain to acute
neuroinflammation.271
Surprisingly, following middle cerebral artery occluision (MCAO) in young animals,
astrocytes instead take on an ‘A2’ phenotype,239 but comparatively little is known about their
functionality or regulation. Unlike A1 astrocytes, A2 astrocytes could be stimulated by pure
hypoxia, or require co-stimulation with other cytokines, such as TGF-β, to effectively make
this transition to an A2 phenotype. Furthermore, while it is tempting to ascribe a ‘beneficial’
role for A2 astrocytes in brain injury, there is no definitive evidence to support this notion.
As such, the functionality of the A2 astrocyte still needs to be elucidated by more
mechanistic studies. Even if A2 astrocytes play a beneficial role in young animals, these
responses may also change in the aged brain, which alters the extracellular microenvironent
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in numerous ways, including a predisposition to increased TGF-β signaling and Aβ
pathology. Overall, more research is needed to better understand how A2 astrocytes shape
their responses to ischemia, and whether this changes with aging.
TGF-β has been shown to reverse the activation of A1 astrocytes,240 returning them to
a more undifferentiated, ‘pan-reactive’ state. However, TGF-β signaling may play a different
role in ischemia-activated A2 astrocytes. Previous work indicates that TGF-β levels are
elevated in mouse models of CAA,218 and that overexpression of TGF-β in wild-type mice
leads to reactive astrogliosis, fibronectin expression and microvascular damage.219,220
Previous work in young animals has shown that knockout of astrocytic TGF-β signaling has
been shown to reduce astrocyte activation and inhibit the formation of a GFAP+ glial scar
after stroke, but this was associated with worse functional recovery.229 This suggests that A2
astrocytes may respond differently to TGF-β than their A1 counterparts, instead being
stimulated by TGF-β, rather than inhibited. This responsivity to TGF-β may also differ in
aging, as they shift to a more A1 phenotype at baseline.271 It is not known how TGF-β
antagonism affects astrocyte activation or functional recovery in the aged animals with
stroke, who may be more sensitive to its negative, pro-fibrotic effects.223,233
Following stroke, aging could alter the specific levels of different TGF-β isoforms, or
shift the balance of downstream signaling pathways, such as the canonical Smad signaling
cascade.221 While previous work has focused on post-stroke Smad2 activation by
phosphorylation,223 Smad3 is actually the major Smad isoform that is involved in modulating
protein expression via direct binding to DNA.272 Phosphorylated Smad3 levels have been
previously shown to disproportionately increase with fibrotic diseases in aged animals,
including pulmonary fibrosis273 and skeletal muscle degeneration.274 Furthermore, Smad3
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knockout has been shown to reduce renal and cardivascular fibrosis, and improve function, in
a mouse model of renovascular hypertension.275 Similar results were found in a mouse
model of hepatic fibrosis, with Smad3 knockouts exhibiting reduced fibrosis after liver
injury.276 In the brain, Smad3 induces APP expression by astrocytes, due to binding to the
zinc finger nuclear factor, CTCF.277 Furthermore, inhibiting Smad2/3 activation in innate
immune cells prevented the formation of amyloid pathology in Tg2576 mice, an animal
model of Alzheimer’s disease.278 While much of this data indicates that TGF-β-Smad3
signaling is a major driver of fibrosis in age-related diseases, it is not known how this
pathway impacts the function of perivascular astrocytes in aging or stroke, and whether this
is specifically associated with altered AQP4 expression and basement membrane fibrosis. As
we described in the preceding chapter, these changes in the perivascular niche may sensitize
the brain to the development of CAA by reducing perivascular CSF flow and increasing the
affinity of the basement membrane for CSF Aβ1-40.
Overall, the role of TGF-β during brain injury remains controversial, and the few
studies performed in aged animals suggest a detrimental effect of astrocytic TGF-β signaling.
Astrocytic endfeet form the outer wall of the PVS, and regulate the composition of the outer
basement membrane, which is involved early in the pathogenesis of CAA.181,196
Furthermore, reactive astrocytes are associated with impaired CSF flow during normal
aging,235 multiple microinfarction,236,237 traumatic brain injury235 and Alzheimer’s
disease.209,238 However, the relationship between TGF-β, perivascular astrocytes and
perivascular CSF flow is not well understood. Additionally, dysregulated TGF-β signaling,
which may occur after stroke in the aged brain,223 could further impact A2 responses to
ischemic injury and induce the abnormal production of ECM proteins, such as
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fibronectin/integrin-α5 complexes. Therefore, I hypothesize that TGF-β signaling in aging
stimulates A2 astrocytes to further impair AQP4-mediated water uptake and increase
basement membrane fibrosis. I further hypothesize that inhibiting TGF-β signaling will
improve perivascular CSF flow and reduce CSF Aβ1-40 deposition in aged mice with
DMCAO.

5.1.3: Experimental design.
Our first aim was to fully evaluate the molecular and cellular mediators underlying
basement membrane remodeling and alterations in CSF flow after stroke. Therefore, we first
hypothesized that aging worsens post-stroke reactive gliosis due to altered TGF-β signaling.
We further hypothesized that TGF-β activates A2 astrocytes to secrete fibronectin and
downregulate AQP4 expression, two major factors that impact perivascular CSF flow. To
test this hypothesis, we first performed DMCAO and examined GFAP, vimentin, AQP4,
Smad2/3 phosphorylation and TGF-β levels at 7 DPI. Then, we cultured primary cortical
astrocytes from both P1 wild-type pups, and examined how oxygen glucose deprivation
(OGD), an in vitro model of ischemia,257 differentially impacts activation and phenotype by
gene microarray, western blot and immunocytochemistry (ICC). Next, we examined whether
TGF-β and Aβ1-40 co-stimulation induced changes in gene/protein expression by the same
methods, and additionally examined how they affected in vitro FITC-Aβ1-40 deposition and
3

H2O uptake. Finally, we verified our results in vivo and measured whether intracisternal

TGF-β injection increased perivascular gliosis, fibronectin expression and reduced the bulk
flow of CSF (measured by intracisternal injection of 3H2O and 14C-Inulin).
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We next hypothesized that TGF-β signaling to astrocytes is the major driver of
basement membrane fibrosis and reductions in CSF flow after stroke. To test this hypothesis
in vivo, we first performed DMCAO in young and aged wild-type mice, and measured
astrocyte reactivity and TGF-β expression after stroke. To explore the potential translational
relevance of global TGF-β inhibition, we performed DMCAO in aged mice and treated them
with a continuous peripheral infusion of a TGF-βR1/R2 antagonist (GW788388 Hydrate),
then measured the impact of chronic treatment on histology, physiology and functional
outcomes.
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5.2: Methods
5.2.1: Animals.
All assays were performed using tissues and cells derived from Mus musculus
(C57/Bl6). For aging studies, young (3 month-old, Charles River) and aged (20 month-old,
National Institute of Aging) wild-type male mice were obtained and housed simultaneously
within UT Health for at least 2 weeks prior to beginning any experiments. In all cases, mice
were fed standard dry chow ad libitum, and kept on a 12-hour light-dark cycle. Additionally,
mice were examined regularly by the veterinary staff, as well as trained members of the lab
for any signs of illness following DMCAO, or gross pathology following sacrifice. All
protocols were approved by the UTHealth IACUC and carried out in an AAALAC-approved
facility. Finally, animals were randomized to experimental conditions, and investigators
were blinded to treatment.

5.2.2: Experimental stroke model.
Permanent DMCAO was performed as described in Chapter 4. Briefly, mice were
anesthetized with isoflurane, the dorsolateral cranium was incised and a burr hole was drilled
to expose the MCA. Following brief MCA cauterization to induce ischemia, the burr hole
was closed with dental cement, and the incision sutured. Sham surgeries were performed
without cauterization. All surgeries were performed under aseptic conditions, and mice were
periodically monitored for signs of pain, infection or weight loss following the procedure.

	
  

102

5.2.3: Animal sacrifice.
Mice were deeply anesthetized with Avertin (250 mg/kg), then the ventral abdomen
was incised and the ribcage was reflected to expose the heart muscle. An 18-gauge butterfly
needle was then placed into the left ventricle, and the right atrium opened with a small
incision. Mice were perfused with ice-cold PBS supplemented with 0.2% heparin using an
automated pump set to a rate of 10 mL/min, until draining perfusates became clear. For
studies requiring fresh tissue, brains were then extracted, cortices dissected from underlying
structures and then snap-frozen on dry ice for future assays. For studies requiring fixed
tissue, mice were first perfused with ice-cold 4% PFA for 5 minutes, and brains were then
extracted and post-fixed in 4% PFA at room temperature for 24 hours, then dehydrated/stored
in 30% sucrose at 4°C prior to sectioning.

5.2.4. Immunohistochemistry.
Fixed brain sections (24 µm thickness) were mounted onto slides, then washed for 3 x
5 minutes in wash buffer (Tris Buffered Saline + 0.1% Tween). Following this, heatmediated antigen retrieval was performed in 100 mM Sodium Citrate buffer + 0.1% Tween at
95°C for 20 minutes in a vegetable steamer. Slides were washed 3 x 5 minutes, then
incubated for 2 hours in blocking buffer (wash buffer supplemented with 0.5% Triton-X, 1%
BSA and 5% normal goat serum) for 2 hours. Then, slides were incubated in blocking buffer
with anti-GFAP-Cy3 (Mouse, 1:1000, Millipore Sigma, cat. C9205), Lycopersicon
esculentum lectin (1:100, Vector Laboratories, cat. DL-1177), anti-AQP4 (Rabbit, 1:5000,
Millipore Sigma, cat. HPA014784), anti-integrin-α5 (Rabbit, 1:100, abcam, cat. EPR7854) or
anti-fibronectin (Rabbit, 1:100, abcam, cat. ab2413) antibodies. Then, slides were washed 3
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x 5 minutes, then incubated with secondary antibodies in blocking buffer (anti-Rabbit (Goat,
abcam, Alexa-Fluor, 1:500, λ = 488, 594 or 647 nm). Following a final 3 x 5 minute
washing step, slides were submerged in Tris-Buffered Saline, then cover-slipped with
Vectashield containing DAPI (Vector Laboratories, cat. H-1200).

5.2.5: Protein isolation, SDS-PAGE and western blotting.
The right cortex was thawed on ice and manually homogenized in buffer containing
1% NP-40, 1 mM PMSF, cOmplete (Roche) and PhosSTOP (Roche). Following sonication
and centrifugation, the supernatant was removed and diluted to 4 mg/mL in 4x Laemmli
Sample Buffer (Bio-Rad, cat. 161-0737) supplemented with 4% β-mercaptoethanol, then
heated to 95°C for 5 minutes. Following sample preparation, 10 µL (40 µg) of each lysate
was run on a 4-15% Criterion TGX 26-well gels (Bio-Rad, cat. 5671085) at 120V for 60
minutes. Protein bands were subsequently transferred to a PVDF membrane, blocked in 5%
BSA or non-fat dry milk and probed with anti-fibronectin (Rabbit, 1:1000, abcam, cat.
ab2413), anti-α5 Integrin (Rabbit, 1:1000, abcam, cat. EPR7854), anti-Vimentin (Rb,
1:1000, abcam, cat. ab9257), anti-GFAP (Rabbit, 1:500, Cell Signaling, cat. 12389S), antipSmad2/3 (Rabbit, 1:500, Cell Signaling, cat. 8828S), anti-Smad2/3 (Rabbit, 1:500, Cell
Signaling, cat. 8685S), anti-β-actin (Mouse/HRP conjugated, 1:50,000, Sigma, cat. A3854)
or anti-vinculin antibody (Rabbit, 1:10,000, abcam, cat. EPR8185). Blots were then probed
with HRP-conjugated goat anti-rabbit secondary antibody (1:10,000, Vector Laboratories,
cat. PI-1000) and imaged using a Bio-Rad ChemiDoc Imager.
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5.2.6: Multiplex assays.
The absolute level of TGF-β1 was quantified using a Bio-Plex Pro TGF-β 3-Plex
Assay (Bio-Rad, cat. 171W4001M). Briefly, cortical lysates were diluted to 8 mg/mL in
NP40 buffer, then underwent acid-mediated antigen retrieval and were further diluted in
dH2O to a final concentration of 1 mg/mL, and supplemented with 0.5% BSA. Plates were
loaded and incubations/washes were performed according to the manufacturer’s instructions.
Following this, plates were read with the Luminex-based Bio-Plex 200 (Bio-Rad) using the
manufacturer’s protocol, and unknown values interpolated with the Bio-Plex Manager
Software (Bio-Rad).

5.2.7: Cell culture techniques
•

Harvesting of primary cortical astrocytes. Mouse pups (P1) were anesthetized on ice,
cleaned with 70% ethanol, and decapitated. Then, under a laminar flow hood, brains
were extracted from the cranium with blunt forceps and placed in sterile Hank’s
Balanced Salt Solution (HBSS, Ca2+/Mg2+-free) in a sterile 3 cm petri dish under a
dissecting microscope. The meninges were then removed and the cortex was
separated from the underlying brain structures with sharp forceps. Isolated cortices
were then placed in fresh, sterile, ice-cold HBSS (Ca2+/Mg2+-free) prior to digestion.
Once all cortices were harvested, the tissue was placed in enzymatic digestion buffer
(MACS Neural Dissociation Kit [~400 µL/brain]), manually disrupted by passing
through a P200 pipet tip 15-20 times, and then digested for 30 minutes at 37°C.
Digests were visually inspected for any remaining clumps, and passed through a P200
pipet tip an additional 15-20 times until a grossly homogenous solution was obtained.
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The enzymes were then quenched via the addition of 600 µL of HBSS (with
Ca2+/Mg2+) per brain, and the total mixture was then centrifuged at 600 x g for 10
minutes at room temperature. Cells were washed with 1 mL HBSS, centrifuged and
then resuspended in 1 mL cell culture media (Dulbecco’s modified eagle medium
[DMEM], 10% Fetal Bovine Serum [FBS], 1% Penicillin-Streptomycin) per brain.
Cells were then stained with Trypan Blue and counted using the Countess II
Automated Cell Counter (Thermo Fisher). Finally, cells were then diluted and plated
on Poly-D-Lysine-coated 12-well plates or glass cover slips at a density of ~2 x 105
live cells/well.
•

Maintenance and purification of primary astrocytes. At 1 day in vitro (1 DIV), the
media was changed to remove dead cells and other debris, then replaced once weekly
until the completion of experiments. Cells were examined periodically to monitor
growth and check for signs of bacterial or fungal contamination. Following
confluence of the astrocyte monolayer, the remaining microglia were then depleted at
14 DIV by exposure to a 50 mM solution of leucine methyl ester (pH = 7.4) for 2
hours, as previously described.279 To further increase the efficacy of the depletion,
plates were then shaken at 200 revolutions per minute (RPM) for 4 hours at 37°C, and
the media exchanged. The following day, the media was changed again to remove
any floating (dead) microglia, and the astrocyte monolayer was visually inspected
under polarized light to confirm successful microglial depletion (fewer than 5% of
visible cells by area).
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•

Oxygen-glucose deprivation and peptide stimulation. Oxygen-glucose deprivation
(OGD) and peptide stimulation experiments were carried out at 19 – 21 DIV in a
balanced salt solution (BSS) containing 125 mM NaCl, 5 mM KCl, 1.2 mM
NaH2PO4, 26 mM NaHCO3, 1.8 mM CaCl2, 0.9 mM MgCl2, 10 mM 4-(2hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), supplemented with 10 mM
glucose for normoxic (NO) controls. Cultures were washed with NO or OGD media
3 times prior to the experiment to remove any serum or antibiotics present in the
normal culture media. Recombinant human TGF-β1 (Peprotech) and Aβ1-40
(Anaspec) was reconstituted in BSS, then diluted to a working concentration of 3
ng/mL and 10µM, respectively. Immediately prior to OGD, media was equilibrated
with 5% CO2 balanced with nitrogen. Following the addition of equilibrated media,
cells were placed in a warmed hypoxic chamber and OGD performed for 6 hours.
Then, cells were re-oxygenated and either placed on ice and immediately harvested
(acute studies), or culture media was supplemented with 10 mM glucose and cells
were allowed to survive for 18 hours at 37°C (chronic studies).

•

Isolation of protein from primary cells. Cells were lysed in 200 µL
radioimmunoprecipitation assay buffer (RIPA) buffer (Sigma) supplemented with 1
mM PMSF (Sigma), cOmplete (Roche) and Phos-Stop (Roche). Cells were manually
disrupted with a P200 pipet tip, then sonicated on ice for 10 seconds. Lysates were
then centrifuged at 18,000 x g for 20 minutes at 4°C. Finally, supernatants were
removed, aliquoted and stored at -80°C prior to further assays.
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•

Astrocytic 3H2O uptake studies. Primary astrocytes were washed 3 x 5 minutes in
BSS with glucose, then exposed to 1 x 106 CPM of 3H2O at 37°C for 30 minutes at
room temperature. Exposing empty wells to 3H2O controlled for background
radioactivity and nonspecific binding of 3H2O to the culture vessel. Then, cells were
rapidly washed with fresh BSS and immediately lysed in Solvable (see Liquid
scintillation counting methods).

•

Astrocytic Aβ1-40 uptake studies. Coverslips containing live cells were incubated in
NO/OGD culture media supplemented with 2 µM FITC-Aβ1-40 or PBS control at
37°C for 30 minutes. Following this, coverslips were washed 3 times with PBS, then
fixed with 4% PFA for 10 minutes. Fixed coverslips were stored at 4°C in PBS prior
to ICC and imaging studies.

•

Immunocytochemistry. Coverslips were first washed with wash buffer (50 mM TrisHCl buffer [pH = 7.8]) 3 x 5 minutes. Then, heat-mediated antigen retrieval was
performed in 100 mM Sodium Citrate buffer + 0.1% Tween at 95°C for 5 minutes in
a microwave oven (10% power). After cooling to room temperature, coverslips were
again washed 3 x 5 minutes in wash buffer, then blocked with triton-carrageenanTBS (TCT) solution (1% Carrageenan, 0.5% Triton-X) for 30 minutes at room
temperature. Next, coverslips were incubated overnight at 4°C with primary
antibodies (GFAP, 1/1000; AQP4, 1/500; Fibronectin, 1/500; and/or Integrin-α5,
1/500). The following day, coverslips were washed 3 x 5 minutes with detergent
wash buffer (50 mM Tris-HCl buffer + 0.1% Triton-X [pH = 7.8]), then incubated
with anti-Rabbit secondary antibodies (1/1000) in TCT for 1 hour at room
temperature. After washing for 3 x 5 minutes with detergent wash buffer, coverslips
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were then submerged in regular wash buffer, then dipped in dH2O and mounted with
Vectashield + DAPI (Vector Laboratories), then sealed with nail polish. Slides were
allowed to cure for 3 days at 4°C prior to imaging. To control for potential
background fluorescence, secondary controls were exposed to identical conditions,
except for incubation with the secondary antibody.
•

Isolation of RNA from primary cells. RNA was harvested and purified using the
RNEasy Mini Kit (Qiagen) according to the manufacturer’s instructions. Briefly,
cells were directly lysed by immersion in lysis buffer supplemented with 1% βmercaptoethanol. Then, lysates were transferred to eppendorf tubes and thoroughly
vortexed at high speed to ensure complete lysis of cells. Next, ethanol was added to a
concentration of 35% and the mixture transferred to the RNEasy spin column.
Following DNAse treatment and repeated washes, RNA was then eluted into RNAse
free water, then stored at -80°C prior to use.

5.2.8: Synthesis of complementary DNA.
Complementary DNA (cDNA) was generated using the iScript cDNA Synthesis Kit
(Bio-Rad) according to the manufacturer’s instructions. Briefly, in each sample, messenger
RNA (mRNA) quality and content was estimated by measuring absorbance (260/280 nm)
with the Nanodrop 2000 (Thermo Fisher), and then concentrations were normalized by
dilution with RNAse-free dH2O. Then, 25 µg of RNA was loaded into the cDNA synthesis
reaction containing 4 µL of RT supermix. These mixtures were then incubated in a thermal
cycler (Bio-Rad, CFX96 Touch) for 5 minutes at 25°C (priming step), then 20 minutes at
42°C (reverse transcription step), then 5 minutes at 85°C (RT inactivation step), and finally
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cooling to 4°C. Following this, the newly synthesized cDNA was then transferred to a fresh
eppendorf tube and stored at -80°C prior to performing qPCR assays.

5.2.9: qPCR measurement of gene expression.
Gene expression was measured using custom PrimePCR Microarrays (Bio-Rad). To
carry out each assay, cDNA samples were diluted 1:1 with dH2O, then 19 µL of diluted
cDNA was mixed with 331 µL of dH2O and 350 µL of SYBR green (Bio-Rad) to a final
volume of 700 µL. Then, 10 µL of this mixture was loaded into wells pre-loaded with
primers (Table 6-1), a genomic DNA control, two RNA quality controls, a no reverse
transcriptase control or a PCR positive control. Then, reactions were incubated in a thermal
cycler (Bio-Rad CFX384 Touch), and gene expression measured over 39 cyclic amplification
steps, according to the manufacturer’s instructions.
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Symbol
Agrn
Amigo2
App
Aspg
B3gnt5
Ccl11
Cd109
Cd14
Cd44
Clcf1
Col16a1
Cp
Cxcl10
Cxcl13
Cxcl16
Emp1
Fbln5
Fkbp5
Fn1
Gapdh
Gbp2
Gfap
Ggta1
H2-D1
H2-T23
Hsbp1
Hspg2
Iigp1
Il6
Il10
Itga5
Itgb1
Lcn2
Osmr
Psmb8
Ptgs2
Ptx3
S1pr3
S100a10
Sdc2
Serpina3n
Serping1
Slc10a6
Sphk1
Spp1
Srgn
Steap4
Tbp1
Tgfb1
Tgfb2
Tgfb3
Tgfbr1
Tgm1
Thbs1
Timp1
Tm4sf1
Tnf
Uggt1
Vim

	
  

Gene Information
Gene Name
agrin
adhesion molecule with Ig like domain 2
amyloid beta (A4) precursor protein
asparaginase homolog (S. cerevisiae)
beta-1,3-N-acetylglucosaminyltransferase 5
chemokine (C-C motif) ligand 11
CD109 antigen
CD14 antigen
CD44 antigen
cardiotrophin-like cytokine factor 1
collagen, type XVI, alpha 1
ceruloplasmin
chemokine (C-X-C motif) ligand 10
chemokine (C-X-C motif) ligand 13
chemokine (C-X-C motif) ligand 16
epithelial membrane protein 1
fibulin 5
FK506 binding protein 5
fibronectin 1
glyceraldehyde-3-phosphate dehydrogenase
guanylate binding protein 2
glial fibrillary acidic protein
glycoprotein galactosyltransferase alpha 1, 3
histocompatibility 2, D region locus 1
histocompatibility 2, T region locus 23
heat shock protein 1
perlecan (heparan sulfate proteoglycan 2)
interferon inducible GTPase 1
interleukin 6
interleukin 10
integrin alpha 5 (fibronectin receptor alpha)
integrin beta 1 (fibronectin receptor beta)
lipocalin 2
oncostatin M receptor
proteasome subunit, beta type 8
prostaglandin-endoperoxide synthase 2
pentraxin related gene
sphingosine-1-phosphate receptor 3
S100 calcium binding protein A10 (calpactin)
syndecan 2
serine peptidase inhibitor, clade A, member 3N
serine peptidase inhibitor, clade G, member 1
solute carrier family 10, member 6
sphingosine kinase 1
secreted phosphoprotein 1
serglycin
STEAP family member 4
TATA box binding protein
transforming growth factor, beta 1
transforming growth factor, beta 2
transforming growth factor, beta 3
transforming growth factor, beta receptor I
transglutaminase 1, K polypeptide
thrombospondin 1
tissue inhibitor of metalloproteinase 1
transmembrane 4 superfamily member 1
tumor necrosis factor
UDP-glucose glycoprotein glucosyltransferase 1
vimentin
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Assay Information
Assay ID
Length
Design
qMmuCID0006603
70
Intronic
qMmuCED0049592
99
Exonic
qMmuCID0017777
88
Intron-spanning
qMmuCID0027304
161
Intron-spanning
qMmuCED0039654
120
Exonic
qMmuCED0044849
83
Exonic
qMmuCED0049647
74
Exonic
qMmuCED0049648
99
Exonic
qMmuCED0061009
86
Exonic
qMmuCED0040924
94
Exonic
qMmuCID0024725
167
Intron-spanning
qMmuCED0045372
89
Exonic
qMmuCED0049500
84
Exonic
qMmuCID0006355
118
Intron-spanning
qMmuCED0044879
96
Exonic
qMmuCED0038081
115
Exonic
qMmuCED0044306
77
Exonic
qMmuCED0046340
84
Exonic
qMmuCED0045687
61
Exonic
qMmuCED0027497
75
Exonic
qMmuCED0048024
74
Exonic
qMmuCID0020163
107
Intron-spanning
qMmuCID0017837
108
Intron-spanning
qMmuCED0041320
60
Exonic
qMmuCED0040619
100
Exonic
qMmuCED0038398
88
Exonic
qMmuCID0021282
119
Intron-spanning
qMmuCED0038266
77
Exonic
qMmuCED0045760
70
Exonic
qMmuCED0044967
84
Exonic
qMmuCID0015586
103
Intron-spanning
qMmuCED0046395
89
Exonic
qMmuCED0045799
64
Exonic
qMmuCID0005690
82
Intron-spanning
qMmuCED0045963
114
Exonic
qMmuCED0047314
107
Exonic
qMmuCED0026777
105
Exonic
qMmuCID0020240
190
Intron-spanning
qMmuCED0049492
119
Exonic
qMmuCED0046013
97
Exonic
qMmuCED0044644
90
Exonic
qMmuCED0060967
107
Exonic
qMmuCID0027010
141
Intron-spanning
qMmuCED0040475
61
Exonic
qMmuCED0061675
93
Exonic
qMmuCID0009102
143
Intron-spanning
qMmuCID0017408
119
Intron-spanning
qMmuCID0040542
102
Intron-spanning
qMmuCED0044726
116
Exonic
qMmuCID0024408
108
Intron-spanning
qMmuCED0045203
61
Exonic
qMmuCID0026554
80
Intron-spanning
qMmuCID0022777
169
Intron-spanning
qMmuCED0048851
105
Exonic
qMmuCED0044729
92
Exonic
qMmuCED0047458
113
Exonic
qMmuCED0004141
119
Exonic
qMmuCID0005905
110
Intron-spanning
qMmuCED0046651
60
Exonic

Table 5-1. PCR assay design. Bio-Rad PrimePCR assays were selected and custom 384well plates created to independently measure the expression of 54 genes.
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5.2.10: Intracisternal injection protocols
•

TGF-β injections. As described in Chapter 3, aCSF containing Na+ (150 mM),
HCO3 (24.1 mM), K+ (3 mM), Ca2+ (1.4 mM), P (1.0 mM) and Mg (0.8 mM) was
prepared in sterile Ultrapure Water. Then, recombinant human TGF-β1 was
reconstituted in aCSF at a concentration of 50 ng/µL and stored at -20°C prior to
experiments. To perform the injection, mice were anesthetized with an
intraperitoneal injection of Ketamine (120 mg/kg) and Xylazine (10 mg/kg), then
placed in a stereotaxic frame. Following exposure of the dorsal neck musculature, the
needle was inserted into the cisterna magna.125 Then, TGF-β1 or vehicle control was
infused into the cisterna magna at a rate of 2 µL/min over 5 minutes, after which mice
were transferred to a warmed cage and allowed to survive for 24 hours prior to
sacrifice.

•

Radiotracer injections. For studies involving radioactive tracers, stock solutions of
14

C-Inulin (Perkin Elmer, ~2 x 105 CPM/uL) and 3H2O (Perkin Elmer, ~2 x 106

CPM/uL) were dissolved in aCSF and radioactivity normalized via liquid scintillation
counting. Then, stock solutions were combined to a final concentration of 1 x 105
CPM/uL 14C-Inulin and 1 x 106 CPM/uL 3H2O in aCSF. Tracer mixtures were kept
on ice for up to 4 hours, then vortexed for 5 seconds immediately prior to infusion.
Tracer was infused into the cisterna magna at a rate of 2 µL/min over 5 minutes, after
which mice were transferred to a warmed cage. Finally, 30 minutes after beginning
the injection, mice were sacrificed by Avertin overdose (250 mg/kg). For radiouptake
measurement, fresh brains were extracted and cortex isolated, then snap frozen and
stored at -80°C for later processing.
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•

Fluorescent tracer injections. For studies involving fluorescent tracers, lyophilized
FITC-Aβ1-40 (100 µM stock, Anaspec) and lysine-fixable 3 kD TR dextran (TR-d3,
3,000 MW, 4% stock, Thermo Fisher) were subsequently dissolved in aCSF, then
combined to a final solution of 10 µM FITC-Aβ1-40 and 2% TR-d3. In all cases, tracer
mixtures were kept on ice for up to 4 hours, then vortexed for 5 seconds immediately
prior to infusion. Tracer was infused into the cisterna magna at a rate of 2 µL/min
over 5 minutes, after which mice were transferred to a warmed cage. Finally, 30
minutes after beginning the injection, mice were sacrificed by Avertin overdose (250
mg/kg). Then, transcardial perfusion with 0.2% heparin-PBS, and 4% PFA was
performed, and brain tissue was then removed and stored in 4% PFA for subsequent
processing.

5.2.11: Alzet pump implantation.
To administer the equivalent of ~10 mg/kg/day dosage of TGF-βR1/R2 antagonist
(GW788388 Hydrate), 10 mg of lyophilized GW788388 Hydrate was reconstituted in a
solution of 50% DMSO, 12.5% ethanol and 37.5% water, then loaded into implantable Alzet
mini osmotic pumps according to the manufacturer’s instructions. Additional sets of pumps
were loaded with vehicle solution to serve as controls. Then, mice were anesthetized with
isoflurane and the pump implanted subcutaneously over the dorsal back musculature.
Following surgery, mice were examined daily for any signs of infection or excessive weight
loss.
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5.2.11: Liquid scintillation counting.
Samples were thawed on ice, then placed in 5 mL glass vials and dissolved in 1 mL
Solvable (Perkin-Elmer) overnight at 37°C. Then, homogenates were vortexed and mixed
with 4 mL Hionic-Fluor scintillation cocktail (Perkin-Elmer). Following this, β-emissions
were measured using a Tri-Carb LSC (Perkin-Elmer), with 3H2O emissions counted at less
than 20 keV, and 14C-Inulin measured counted between 20 and 150 KeV. Control vials
containing aCSF alone, aCSF + 14C-Inulin and aCSF + 3H2O were used to account for
background radiation, as well as to normalize emission signals from samples for subsequent
analyses.

5.2.12: Fluorescent microscopy and tracer imaging.
Following perfusion, brains were extracted and post-fixed for 24 hours in 4% PFA.
Then, brains were dehydrated in 30% sucrose, frozen to -20°C and sectioned to 24 µm
(IHC/cresyl violet staining) or 100 µm (tracer quantification) sections. Sections were then
mounted onto slides and coverslipped. For experiments involving colocalization with lectin,
sections were first stained with Lycopersicon esculentum (Tomato) lectin (see
Immunohistochemistry). Sections were imaged under fluorescence with a Leica DMi8
microscope at 10X magnification. A blinded investigator imaged the lateral cortex (0.38 mm
anterior to Bregma, 2.5 mm lateral, 1.5 mm deep). Then, 100 µm Z stack images were
obtained, and maximum intensity projections performed with LAS X software. Images were
then quantified in ImageJ (see Data Analysis).
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5.2.13: DigiGait.
The impact of aging, stroke and genetic/pharmacological manipulation on motor
function was assessed using DigiGait (Mouse Specifics) at 6 and 13 DPI in a double-blinded
manner. Mice were first acclimated to the system, and then the speed was gradually
increased to 15 cm/second in young animals, and 10 cm/second in aged animals.
Locomotion was recorded for 60 seconds, and then parameters of gait analyzed with DigiGait
software.

5.2.14: Data Analysis.
•

Quantification of protein expression. Intensity values for each band were measured
using the Bio-Rad ImageAnalyzer software. Then, each intensity value was
normalized by dividing it by the intensity of the loading control (either Vinculin or βactin). Finally, these values were normalized to the mean value of the control group,
plotted and statistically analyzed in Prism.

•

Quantification of gene expression. Cycle threshold (CT) values for every gene of
interest, loading control and quality control were first exported from Bio-Rad CFX
software into Microsoft Excel. Given the large number of samples and genes
involved (~3,840 assays), prior to further analysis, samples of poor quality were
removed (~10%) based on the following pre-defined criteria: (1) presence of genomic
DNA contamination, (2) poor RNA quality, (3) positive no RT control, or (4) loading
control not detected. Then, relative gene expression was estimated by the following
equation: ΔΔCT = (CT1 – CT1/GAPDH) – (CT2 – CT2/GAPDH), where CT1 is expression
of the gene of interest in sample 1, CT2 is the mean expression of the gene of interest
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in the control samples (NO + Vehicle treated), and CTGAPDH is the expression of the
loading control (GAPDH). Since CT values are expressed on a logarithmic scale, to
convert these values to fold-change, we then used the formula Expression = 2-ΔΔCT.
After this last conversion step, fold-change values were imported into Prism, and any
statistical outliers were removed on a gene-by-gene basis based on a positive Grubb’s
test (pre-determined threshold set at p < 0.05). Finally, to generate a heat map of
genes related to astrocyte phenotype, expression values were Z-transformed based on
the sample population mean and standard deviation (SD) for each individual gene.
•

Atrophy quantification. High resolution images of cresyl violet-stained coronal brain
sections (24 µm) were obtained. Then, ventricular volume and hemisphere size were
quantified as previously described.255,256 Tissue atrophy percentage was calculated by
the formula: % tissue loss = 100 - ([total ipsilateral tissue/total contralateral tissue]
× 100).

•

Tracer intensity. Tracer influx was quantified by measuring intensity as a function of
tissue depth using ImageJ. Then, average intensity values were imported into Excel,
and integrated into 50 µm bins. Absolute binned intensity values were then plotted as
raw intensity (A.U.). To reduce experimental variability and further improve the
quality of our data, tracer intensity in the injured hemisphere was then normalized to
intensity in the contralateral hemisphere, and then converted to a percentage value
prior to statistical analysis.

•

Immunohistochemical quantification. IHC images were acquired and quantified in
a double-blinded manner. Based on lectin staining, ROI’s were drawn around 3 periinfarct vessels/image across 3 brain sections for a total of 27 vessels/brain. Threshold
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was held constant between brains, and the area and average pixel intensity of AQP4,
GFAP, fibronectin and integrin-α5 was measured relative to the ROI.
•

Statistics. All statistical analyses were performed using Prism 7. Data are reported as
mean (+/-) SEM with the number of animals/repetitions per group. When only two
groups were compared, Student’s t-test (two-tailed) was used to compare normally
distributed data of equivalent variance, and Welch’s correction was applied when data
were normally distributed, but of unequal variance (denoted in figure legends). When
three groups were compared, one-way ANOVA with Tukey’s test for multiple
comparisons was performed. When four or more groups were compared, two-way
ANOVA with either Tukey’s or Dunnet’s test for multiple comparisons was utilized
(denoted in figure legends). Asterisks indicate statistical significance levels based on
the P-value: *p < 0.05, **p < 0.01, ***p < 0.001.
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5.3: Results
5.3.1: DMCAO produced widespread perivascular reactive astrogliosis that worsened with
aging.
To first characterize how stroke alters perivascular astrocyte phenotypes in vivo, we
performed DMCAO on young (3 month-old) animals and then examined their brains at 7 DPI
by IHC (Fig. 5-1A). We found that DMCAO dramatically increased the expression of
GFAP+ reactive astrocytes in the peri-infarct cortex, striatum and white matter, which was
associated with major increases in lectin-stained glysocylated basement membrane
components throughout vessels within the injured hemisphere (Fig. 5-1A, i. - ii.). We then
performed high magnification 3-dimensional reconstruction of perivascular astrocytes and
found that DMCAO also altered the morphology of glial endfeet, inducing widespread
changes characterized by hypertrophy, increased GFAP expression and reduced AQP4
polarization (Fig. 5A, iii. – viii.).
Then, to assess whether aging also increased perivascular gliosis, we performed
DMCAO in young (3 month) and aged (20 month) old animals, and similarly assessed
astrocyte morphology (Fig. 5-1B). We found that aged animals with stroke exhibited further
increases in GFAP expression within perivascular reactive astrocytes compared to their
younger counterparts (Fig. 5-1B, iv.) Finally, to confirm age-induced changes in reactive
gliosis quantitatively, we then obtained cortical lysates at 7 DPI and assessed the expression
of both GFAP and vimentin, an additional marker of reactive gliosis, by western blot (Fig. 51C, i.). We found that aging (F[1, 19] = 20.96, p < 0.001) and DMCAO (F[1, 19] = 50.75, p
< 0.001) both produced statistically significant increases in cortical GFAP expression, with a
trending interaction effect between aging and DMCAO (Fig. 5-1C, ii., F[1, 19] = 3.51, p =
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0.076). Similarly, we also found that aging (Fig. 5-1C, iii., F[1, 18] = 11.17, p = 0.004) and
DMCAO (F[1, 18] = 68.94, p < 0.001) both increased vimentin expression within the cortex,
with a significant interaction effect (F[1, 18] = 8.85, p = 0.008). Overall, these data indicate
that stroke induces perivascular astrocyte reactivity, which worsens with aging. These
stroke-induced changes are associated with altered basement membrane glycosylation and
impaired AQP4 polarization to astroglial endfeet.
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Figure 5-1. Reactive astrogliosis occurs after DMCAO and is worse in aged animals.

	
  

(A.) (i., ii.) Representative fluorescent mosaic micrographs from aged mice showing
increased levels of lectin and GFAP staining throughout the injured hemisphere after
DMCAO (7 DPI). (iii. – viii.) 3-dimensional reconstruction showing increased GFAP
staining and reduced AQP4 polarization within the perivascular region following DMCAO in
aged animals. (B.) Comparison of cortical GFAP staining outside of the ischemic penumbra
between young and aged mice. White arrows denote high levels of perivascular GFAP
staining in aged mice with DMCAO. (C.) Western blot analysis showed the highest levels of
GFAP and Vimentin expression in aged mice with DMCAO. n = 5 – 8 mice per group. Data
are analyzed by Tukey’s post-hoc test for multiple comparisons. Significance: **p < 0.01,
***p < 0.001. Scale Bar = 50 µm.
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5.3.2. DMCAO differentially induces TGF-β-Smad signaling pathways with aging.
Previous work has shown that stroke induces TGF-β signaling, which may increase
with aging.223 However, there is limited data on how the absolute levels of individual TGF-β
isoforms change after stroke in aged animals, or how downstream Smad phosphorylation is
affected. We found that DMCAO increased TGF-β1 levels at 7 DPI in both age groups (F[1,
18) = 74.05, p < 0.001), with no effect of aging (Fig. 5-2A). However, we observed that
aging differentially affected downstream Smad2/3 phosphorylation by western blot (Fig. 52B). Total levels of phosphorylated Smad2 (phospho-Smad2) increased following DMCAO
(Fig. 5-2C, i., F[1, 19] = 7.88, p = 0.013), with a significant interaction effect between aging
and DMCAO (F[1, 19] = 11.84, p = 0.003). In contrast, total levels of Smad2 significantly
increased with aging (Fig. 5-2C, ii., F[1, 19] = 34.35, p < 0.001), and reduced following
DMCAO in aged, but not young animals (interaction, F[1, 19] = 14.71, p = 0.001). Relative
Smad2 phosphorylation was lower in aged animals (Fig. 5-2C, iii., F[1, 19] = 9.79, p =
0.006), with a trending increase in mice with DMCAO (F[1, 19] = 2.81, p = 0.11) and no
significant interaction effect. In contrast, total levels of phospho-Smad3 increased with aging
(Fig. 5-2D, i., F[1, 19] = 26.63, p < 0.001), with a significant interaction between aging and
DMCAO (F[1, 19) = 16.03, p < 0.001). There was also a weak interaction effect on total
Smad3 levels (Fig. 5-2D, ii., F[1, 19] = 4.41, p = 0.049), and a main effect of age on
increasing Smad3 phosphorylation (Fig. 5-2D, iii., F[1, 19] = 7.06, p = 0.02). Overall, these
data indicate that Smad2 signaling predominates in young animals with DMCAO, while
Smad3 signaling may play a more prominent role in aged animals.
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Figure 5-2. TGF-β signaling is differentially activated by aging and DMCAO. (A.)
Cortical TGF-β1 levels similarly increase after DMCAO in young and aged mice. n = 5 – 8
per group. (B.) Representative western blot images of Smad proteins. (C., D.) Smad2
phosphorylation is higher in young animals, while Smad3 phosphorylation predominates in
aged animals. n = 5 – 7 per group. Data are analyzed by Tukey’s post-hoc test for multiple
comparisons. Significance: *p < 0.05, **p < 0.01, ***p < 0.001.
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5.3.3. Exposure to OGD, TGF-β and Aβ1-40 acutely impact astrocyte polarization, ECM
production and cytokine expression in vitro.
Previous studies have shown that a significant number of reactive astrocytes take on
an ‘A2’ phenotype after stroke in vivo,239 but the relative effects of hypoxia, TGF-β and Aβ140

on the post-stroke induction of A2 astrocytes is not known. Therefore, we evaluated

whether OGD, an in vitro model of ischemic stroke, would stimulate the transcription of A2
genes. We further hypothesized that this transition would be inhibited by co-stimulation with
recombinant TGF-β1 and Aβ1-40 peptides. To test this hypothesis, we generated primary
astrocyte cultures from P1 mouse pups, then subjected the astrocyte monolayer to 6 hours of
OGD in the presence of vehicle, TGF-β1 or Aβ1-40 and collected RNA for qPCR microarray.
As we expected, we found that OGD induced an A2 phenotype, however, this was not
significantly impacted by TGF-β costimulation (Fig. 5-3A; see Table 5-2 for F-values). In
contrast, we found that Aβ1-40 stimulation induced a classical pro-inflammatory A1
phenotype under normoxic conditions, and suppressed the transition to A2 phenotype under
OGD conditions (Fig. 5-3A).
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Figure 5-3. Expression of cellular phenotype and ECM-related genes in primary
astrocytes following acute stimulation. (A.) Heat map showing variation in expression of
genetic markers of astrocyte phenotype following with ischemia and/or co-stimulation.
ddCT values are plotted as Z-scores.. (B.) (i. – viii.) Expression (ddCT) of ECM-related
genes. (ix.) Expression of APP. n = 5 – 8 per group. Heat map data in panel (A) are
analyzed by two-way ANOVA with Dunnet’s test for multiple comparisons to compare ddCT
values of experimental groups against vehicle/NO control. All other expression data in panel
(B) are analyzed by two-way ANOVA with Tukey’s post-hoc test for multiple comparisons.
Significance: *p < 0.05, **p < 0.01, ***p < 0.001.
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Agrn
Amigo2
App
Aspg
B3gnt5
Ccl11
Cd109
Cd14
Cd44
Clcf1
Col16a1
Cp
Cxcl10
Cxcl16
Fbln5
Fkbp5
Fn1
Gbp2
Gfap
Ggta1
H2-D1
H2-T23
Hsbp1
Hspg2
Iigp1
Il10
Il6
Itga5
Itgb1
Lcn2
Osmr
Psmb8
Ptgs2
Ptx3
S100a10
S1pr3
Sdc2
Serpina3n
Serping1
Sphk1
Spp1
Srgn
Steap4
Tgfb1
Tgfb2
Tgfb3
Tgfbr1
Tgm1
Thbs1
Timp1
Tm4sf1
Tnf
Uggt1
Vim

	
  

Interaction
F{DFn, DFd)
P-value
F (2, 47) = 5.8
P=0.005
F (2, 39) = 0.4
P=0.661
F (2, 47) = 3.4
P=0.043
F (2, 35) = 0.7
P=0.501
F (2, 47) = 2.4
P=0.101
F (2, 31) = 3.4
P=0.048
F (2, 47) = 1.3
P=0.281
F (2, 47) = 38
P<0.001
F (2, 47) = 14.1
P<0.001
F (2, 47) = 3.8
P=0.029
F (2, 40) = 4
P=0.026
F (2, 47) = 5.4
P=0.008
F (2, 46) = 90.4
P<0.001
F (2, 45) = 9.7
P<0.001
F (2, 44) = 4.4
F (2, 44) = 1.9

P=0.018
P=0.159

F (2, 44) = 3.6
F (2, 47) = 84.2
F (2, 47) = 0.1
F (2, 47) = 0.3
F (2, 47) = 11.2
F (2, 47) = 23.2
F (2, 47) = 0.2
F (2, 46) = 1.2
F (2, 44) = 118
F (2, 43) = 6.9
F (2, 44) = 5
F (2, 45) = 0.5
F (2, 47) = 0.2
F (2, 46) = 9.5
F (2, 47) = 1.2
F (2, 47) = 33.4
F (2, 43) = 0.3
F (2, 46) = 3.6
F (2, 47) = 1.3
F (2, 46) = 1.5
F (2, 46) = 2.2
F (2, 47) = 0.1
F (2, 46) = 0.27
F (2, 42) = 3.2
F (2, 47) = 0.8
F (2, 46) = 7.5
F (2, 45) = 10.4
F (2, 46) = 6
F (2, 47) = 0.6
F (2, 42) = 2.3
F (2, 45) = 0.6
F (2, 35) = 1.4
F (2, 47) = 4.4
F (2, 45) = 1
F (2, 47) = 0.8
F (2, 40) = 123
F (2, 47) = 1.1
F (2, 47) = 0.6

P=0.037
P<0.001
P=0.939
P=0.714
P<0.001
P<0.001
P=0.858
P=0.312
P<0.001
P=0.003
P=0.011
P=0.585
P=0.861
P<0.001
P=0.312
P<0.001
P=0.749
P=0.034
P=0.285
P=0.224
P=0.128
P=0.91
P=0.768
P=0.053
P=0.467
P=0.002
P<0.001
P=0.005
P=0.57
P=0.115
P=0.57
P=0.255
P=0.017
P=0.372
P=0.443
P<0.001
P=0.343
P=0.5730

S
**
ns
*
ns
ns
*
ns
***
***
*
*
**
***
***
*
ns
*
***
ns
ns
***
***
ns
ns
***
**
*
ns
ns
***
ns
***
ns
*
ns
ns
ns
ns
ns
ns
ns
**
***
**
ns
ns
ns
ns
*
ns
ns
***
ns
ns

Perfusion
F{DFn, DFd)
P-value
F (1, 47) = 25
P<0.001
F (1, 39) = 4.1
P=0.05
F (1, 47) = 3.6
P=0.066
F (1, 35) = 0.1
P=0.706
F (1, 47) = 5.3
P=0.026
F (1, 31) = 0.1
P=0.764
F (1, 47) = 0.4
P=0.506
F (1, 47) = 94.7 P<0.001
F (1, 47) = 26.5 P<0.001
F (1, 47) = 61.2 P<0.001
F (1, 40) = 1.4
P=0.251
F (1, 47) = 1.5
P=0.232
F (1, 46) = 60.7 P<0.001
F (1, 45) = 0.3
P=0.614
F (1, 44) = 0.1
F (1, 44) = 15

P=0.794
P<0.001

F (2, 44) = 2.5
F (1, 47) = 118
F (1, 47) = 20.2
F (1, 47) = 21.2
F (1, 47) = 114
F (1, 47) = 113
F (1, 47) = 0.6
F (1, 46) = 0.5
F (1, 44) = 140
F (1, 43) = 90.8
F (1, 44) = 53.5
F (1, 45) = 28.5
F (1, 47) = 0.01
F (1, 46) = 14.7
F (1, 47) = 50.7
F (1, 47) = 64.5
F (1, 43) = 66.4
F (1, 46) = 3.9
F (1, 47) = 3.7
F (1, 46) = 61.4
F (1, 46) = 3
F (1, 47) = 5.7
F (1, 46) = 27.4
F (1, 42) = 48.7
F (1, 47) = 0.8
F (1, 46) = 3
F (1, 45) = 22.1
F (1, 46) = 35.9
F (1, 47) = 0.6
F (1, 42) = 3.3
F (1, 45) = 3
F (1, 35) = 7.9
F (1, 47) = 59.6
F (1, 45) = 1.7
F (1, 47) = 2.9
F (1, 40) = 131
F (1, 47) = 0.2
F (1, 47) = 6

P=0.092
P<0.001
P<0.001
P<0.001
P<0.001
P<0.001
P=0.44
P=0.486
P<0.001
P<0.001
P<0.001
P<0.001
P=0.918
P<0.001
P<0.001
P<0.001
P<0.001
P=0.055
P=0.06
P<0.001
P=0.09
P=0.021
P<0.001
P<0.001
P=0.366
P=0.089
P<0.001
P<0.001
P=0.435
P=0.077
P=0.09
P=0.008
P<0.001
P=0.201
P=0.094
P<0.001
P=0.665
P=0.018
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S
***
*
ns
ns
*
ns
ns
***
***
***
ns
ns
***
ns
ns
***
ns
***
***
***
***
***
ns
ns
***
***
***
***
ns
***
***
***
***
ns
ns
***
ns
*
***
***
ns
ns
***
***
ns
ns
ns
**
***
ns
ns
***
ns
*

Co-Stimulation
F{DFn, DFd)
P-value
F (2, 47) = 0.7
P=0.498
F (2, 39) = 3
P=0.063
F (2, 47) = 1.3
P=0.281
F (2, 35) = 0.6
P=0.537
F (2, 47) = 2.1
P=0.137
F (2, 31) = 0.3
P=0.744
F (2, 47) = 0.7
P=0.483
F (2, 47) = 32.8
P<0.001
F (2, 47) = 1
P=0.375
F (2, 47) = 3.3
P=0.046
F (2, 40) = 0.7
P=0.509
F (2, 47) = 6.4
P=0.004
F (2, 46) = 101
P<0.001
F (2, 45) = 14.1
P<0.001
F (2, 44) = 5
F (2, 44) = 1.3

P=0.011
P=0.274

F (1, 44) = 2.2
F (2, 47) = 96.6
F (2, 47) = 5.5
F (2, 47) = 1.9
F (2, 47) = 10.7
F (2, 47) = 22.2
F (2, 47) = 23
F (2, 46) = 1.6
F (2, 44) = 128
F (2, 43) = 6.5
F (2, 44) = 23.5
F (2, 45) = 1.9
F (2, 47) = 0.3
F (2, 46) = 14.3
F (2, 47) = 16.2
F (2, 47) = 22.7
F (2, 43) = 0.6
F (2, 46) = 10.6
F (2, 47) = 0.2
F (2, 46) = 5
F (2, 46) = 3.6
F (2, 47) = 0.6
F (2, 46) = 4
F (2, 42) = 3.2
F (2, 47) = 3.8
F (2, 46) = 1.4
F (2, 45) = 12.3
F (2, 46) = 2.5
F (2, 47) = 9.8
F (2, 42) = 2.3
F (2, 45) = 0.2
F (2, 35) = 12
F (2, 47) = 7.9
F (2, 45) = 0.7
F (2, 47) = 3.7
F (2, 40) = 137
F (2, 47) = 0.3
F (2, 47) = 1.6

P=0.145
P<0.001
P=0.007
P=0.16
P<0.001
P<0.001
P<0.001
P=0.205
P<0.001
P=0.004
P<0.001
P=0.162
P=0.767
P<0.001
P<0.001
P<0.001
P=0.573
P<0.001
P=0.835
P=0.011
P=0.036
P=0.536
P=0.024
P=0.049
P=0.03
P=0.251
P<0.0001
P=0.096
P<0.001
P=0.108
P=0.856
P<0.001
P=0.001
P=0.523
P=0.031
P<0.001
P=0.75
P=0.214

S
ns
ns
ns
ns
ns
ns
ns
***
ns
*
ns
**
***
***
*
ns
ns
***
**
ns
***
***
***
ns
***
**
***
ns
ns
***
***
***
ns
***
ns
*
*
ns
*
*
*
ns
***
ns
***
ns
ns
***
**
ns
*
***
ns
ns

Table 5-2. Effects of perfusion, co-stimulation and interaction on gene expression in
primary cultured astrocytes. Tabulation of F-values, degrees of freedom and p-values for
all PCR assays detailed in Fig. 5-3 through Fig. 5-5. n = 5 – 8 per group. Data are analyzed
by two-way ANOVA. Significance: ns, no significance, *p < 0.05, **p < 0.01, ***p < 0.001.
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We next broadly assessed how these stimuli impacted the production of ECM
components by primary astrocytes. To accomplish this, we examined the mRNA levels of
agrin (AGRN), collagen XVI (COL16A1), fibulin-5 (FBLN5), fibronectin (FN1), perlecan
(HSPG2), syndecan-2 (SDC2), integrin-α5 (ITGA5) and integrin-β1 (ITGB1) immediately
following OGD (Fig. 5-3B; Table 5-2). We found that exposure to OGD reduced agrin
expression (p < 0.001) and upregulated integrin-α5 (p = 0.001). Treatment with vehicle,
TGF-β1 or Aβ1-40 differentially impacted fibulin (p = 0.011) and syndecan-2 expression (p =
0.036). Finally, we also observed statistically significant interaction effects between OGD
and co-stimulation on the expression of agrin (p = 0.005), collagen XVI (p = 0.026), fibrillin
(p = 0.018) and fibronectin (p = 0.037). Overall, these data indicate that A2 astrocytes
produce a unique compliment of ECM proteins following ischemia, which is further
modulated by exposure to TGF-β1 or Aβ1-40 in the extracellular milieu during ischemia.
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Figure 5-4. Expression of TGF-β-related genes in primary astrocytes following acute
stimulation. (A. – D.) Expression (ddCT) values of TGF-β signaling genes. n = 5 – 8 per
group. Data are analyzed by two-way ANOVA with Tukey’s post-hoc test for multiple
comparisons. Significance: *p < 0.05, **p < 0.01, ***p < 0.001.
We then examined the impact of OGD and co-stimulation on the expression of TGF-β
signaling components. To assess this, we measured mRNA levels of TGF-β1 (TGFB1),
TGF-β2 (TGFB2), TGF-β3 (TGFB3) and TGF-βR1 (TGFBR1) immediately following OGD
(Fig. 5-4; Table 5-2). We found that OGD exposure reduced the expression of TGF-β1 (p <
0.001) and TGF-β3 (p = 0.038), and concurrently increased the expression of TGF-βR1 (p =
0.02). Treatment with exogenous TGF-β1 or Aβ1-40 increased astrocytic TGF-β1 expression
(p = 0.003), but reduced the expression of TGF-β2 (p < 0.001). Finally, we also observed
statistically significant interaction effects between OGD and treatment on the expression of
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TGF-β1 (p = 0.002). Overall, these data suggest that A2 astrocytes may exhibit increased
sensitivity to TGF-β signaling due to increased expression of TGF-βR1, but this might be
balanced by downregulation of astrocytic production of TGF-β isoforms following
stimulation by OGD, TGF-β or Aβ1-40. However, further studies of downstream Smad
activation are required to address this point.
Finally, we also sought to characterize the impact of OGD and co-stimulation on the
expression of various cytokines related to ischemic stroke and CAA. To assess this, we
measured mRNA levels of C-X-C motif chemokine 10 (CXCL10), C-X-C motif chemokine
16 (CXCL16), IL-6 (IL6), interleukin-10 (IL-10, IL10), osteopontin (SPP1) and TNF-α (TNF)
immediately following OGD (Fig. 5-5; Table 5-2). We found that OGD increased IL-6 (p <
0.001) and IL-10 levels (p < 0.001), reduced TNF-α expression (p < 0.001) and had
differential impacts on CXCL10 (p < 0.001) and CXCL16 (p < 0.001) expression. Treatment
with TGF-β1 or Aβ1-40 increased the expression of IL-6 (p < 0.001), TNF-α (p < 0.001),
CXCL10 (p < 0.001), CXCL16 (p < 0.001), but reduced IL-10 expression (p = 0.003) and
differentially impacted SPP1 expression (p = 0.031). Finally, we also observed a statistically
significant interaction between OGD and treatment on the expression of IL-6 (p < 0.001), IL10 (p = 0.004), TNF-α (p < 0.001), CXCL10 (p < 0.001) and CXCL16 (p < 0.001). Overall,
these data indicate that stimulation with OGD, TGF-β1 and Aβ1-40 all generally upregulated
cytokine expression by reactive astrocytes, with the notable exception of the antiinflammatory cytokine IL-10, which was suppressed by both TGF-β1 and Aβ1-40.
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Figure 5-5. Expression of inflammatory cytokine genes in primary astrocytes following
acute stimulation. (A. – D.) Expression (ddCT) of inflammatory cytokine genes. n = 5 – 8
per group. Data are analyzed by two-way ANOVA with Tukey’s post-hoc test for multiple
comparisons. Significance: *p < 0.05, **p < 0.01, ***p < 0.001.
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5.3.4. Chronic TGF-β exposure modulates astrocytic ECM production, and may ‘prime’
the ECM for the deposition of Aβ1-40.
Next, we sought to determine whether chronic TGF-β stimulation influences ECM
composition and its affinity for Aβ1-40 deposition. Our previous studies, detailed in Chapter
4, found that fibronectin and integrin-α5 form a complex that binds soluble Aβ1-40 within the
basement membrane after stroke. However, neither the cell types nor the upstream signaling
mechanisms by which stroke increases fibronectin/integrin-α5 expression were explored in
those studies. Therefore, we next hypothesized that chronic stimulation with TGF-β would
induce the deposition of exogenous Aβ1-40 due to upregulation of fibronectin and integrin-α5
by astrocytes.
To test this hypothesis, we first treated primary astrocytes with recombinant TGF-β1
peptide for 24 hours, then measured the binding of exogenous Aβ1-40 to the ECM following
incubation in a 2 µM solution of FITC-Aβ1-40 for 30 minutes. We found that TGF-β1
treatment increased the uptake of FITC-Aβ1-40 by the astrocyte monolayer (Fig. 5-6A, i., t[5]
= 5.94, p = 0.002). In contrast with our acute studies of gene expression, examination of
total protein levels by western blot further showed that chronic TGF-β1 treatment
significantly increased the expression of fibronectin (Fig. 5-6A, iii., t[6] = 4.91, p = 0.003),
and there was also a nonsignificant trend for increased integrin-α5 expression with treatment
(Fig. 5-6A, iv., t[3] = 1.74, p = 0.172, t-test with Welch’s correction). Chronic TGF-β1
treatment significantly reduced GFAP expression (Fig. 5-6A, v., t[6] = 3.19, p = 0.011), with
a nonsignificant trend for decreased vimentin expression (Fig. 5-6A, vi., t[6] = 1.14, p =
0.296), indicating reduced expression of ‘pan-reactive’ astrocyte activation markers. To
determine whether increased FITC-Aβ1-40 binding was directly related to the increase in
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ECM protein expression, we then performed ICC and found that FITC-Aβ1-40 binding
colocalized with regions of increased fibronectin (Fig. 5-6B, vehicle [i – iii.], TGF-β1 [vii. –
ix.]) and integrin-α5 expression (Fig. 5-6B, vehicle [iv. – vi.], TGF-β1 [x. – xii.]). Overall,
these results indicate that astrocytes are a source of both fibronectin and integrin-α5
expression, and also show that fibronectin expression is stimulated by TGF-β1 treatment in
vitro. They further confirm that these increases in fibronectin are directly associated with
increased Aβ1-40 binding, although it does not rule out increased endocytosis of FITC-Aβ1-40
as a potential contributor to this phenotype.
Next, to confirm the in vivo relevance of TGF-β1-induced stimulation of fibronectin
expression, we intracisternally injected naive young mice with recombinant TGF-β1, and
then collected the cerebral cortex for western blot and IHC analysis 24 hours later. Similar to
our in vitro studies, we found that TGF-β1 treatment upregulated fibronectin expression (Fig.
5-6C, ii., t[5] = 2.62, p = 0.047). However, TGF-β1 treatment had no impact on GFAP
levels (Fig. 5-6C, ii., t[5] = 0.058, p = 0.956). We further confirmed that our injections
successfully activated TGF-β signaling by examining Smad phosphorylation. We found that
chronic treatment with TGF-β1 increased phospho-Smad2 expression (Fig. 5-6C, iv., t[5] =
4.03, p = 0.01), but did not significantly alter the levels of total Smad2 (Fig. 5-6C, vi., t[5] =
0.64, p = 0.55), producing a relative increase in Smad2 phosphorylation (Fig. 5-6C, vi., t[5] =
3.47, p = 0.018). We verified that these changes occured within perivascular astrocytes by
IHC (Fig. 5-6D), and found that TGF-β1 treatment increased the association of astrocytes
with the vasculature, as well as fibronectin expression. Overall, these results confirm our in
vitro findings that TGF-β stimulates fibronectin expression within the ECM, and further
shows that these changes occur within the basement membrane in vivo.
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Figure 5-6. TGF-β stimulation increases Aβ1-40 binding and fibronectin expression. (A.)
(i.) Quantification of Aβ1-40 binding by primary astrocyte cultures treated with TGF-β. n = 3
per group. (ii.) Representative western blots of primary astrocytes treated with vehicle or
TGF-β. (iii. – vi.) Quantification of protein expression changes by western blot. (B.) ICC
showing colocalization of exogenous FITC-Aβ1-40 with ECM proteins in primary astrocytes.
n = 4 – 5 per group. (C.) (i.) Representative western blots of brain tissue from mice that
received intracisternal injection of vehicle or TGF-β. (ii. – vi.) Quantification of protein
expression changes by western blot. n = 3 – 4 per group. (D.) IHC localizing increased
fibronectin expression in mice treated with TGF-β localizes with the basement membrane of
brain cortical vessels. All data are analyzed by Student’s t-test. Significance: *p < 0.05, **p
< 0.01. Scale bar = 100 µm.
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Figure 5-7. OGD increases Aβ1-40 binding in primary astrocytes. (A.) Fluorescent images
showing that FITC-Aβ1-40 binding increases with OGD, and was highest in cultures that were
co-stimulated with Aβ1-40 during OGD. (B.) Quantification of FITC-Aβ1-40 binding. n = 3
per group. Data are analyzed by two-way ANOVA with Tukey’s post-hoc test for multiple
comparisons. *p < 0.05, ***p < 0.001.

5.3.5. Ischemia, TGF-β and Aβ1-40 interact to further increase the uptake of Aβ1-40 within
the astrocyte monolayer.
We next sought to further characterize how ischemia, TGF-β and Aβ1-40 interact to
increase the in vitro binding of Aβ1-40 to the ECM produced by primary cultured astrocytes
(Fig. 5-7A). We hypothesized that OGD would increase the uptake of FITC-Aβ1-40, which
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would be further accelerated by co-stimulation with recombinant TGF-β1 and Aβ1-40. We
found that FITC-Aβ1-40 uptake was increased by both OGD (Fig. 5-7B, F[1, 14] = 27.78, p =
0.001) and co-stimulation (F[2, 14] = 4.95, p = 0.024). We also observed a statistically
significant interaction effect between OGD and co-stimulation on FITC-Aβ1-40 uptake (Fig.
5-7B, F[2, 14] = 5.01, p = 0.023). Overall, these data indicate that ischemia, TGF-β and Aβ140

interact to increase the in vitro uptake of FITC-Aβ1-40 within the astrocyte monolayer.

However, further work is needed to address the mechanism of this phenomenon, in particular
how pre-treatment with Aβ1-40 induces such dramatic increases in FITC-Aβ1-40 uptake, and
why this increase in uptake appears to be conditional on exposure to OGD conditions.

5.3.6. TGF-β stimulation alters astrocytic AQP4 polarization and impairs water uptake
both in vitro and in vivo.
Our initial studies showed that DMCAO upregulated TGF-β1 expression (Fig. 5-2A)
and altered AQP4 polarization on reactive astrocytes (Fig. 5-1A). Therefore, we
hypothesized that TGF-β impairs AQP4 polarization, water uptake and bulk flow. To
address this hypothesis, we first stimulated primary cultured astrocytes with recombinant
TGF-β1 for 24 hours, and assessed the impact on AQP4 polarization by ICC (Fig. 5-8A).
We found that TGF-β1 treatment altered the pattern of AQP4 staining and induced swelling
of cultured astrocytes (Fig. 5-8A, i – ii.). To measure the functional consequences of these
histological changes, we examined the in vitro uptake of 3H2O, a substrate for AQP4, for 30
min into the astrocyte monolayer, and found that it was significantly reduced by TGF-β1
treatment (Fig. 5-8A, iii., t[8] = 2.31, p = 0.049). To confirm these findings in vivo, we
injected naive young mice with TGF-β1 and examined AQP4 polarization, as well as the
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uptake of 3H2O uptake and 14C-inulin (used as an extracellular space marker) from the CSF.
We found that treatment with TGF-β1 significantly reduced uptake of 3H2O (Fig. 5-8B, ii.,
t[10] = 3.77, p = 0.004) and 14C-inulin (Fig. 5-8B, iii., t[7] = 2.75, p = 0.029) from the CSF.
This indicates that TGF-β1 treatment is sufficient to impair CSF flow in the healthy young
brain, suggesting that it may also contribute to impairments in aging and after stroke.

	
  

140

	
  
	
  
Figure 5-8. TGF-β stimulation alters AQP4 polarization and impairs water uptake. (A.)
(i., ii.) Fluorescent micrographs showing altered AQP4 polarization in TGF-β-treated
primary astrocytes by ICC. (iii.) Quantification of 3H2O uptake by primary astrocytes treated
with vehicle or TGF-β. n = 4 – 8 per group. (B.) Quantification of (i.) 3H2O and (ii.)

14

C-

Inulin uptake by mice intracisternally injected with vehicle or TGF-β. n = 3 – 4 per group.
Data are analyzed by Student’s t-test. Significance: *p < 0.05, **p < 0.01.
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5.3.7: Early TGF-βR1 antagonism following DMCAO increases infarct volume and may
modulate astrogliosis in an age-dependent manner. In order to further examine the
translational value of TGF-β antagonism in modulating injury severity, astrogliosis and
basement membrane fibrosis after stroke, we first performed a pilot study with continuous
peripheral administration of GW788388 (10 mg/kg/day), a TGF-βR1/R2 antagonist, from 3 –
7 DPI in young (3 month) and aged (20 month)-old mice with DMCAO. Similar to previous
studies using conditional knockout mice,229 we hypothesized that early inhibition of TGF-β
signaling would slightly increase injury volume, but would have the beneficial effect of
reducing gliosis. We also newly hypothesized that this would reduce fibronectin and
integrin-α5 expression in the injured cortex. Somewhat unexpectedly, we found that early
TGF-β antagonism significantly increased injury volume (Fig. 5-9A, F[1, 4] = 22, p = 0.009),
which worsening with aging (F[1, 4] = 10.02, p = 0.034). We next examined the impact on
gliosis by western blot, and found similar trending interaction effects of aging and early
TGF-β antagonism on the expression of GFAP (Fig. 5-9B, i., F[1, 8] = 2.92, p = 0.127) and
vimentin (Fig. 5-9B, ii., F[1, 8] = 2.54, p = 0.149) at 7 DPI. Finally, we similarly examined
the impact of treatment on ECM remodeling, and found similar trending interactions in the
expression of fibronectin (Fig. 5-9C, i., F[1, 8] = 4.66, p = 0.063) and integrin-α5 (Fig. 5-9C,
ii., F[1, 8] = 2.91, p = 0.127) at 7 DPI by western blot. Overall, these preliminary data are
interesting in that they show a potential age dimorphism in the role of TGF-β signaling in
regulating gliosis and ECM remodeling after stroke, with a potential slight benefit to aged
animals despite increases in injury volume.
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Figure 5-9. Age-specific effects of subacute TGF-βR1 antagonism following DMCAO.
(A.) (i.) Quantification of cavity size at 7 DPI. (ii.) Representative cresyl violet stained
coronal sections from vehicle and drug-treated aged mice. n = 2 per group. (B.) GFAP and
vimentin expression at 7 DPI quantified by western blot. n = 3 per group. (C.) Fibronectin
and integrin-α5 expression at 7 DPI quantified by western blot. n = 3 per group. Data are
analyzed by two-way ANOVA with Tukey’s post-hoc test for multiple comparisons. *p <
0.05.
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5.3.8: Delayed TGF-βR1 antagonism following DMCAO reduces gliosis and ECM
remodeling, while also improving perivascular CSF flow in aged animals.
Based on the mixed results of the preceding pilot study, we next modified the dosing
regimen by shifting the treatment window to 7 – 14 DPI in aged (20 month-old) mice by
Alzet pump. We hypothesized that delayed TGF-βR1/R2 antagonism after DMCAO would
reduce gliosis and fibronectin/integrin-α5 expression, but have no major impact on injury
volume or motor recovery in aged animals. We further hypothesized that these reductions in
astrogliosis and basement membrane fibrosis would correlate with improved perivascular
CSF flow and reduced FITC-Aβ1-40 deposition.
We found that DMCAO increased GFAP expression, which was rescued by treatment
with the TGF-βR1/R2 antagonist (F[2, 12] = 6.2, p = 0.014). We also found that DMCAO
increased fibronectin expression, which was significantly reduced by treatment (F[2, 12] =
5.8, p = 0.017). These changes in fibrosis were correlated with alterations in perivascular
CSF flow. We found that DMCAO significantly inhibited glymphatic influx of CSF
(measured as dextran [d3] uptake), which was rescued by treatment (Fig. 5-10D, i., F[2, 12]
= 5.38, p = 0.022). Despite these reductions in overall CSF flow, we saw no corresponding
impact on relative FITC-Aβ1-40 uptake (Fig. 5-10D, ii., F[2 , 12] = 0.81, p = 0.469).
However, normalization to d3 levels, which accounts for individual differences in overall
CSF flow, showed a relative increase in FITC-Aβ1-40/d3 ratio with DMCAO that was rescued
by treatment (Fig. 5-10D, iii., F[2, 12] = 5.93, p = 0.016). Overall, these data show that
TGF-β signaling impairs perivascular CSF flow after DMCAO, which is associated with a
disequilibrium in the transport of Aβ1-40. Treatment improved CSF flow and reduced this
imbalance in Aβ1-40 transport.
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Figure 5-10. Delayed TGF-βR1 antagonism reduces fibrosis and improves perivascular
flow following DMCAO in aged mice. (A.) Representative images showing increased
GFAP and fibronectin expression in the peri-infarct cortex following DMCAO, which is
rescued with GW788388 treatment. (B.) Fluorescence intensity quantification of GFAP and
fibronectin expression. (C.) Representative images showing reduced dextran and increased
Aβ1-40 distribution following DMCAO, which is rescued with GW788388 treatment. (D.)
Fluoresence intensity quantification of tracer uptake. n = 4 – 5 per group. Data are analyzed
by two-way ANOVA with Tukey’s post-hoc test for multiple comparions. *p < 0.05.
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5.4: Discussion.
5.4.1: Aging alters TGF-β signaling and reactive gliosis after stroke.
The current study builds on previous work examining the impact of stroke on glial
scar formation in aged animals by our laboratory and others,223,229,233 and offers new insight
into age-related alterations in canonical TGF-β signaling pathways. Similar to previous
studies, we found that DMCAO produced a large, GFAP+ glial scar in the ischemic
penumbra by 7 DPI in young animals. We further showed that this was associated with
alterations in ECM glycosylation, measured by lectin staining, indicating increases in
glycosylated proteins including heparan sulfate proteoglycans (HSPGs), chondroitin sulfate
proteoglycans (CSPGs) and/or other glycosylated proteins such as fibronectin. While these
changes have been previously shown to occur after experimental stroke, we newly observed
that the glial scar extended beyond the ischemic penumbra and into the surrounding PVS,
which form a continuous network through the ipsilateral cortex and striatum. We found that
stroke produced a striking increase in GFAP+ perivascular reactive astrocytes, which was
associated with abnormal lectin staining, indicating potentially major alterations in the
basement membrane. We also found that the polarization of the omnipresent water channel,
AQP4, was also disrupted in gliotic vessels.
Together, these changes may prime the basement membrane for the development of
CAA in three ways (as described in detail in Chapter 4): (1) altering the tortuosity of the
perivascular microenvironment for the diffusion of solutes (2) increasing the affinity of the
basement membrane for Aβ1-40 due to alterations in protein composition (e.g. fibronectin
expression), or (3) impairing water transport, and thus slowing the bulk flow of CSF, by
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mislocalization of AQP4. Similar changes have been shown to occur in animal models of
CAA,280 and with constitutive TGF-β overexpression.219
We further found that aging induced an increase in perivascular reactive gliosis, and
was associated with further increases in total GFAP and vimentin expression throughout the
injured hemisphere. Since TGF-β signaling is increased in aged animals with stroke,223 and,
in a separate paper, was also found to be a major contributor to glial scar formation by
signaling to astrocytes after stroke,229 we elected to explore this further by first examining the
levels of TGF-β in whole cortical lysate by multiplex ELISA, and then by probing the
phosphorylation of downstream canonical Smad signaling pathways by western blot. While
we found that young and aged animals exhibited similar concentrations of TGF-β1, the
predominant TGF-β isoform, we found interesting differences in the downstream Smad
signaling pathways, indicating that aging induces a potentially dysregulated response to
TGF-β signaling following stroke. In young animals, this TGF-β stimulation is associated
with increases in Smad2/3 phosphorylation, however, this is balanced by increases in
Smad2/3, potentially acting to blunt these changes. In contrast, Smad2/3 levels decline in
aged animals with stroke, and the relative levels of phosphorylation increase. This decline in
total Smads could help to explain the increased sensitivity of the aged brain to TGF-β
signaling (and the gliotic response). In particular, relative increases in Smad3
phosphorylation could provide a potent stimulus for the transcription of ‘reactive’ genes
following stroke, although our in vitro data show that TGF-β stimulation alone is not
sufficient to induce increases in classical markers of astrocyte reactivity, including GFAP
expression. This discrepancy suggests that TGF-β plays a role in modulating the response to
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hypoxia or other stimuli, rather than directly inducing astrocyte reactivity, as was previously
thought.

5.4.2: Astrocyte polarization is differentially regulated by hypoxia, TGF-β and Aβ1-40.
Recent work found that reactive astrocytes represent a more diverse population of
cells than previously thought.239 While all reactive astrocytes generally express so-called
‘pan-reactive’ markers, such as GFAP and vimentin, depending on the stimulus, astrocytes
can take on two distinct genotypes: A1 and A2.239 Using in vivo mouse models, A1
astrocytes were shown to be induced by peripheral LPS stimulation, while A2 were shown to
be induced following MCAO.239 However, a very recent paper found this to be incorrect, as
A1 astrocytes lack toll-like receptor-4 and, therefore, could not directly respond to LPS.240
Instead, the study showed that A1 astrocytes were induced by the microglial cytokines IL-1β,
IL-6 and TNF-α.240 To date, no such study has followed up on whether A2 astrocytes are
induced by hypoxia, or if they instead similarly require co-stimulation with microglial
cytokines. Furthermore, while A1 astrocytes have generally detrimental effects following
activation (mislocalization of AQP4, induce aberrant synaptic function and secretion of
neurotoxic products), the actual phenotype of activated A2 astrocytes is not known.
To address this gap in the literature, and to determine how A2 astrocytes are induced
following stroke, we first sought to determine the specific factors that are sufficient to induce
an A2 phenotype in vitro. We elected to model stroke in vitro by performing OGD on
astrocyte monolayers. Although it is nearly impossible to isolate a truly ‘pure’ population of
astrocytes from primary glial cultures, we chose to use microglia-depleted primary astrocyte
monolayers to increase the relevance to our in vivo studies. When we performed OGD and
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collected RNA from our cultured astrocytes, we newly found that hypoxia alone was
sufficient to induce an A2 astrocyte phenotype without any exogenous co-stimulation.
Additionally, while previous studies found that even delayed treatment with TGF-β inhibits
A1 astrocyte activation, we found that the A2 phenotype remained intact even with TGF-β
co-stimulation. Finally, to provide some insight for future studies into the role of Aβ1-40 in
modulating the phenotype of astrocytes, we assessed the impact of Aβ1-40 stimulation under
both normoxic and hypoxic conditions. We newly found that Aβ1-40 induces classical A1
astrocyte activation with NO, and inhibits the transition to A2 that normally occurs under
hypoxic conditions. This very interesting finding suggests that stroke and AD may produce
opposing astrocyte phenotypes, which may be significant in the pathogenesis of vascular
dementia.

5.4.3: Reactive astrocyte subsets produce different patterns of extracellular matrix and
cytokines, which can be further modified by co-stimulation.
Since understanding astrocytic basement membrane production was a major goal of
our studies, we next assessed the transcription of ECM genes by astrocytes under hypoxia
and co-stimulation. We found that OGD-induced A2 astrocytes upregulated fibronectin,
integrin-α5 and (potentially) perlecan expression, yet down-regulated expression of other
ECM-related genes, including agrin, collagen XI and fibulin-5. They also showed no
significant changes in integrin-β1, demonstrating again that integrin-α5 is the major subunit
that changes with ischemia. These findings are in line with our previous studies, outlined in
Chapter 4, which showed that stroke induced the upregulation of fibronectin and integrin-α5
within the basement membrane in vivo, and newly show that astrocytes are a major source of
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these proteins. Future studies should assess whether downregulation of agrin, collagen XVI
or fibulin-5 also contributes to the deposition of CSF Aβ1-40 and the formation of CAA
plaques after stroke.
We also examined how cytokine expression changes under hypoxia and/or costimulation. We first examined changes in TGF-β-related genes, and found that OGD
reduced the expression of TGF-β1, but increased the expression of TGF-βR1. This is
interesting, because it suggests that activated astrocytes may be more sensitive to TGF-β1
due to increased receptor expression. When we examined other cytokines, we found that Aβstimulated A1 astrocytes produced significantly more TNF-α, CXCL10 and CXCL16, which
was inhibited by hypoxia. In contrast, A2 astrocytes produced high levels of IL-6 and IL-10.
TGF-β simultaneously stimulated IL-6 (pro-inflammatory cytokine) and inhibited IL-10
(anti-inflammatory cytokine) production, suggesting that it could be shifting the phenotype of
A2 astrocytes to a more pro-inflammatory state. This needs to be clarified with further
studies examining a wider panel of inflammatory cytokines and surface markers.

5.4.4: TGF-β modifies multiple astrocyte functions that are involved in CSF flow.
While previous studies have shown that TGF-β induces fibrosis with injury, it was
not known how it impacted astrocyte ECM production, or how these ECM changes modulate
the deposition of Aβ1-40. Our results indicate that TGF-β stimulation upregulates fibronectin,
which was confirmed in vivo. It also increased in vitro Aβ1-40 uptake, which colocalized with
regions of increased fibronectin/integrin-α5 expression, indicating that this deposition
occured extracellularly. In light of our results from Chapter 4, this finding supports the
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hypothesis that TGF-β induces astrocytes to modify the basement membrane in a way that
favors CSF Aβ1-40 deposition.
Although previous studies have shown an association between reactive astrogliosis,
altered AQP4 polarization and impaired CSF flow, it was not know whether TGF-β
stimulation was sufficient to induce these phenotypes. Our results indicate that TGF-β
altered AQP4 expression on astrocytes and induced cell swelling, which impaired water
uptake. The impact of TGF-β on these physiological parameters was also confirmed in vivo,
which occured in the absence of significant increases in GFAP expression. This indicates
that classical markers of astrocyte reactivity do not fully predict the functionality of
perivascular astrocytes, instead requiring the use of A1 and A2-specific markers.

5.4.5: Inhibition of TGF-β signaling rescued fibrosis and perivascular CSF flow in aged
animals.
We first examined the impact of TGF-βR1 antagonism in the subacute phase of injury
(3 – 7 DPI), and found that it increased injury volume in both you and aged animals. We
also found an interesting trend, which suggests an age-specific impact of TGF-βR1
antagonism in young and aged mice. While both groups exhibited an increase in injury size,
only young mice had a corresponding increase in gliosis and ECM fibrosis. This suggests
that TGF-β antagonism may actually reduce gliosis in aged mice, but this effect is masked by
an increase in injury volume. To test this theory, we repeated the experiment in aged mice,
but delayed the inhibitor treatment until 7 – 14 DPI to further avoid potential impacts on
injury volume. When we used this dosing regimen, we found that TGF-βR1 antagonism
significantly reduced GFAP and fibronectin expression. Furthermore, this was associated
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with increased perivascular CSF flow and a relative decrease in CSF Aβ1-40 deposition. This
suggests that this therapy could be used to favorably modulate CSF-ISF exchange in a way
that boosts the bulk flow of CSF without also increasing the deposition of CSF Aβ1-40. This
could be useful in the treatment of CAA in stroke survivors.
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CHAPTER 6
Serum Biomarkers of Basement Membrane Fibrosis Are Diagnostic of
CAA After Intracerebral Hemorrhage

6.1: Introduction
6.1.1: Overview.
Our preclinical studies, detailed in the preceding chapters, indicate that TGF-β
signaling to astrocytes may drive post-stroke CAA by inducing a set of ECM changes termed
‘basement membrane fibrosis,’ impairing CSF flow. In particular, fibronectin appears to
play a major role early in the disease process by sequestering CSF Aβ1-40, potentially causing
the classic “outside-in” induction of CAA pathology that is typically observed in cortical
vessels. Based on these findings, we also sought to explore the contribution of MMPs, which
are a set of upstream enzymes that release both of these proteins from the ECM during states
of inflammation. The studies detailed in this chapter indicate that TGF-β, MMPs and
fibronectin are biomarkers of CAA-related intracerebral hemorrhage (ICH) in human
patients. These interesting results further validate our previous findings in animal models,
and increase their potential translational value to human disease.

6.1.2: Significance.
ICH is caused by acute rupture of cerebral vessels, and affects approximately 2
million individuals each year.281 While hypertension remains the most common cause of
spontaneous ICH, accounting for half of brain hemorrhages,1 CAA is an additional major
cause of lobar ICH that will likely increase due to our aging population.97 While probable
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CAA can be diagnosed by a set of MRI-based radiologic measurements termed the Boston
criteria, definitive diagnosis requires an invasive brain biopsy that is not feasible for most
patients.20,282 In theory, identification of a CAA-specific blood biomarker profile could
facilitate an earlier, cheaper and less invasive diagnosis of CAA. Additional information
about the underlying pathology and the prospects for recovery could help to guide
individualized patient care, significantly improving the clinical management of CAA and
patient outcomes after ICH.
CAA is a chronic disease process that involves the progressive accumulation of
vascular amyloid plaques, leading to reduced vessel integrity, cognitive decline and increased
susceptibility to ICH.23 Underlying CAA may alter vascular responses to acute ICH, which
could produce a unique molecular signature that can be measured peripherally. This
molecular signature may involve fibronectin, TGF-β and MMPs, which are all interrelated
molecules that are upregulated centrally in the brains of CAA patients,251,283 as well as
peripherally in the general response to ICH. During ICH, MMPs act to enzymatically
degrade basement membrane fibronectin284–286 and also cleave latent TGF-β, releasing the
active form into the brain extracellular space.287,288 Degradation of the basement membrane
leads to BBB disintegration, inducing extravasation of vascular components into the brain
parenchyma, leading to increased fluid uptake, and recruitment of peripheral immune cells –
all contributing to secondary injury.289 In contrast, release of TGF-β plays a major role in the
resolution of brain injury via inducing phagocytosis and the formation of fibrotic scar
tissue.228,290 Alterations in this divergent pathway could influence recovery from ICH, and
could also provide insight into the existence of underlying CAA pathology.
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While the role of these mediators in ICH has been studied to a greater extent in
animal models, there is less literature on whether they can be used as prognostic markers
clinically. Given the central role that MMPs, TGF-β and fibronectin are thought to play in
the pathophysiology of secondary injury and recovery from ICH, we hypothesize that the
levels of these mediators are not only associated with initial injury severity, but also with
long-term functional deficits. Furthermore, due to significant overlap between expression of
these markers in CAA and ICH, opening up the potential for disease-specific interactions, we
also hypothesize that these mediators can also be used to diagnose CAA in the context of
ICH.

6.1.3: Experimental design.
For all experiments, we utilized ICH patient data and serum samples from clinical
repositories at both UT Health and Hartford Hospital. To test the hypothesis that the serum
levels of these proteins are biomarkers of injury severity, we performed spearman correlation
of these putative biomarkers against clinical measures of severity, including hematoma
volume, radiologic measures of edema, as well as neurological scales of acute injury. Then,
to determine whether these biomarkers were independent predictors of functional recovery,
we developed a multivariable model to compare initial biomarker levels (< 5 DPI) and
modified Rankin Scale (mRS) score at 90 DPI, which controlled for injury severity and other
confounding clinical variables. Finally, to test the hypothesis that these biomarkers can be
used alone or in combination to diagnose CAA, we performed receiver operating
characteristic (ROC) analysis to determine whether these cytokines can discriminate between
CAA and non-CAA hemorrhage in two independent cohorts.
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6.2: Methods
6.2.1: Study population.
The current study utilized ICH patient data and serum samples from Hartford
Hospital and the University of Texas Health Science Center in Houston (n = 63 patients).
The study was approved by the Institutional Review Boards at both institutions, and all
patients participating were consented. Patient data were abstracted from prospective ICH
databases detailing admission data, radiology, hospital course and functional outcomes.
Patients with hemorrhages due to underlying vascular lesions or traumatic brain injury were
excluded from the study. For analysis of biomarker correlation with injury etiology, patients
were divided into three groups: lobar hemorrhage of suspected CAA etiology (n = 21) and
deep hemorrhage (n = 42). Lobar and deep hemorrhages were defined by the location of the
ictus on CT, as interpreted by an independent neuroradiologist and confirmed by an
experienced neurologist. Probable CAA was defined via the Boston criteria and was
supported by pathological evidence in the majority of patients.20,31

6.2.2: Measurement of neurological function.
Initial ICH severity was assessed using ICH score,291 National Institute of Health
Stroke Scale (NIHSS),292 Glasgow Coma Scale (GCS)293 and mRS.294 Additionally, longterm functional outcomes were assessed by mRS at time of discharge and at 90 DPI.

6.2.3: Radiologic measurements.
Our primary radiologic outcomes were hematoma volume and intraventricular
hemorrhage (IVH) volume as quantified via computer-based analysis with MIPAV
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(Medical Image Processing, Analysis, and Visualization) software. IVH was scored on a 10point scale developed at UT Health.295 Hematoma and IVH volumes were determined
throughout the patient’s entire hospitalization via review of every head CT obtained as a part
of routine clinical care until discharge.

6.2.4: Serum sample collection.
Serum samples were obtained from our study cohort at pre-specified time points from
0 to 5 days post-ictus. Serial samples were collected from each patient when possible, for a
total of 136 serum samples. In order to minimize timing bias, all biosamples were timed from
the onset of ICH ictus and collected by a biospecimen collection team who were blinded to
the clinical status of the patient. Samples were processed within 1 hour of collection and
stored at -80 degrees Celsius until use.

6.2.5: Measurement of serum analytes.
Samples were thawed on ice for 1 hour and thoroughly vortexed prior to beginning
any assays. Serum fibronectin was measured using the Human Fibronectin Quantikine
ELISA Kit (R&D Systems). Following activation of latent TGF-β by acidification, TGF-β1,
TGF-β2 and TGF-β3 were measured using the Bio-Plex Pro TGF-β 3-PLEX Assay (BioRad). Similarly, MMP1, MMP2, MMP3, MMP7, MMP8, MMP9, and MMP10 were
measured using the Bio-Plex Pro Human MMP Panel (Bio-Rad). All assays were performed
and read according to the manufacturer’s instructions.
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6.2.6: Statistics.
Descriptive statistics, including frequency, percent, mean, median, SD, interquartile
range (IQR), were provided for demographics and admission variables in the subgroups of
CAA hemorrhage, hypertensive hemorrhage, and overall groups. Wilcoxon rank sum test
was used to compare values between CAA and hypertensive hemorrhage (Table 6-1).
Cytokine levels were averaged between repeated samples from 0 – 5 DPI. For the combined
CAA and hypertensive group, spearman correlation method was used to evaluate their
relation to initial injury scores. P values were adjusted by Benjamini and Hochberg procedure
(1995)20 to control the false discovery rate (FDR) at 0.05 (Table 6-2). Similar correlation
analysis was done for mRS at discharge and at 90 days (Table 6-3). Furthermore, a
multivariable model was used to study the association between mRS at 90 days and several
early cytokine levels separately, adjusted for hemorrhage type, age, systolic blood pressure,
hematoma volume, GCS score, IVH and coagulopathy. Descriptive statistics (median and
IQR) was provided for early cytokine levels and Wilcoxon rank sum test was used to
compare them between CAA and hypertension hemorrhage (Table 6-4). P values are
adjusted to control FDR within 0.05. Univariate or multivariable logistic regression was used
to provide receiver operating characteristic (ROC) curve to discriminate between CAA and
hypertensive hemorrhage, which was quantified in SAS as the area under the curve (AUC)
(Fig. 6-1). All p values were adjusted similarly to control FDR at 0.05. All data analyses
were performed in SAS software 9.4 (Cary, NC).
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6.3: Results
6.3.1: Fibronectin, MMPs and TGF-β are differentially associated with initial hemorrhage
burden.
To assess whether peripheral markers were related to injury severity, serum samples
were first obtained from a total of 62 ICH patients that were subdivided by radiologic
findings; 21 were patients with acute lobar hemorrhage that met the Boston criteria for
definite or probable CAA, and 41 were patients with deep hypertensive hemorrhages.
Groups significantly differed by age, systolic blood pressure, stroke severity (NIHSS, GCS)
as well as injury volume and IVH (Table 6-1).
Following correction for the FDR (p < 0.5), we found several cytokines correlated
with injury severity in our initial univariate analysis (Table 6-2). All three families of
cytokines were associated with initial neurological function, as measured by the Glasgow
Coma Scale (GCS). Specifically, elevated serum fibronectin was associated with better
neurological function on admission (GCS, p = 0.003). In contrast, elevated TGF-β1 (p =
0.003), TGF-β2 (p = 0.005) and TGF-β3 (p = 0.004) correlated with worse initial
neurological deficits. Similarly, patients with high levels of MMP1 (p = 0.003), MMP3 (p =
0.032), MMP8 (p = 0.003), MMP9 (p < 0.001) and MMP10 (p = 0.002) also exhibited worse
neurological deficits on admission. When the ICH score was used to estimate injury severity,
we found that MMP3 (p = 0.041), MMP8 (p = 0.041), MMP9 (p = 0.012) and MMP10 (p =
0.041) were also positively associated with increased injury severity. Finally, MMP10 also
correlated with increased IVH (p = 0.002). In summary, these results indicate that
fibronectin, TGF-β and MMP isoforms are biomarkers of initial injury severity in our cohort
of ICH patients.
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Characteristics

Total
Cohort
(n = 63)

CAA
Hemorrhage
(n = 21)

Hypertensive
Hemorrhage
(n = 42)

P-value

Significance

Age, years (mean [SD])

67.79
(14.38)

75.76 (9.64)

63.71 (14.78)

p = 0.003

**

Female (n [%])

26 (41.94)

10 (47.62%)

16 (39.02%)

p = 0.516

ns

Black (n [%])

10 (16.39)

2 (9.52%)

8 (19.51%)

p = 0.367

ns

White (n [%])

39 (63.93)

16 (76.19%)

23 (56.1%)

p = 0.367

ns

Asian (n [%])

3 (4.92)

0 (0%)

3 (7.32%)

p = 0.367

ns

Hispanic/other (n [%])

9 (14.75)

2 (9.52%)

7 (17.07%)

p = 0.367

ns

Admission systolic blood
pressure, mm Hg (mean
[SD])

188.04
(32.34)

171.55
(27.23)

202 (30.44)

p = 0.03

*

Admission diastolic blood
pressure, mm Hg (mean
[SD])

109.83
(35.25)

96.45 (16.63)

121.15 (42.99)

p = 0.145

ns

GCS (median [IQR])

14 (4.25)

15 (1)

9.5 (4.5)

p = 0.039

*

ICH score (median [IQR])

2 (2)

1 (1.5)

2 (2)

p = 0.667

ns

NIHSS (median [IQR])

12 (17.5)

7 (10)

17 (17.25)

p < 0.001

***

Initial hematoma volume,
3
cm (mean [SD])

25.76
(22.74)

37.44 (28.04)

19.08 (15.98)

p = 0.015

*

IVH score (median [IQR])

0 (5.5)

0 (0)

16 (6)

p = 0.006

**

Race

Table 6-1. Demographics and admission variables by study group. Data are analyzed by
Wilcoxin Rank Sum Test. *p < 0.05, **p < 0.01, ***p < 0.001.
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Admission
Variable

Age

NIHSS

GCS

ICH Score

Initial Hematoma
Volume

IVH Score

Cytokine

Correlation

P-value, raw

Significance,
raw

P-value,
FDR
adjusted

Significance,
FDR adjusted

TGF-β1

-0.293

p = 0.021

*

0.144

ns

TGF-β3

-0.271

p = 0.033

*

0.144

ns

MMP9

-0.263

p = 0.039

*

0.144

ns

TGF-β1

0.356

p = 0.007

**

0.058

ns

TGF-β3

0.34

p = 0.01

*

0.058

ns

MMP1

0.286

p = 0.032

*

0.09

ns

MMP9

0.296

p = 0.027

*

0.09

ns

Fibronectin

0.495

p < 0.001

***

0.003

**

TGF-β1

-0.484

p < 0.001

***

0.003

**

TGF-β2

-0.431

p = 0.004

**

0.005

**

TGF-β3

-0.446

p = 0.003

**

0.004

**

MMP1

-0.472

p = 0.001

**

0.003

**

MMP3

-0.338

p = 0.027

*

0.032

*

MMP8

-0.471

p = 0.001

*

0.003

**

MMP9

-0.596

p < 0.001

***

p < 0.001

***

MMP10

-0.52

p < 0.001

***

0.002

**

TGF-β1

0.269

p = 0.039

*

0.072

ns

TGF-β3

0.278

p = 0.033

*

0.072

ns

MMP1

0.327

p = 0.012

*

0.041

*

MMP8

0.315

p = 0.015

*

0.041

*

MMP9

0.414

p = 0.001

**

0.012

*

MMP10

0.345

p = 0.008

**

0.041

*

TGF-β2

0.289

p = 0.033

*

0.198

ns

MMP3

0.283

p = 0.036

*

0.198

ns

MMP8

0.49

p = 0.018

*

0.065

ns

MMP9

0.524

p = 0.01

*

0.057

ns

MMP10

0.609

p = 0.002

**

0.023

*

Table 6-2. Early cytokine levels and their relation to initial injury scores. Data are
analyzed by Spearman correlation, and both raw and FDR-corrected P-values are presented.
Raw and FDR-adjusted significance: *p < 0.05, **p < 0.01, ***p < 0.001, ns: no
significance.
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Outcome
Variable

mRS at
discharge

mRS at 90
days

P-value,
FDR
adjusted

Significance,
FDR
adjusted

*

0.143

ns

0.028

*

0.143

ns

0.326

0.043

*

0.143

ns

Fibronectin

-0.302

0.049

*

0.089

ns

TGF-β1

0.478

0.001

**

0.012

*

TGF-β2

0.39

0.01

*

0.035

*

TGF-β3

0.456

0.002

**

0.012

*

MMP1

0.376

0.013

*

0.035

*

MMP9

0.312

0.042

*

0.089

ns

Cytokine

Correlation

P-value, raw

Significance,
raw

TGF-β1

0.336

0.037

TGF-β3

0.352

MMP9

Table 6-3. Early cytokine levels as predictors of functional outcome scores. Data are
analyzed by Spearman correlation, and both raw and FDR-corrected P-values are presented.
Raw and FDR-adjusted significance: *p < 0.05, **p < 0.01, ***p < 0.001, ns: no
significance.
	
  
6.3.2: Early elevations of TGF-β predict the degree of long-term functional deficits.
We next evaluated whether serum fibronectin, TGF-β and/or MMPs were predictive
of functional outcomes in our ICH patients. Specifically, we analyzed whether cytokine
levels were associated with mRS at discharge and at 90 days by univariate analysis (Table 63). While no cytokines significantly correlated with mRS at discharge, increased levels of
TGF-β1 (p = 0.012), TGF-β2 (p = 0.035), TGF-β3 (p = 0.012) and MMP1 (p = 0.035) were
all significantly associated with poor mRS at 90 DPI. To confirm these findings, we then
performed a multivariate regression to determine whether these effects were independent of
group differences in admissions data (identified in Table 6-1). Even when hemorrhage type,
age, systolic blood pressure, hematoma volume, GCS score, IVH score and coagulopathy
diagnosis were controlled for, TGF-β1 (p = 0.013), TGF-β2 (p = 0.041) and TGF-β3
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Cytokine

CAA
Median (IQR)

Hypertensive
Median (IQR)

P-value, raw

Significance,
raw

P-value, FDRadjusted

Significance,
FDRadjusted

Fibronectin

238.92
(136.23)

301.57 (120.76)

p = 0.027

*

0.2569

ns

TGF-β1

33016.03
(78087.73)

37810.92
(25226.81)

p = 0.094

ns

0.2569

ns

TGF-β2

1439.43
(9633.69)

1437.38
(197.48)

p = 0.925

ns

0.9248

ns

TGF-β3

1300.95
(1795.86)

1337.94
(307.26)

p = 0.257

ns

0.4035

ns

MMP1

837.35
(1491.25)

611.56
(2100.66)

p = 0.693

ns

0.7627

ns

MMP2

21995.26
(11778.3)

17540.91
(11822.09)

p = 0.14

ns

0.2569

ns

MMP3

3384.31
(6346.49)

4946.22
(7424.91)

p = 0.547

ns

0.6687

ns

MMP7

2044.58
(1374.17)

2702.82
(1530.49)

p = 0.129

ns

0.2569

ns

MMP8

2292.1
(3026.67)

2473.47
(4843.15)

p = 0.422

ns

0.5796

ns

MMP9

22055.53
(12685.96)

28395.04
(39910.81)

p = 0.122

ns

0.2569

ns

MMP10

1670.3
(892.67)

2237.56
(2138.41)

p = 0.071

ns

0.2569

ns

Table 6-4. Comparison of serum cytokine values in CAA and hypertensive hemorrhage
patient populations. In general, individual cytokine values did not discriminate between
CAA and hypertensive hemorrhage. Data were analyzed by Wilcoxon rank sum test, and
both raw and FDR-corrected P-values are presented. Raw and FDR-adjusted significance:
*p < 0.05, **p < 0.01, ***p < 0.001, ns: no significance.

(p = 0.018) remained significant predictors of mRS at 90 DPI. Overall, these data indicate
that elevated serum levels of TGF-β1, TGF-β2 and TGF-β3 are biomarkers of poor long-term
functional recovery, independent of initial injury, baseline characteristics or type of ICH.
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Figure 6-1. Biomarkers of small vessel fibrosis discriminate between CAA and
hypertensive hemorrhage. (A) ROC curve comparing CAA and hypertensive hemorrhage
within the UT Health cohort. (B) ROC curve comparing CAA and hypertensive hemorrhage
within the Hartford Hospital cohort.

6.3.3: Serum biomarkers distinguish CAA from deep hypertensive hemorrhages.
In order to determine whether these biomarkers could function as a diagnostic panel
for CAA, we first compared individual cytokine levels between CAA and deep hypertensive
hemorrhage ICH patients (Table 6-4). Univariate analysis showed that CAA patients tended
to have lower serum levels of fibronectin and MMPs after ICH, however, none reached
statistical significance following FDR correction (Table 6-4). However, when fibronectin,
MMPs and TGF-β were included in an exploratory multivariable ROC model, the AUC was
0.8701 (Fig. 6-1A), which was also found in a second exploratory cohort (AUC = 0.8393)
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(Fig. 6-1B). These results indicate that this test may reliably distinguish between CAA and
deep hypertensive hemorrhage, but requires further validation in larger independent cohorts.
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6.4: Discussion
In the current study, we extensively characterized the expression profile of multiple
MMP isoforms along with two downstream targets, TGF-β and fibronectin, in the serum of
patients with CAA and hypertensive ICH. We found that these cytokines were modulated by
both hemorrhage etiology and initial hemorrhage burden. Importantly, we also delineated
cytokine profiles that can be associated with (1) positive diagnosis of CAA and (2) long-term
functional outcomes. Overall, these preliminary findings highlight multiple candidate
families of biomarkers that could one day be used to improve the diagnosis and management
of ICH. Our ultimate goal is to identify candidate blood biomarkers for CAA-related ICH.
CAA diagnosis is currently accomplished by cortical biopsy20 or a complex set of radiologic
measurements termed the Boston criteria.282 However, there are disadvantages to both
strategies, including cost, invasiveness and requirement for extensive technical expertise,
making these tests prohibitively challenging outside of highly specialized medical centers.
Therefore, identification of biomarkers could one day lead to a simple blood test that could
enable CAA diagnosis in a broader clinical setting.
Previous work has shown that CAA is associated with local (e.g. brain tissue)
changes in TGF-β,251,296,297 fibronectin,251,297 and MMP activation.298,299 However, there is a
general lack of studies examining these cytokines peripherally (e.g. in the serum) of CAA
patients with ICH. We found that CAA was associated with a distinct pattern of cytokine
expression. Similar to previous work, we found that TGF-β alone was not diagnostic for
CAA.300 However, when TGF-β was included with fibronectin and MMPs, the panel as a
whole could reliably distinguish CAA from deep hypertensive hemorrhage in two
independent exploratory cohorts. Further studies with larger patient cohorts are warranted to
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explore individual cytokines that failed to reach statistical significance, which could further
improve the diagnostic potential of the cytokine panel in lobar ICH.
We also sought to determine how the expression profiles of MMPs, TGF-β, and
fibronectin relate to clinical characteristics at admission. MMP9 has been previously
associated with edema and neurologic deterioration after ICH.301 While one previous study
found that acute reductions in TGF-β were associated with worse long-term outcomes after
ICH, that study did not differentiate patients by likely CAA and examined platelet-depleted
plasma228 Finally, previous work using cellular fibronectin-specific antibodies suggested
high levels of cellular fibronectin in the serum was associated with hematoma expansion and
poorer outcomes,302 however, cellular fibronectin likely represents a small portion of the total
circulating fibronectin, measured in our study. Our data indicates that elevated expression of
TGF-β and several MMP isoforms were associated with greater initial hemorrhage burden,
while total serum fibronectin levels were associated with reduced injury severity. Serum
fibronectin could competitively inhibit MMPs by occupying the MMP active site; further
work in animal models is required to determine a potential mechanism linking fibronectin
and reduced ICH severity.
Additionally, we also examined whether serum levels of MMPs, TGF-β, and
fibronectin could serve as prognostic blood biomarkers of long-term functional outcome.
Previous work has suggested high levels of cellular fibronectin and MMP9 are associated
with hematoma expansion,302 but there is minimal data regarding long-term prognostication
(for instance, at 90 DPI).228,301 One study found that MMP3 and MMP9 levels correlated with
worse functional outcomes after ICH.303 While we found a similar association between mRS
and MMP9 in our univariate analysis, it did not reach the FDR threshold in our study due to
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the higher number of cytokines analyzed. However, we did find that patients with higher
early levels of TGF-β isoforms exhibited worsened functional outcomes after ICH. While
TGF-β may be beneficial in acute injury, chronic exposure to this potent cytokine stimulates
astrocytes to hypertrophy, divide, and secrete a variety of extracellular matrix proteins,
leading to increased glial scarring, that has been shown to impede recovery in animal models
of brain injury, in part by reducing angiogenesis and axonal reorganization.251,304,305,223,306 As
such, TGF-β measurement during acute injury may allow healthcare providers to better
identify patients who are most at-risk for long-term disability as early as 24 hours after ICH,
independent of clinical severity.
Altogether, our study suggests these markers of BBB remodeling and fibrosis are
differentially expressed in CAA and hypertensive hemorrhage, and may serve as serum
biomarkers of initial injury severity and long-term functional outcomes. Further work is
needed to confirm these findings and to refine these targets into a diagnostic panel for CAA.
A better understanding of the differences in the pathophysiology of deep and lobar
hemorrhage may aid in future site-specific biomarker identification and the eventual
development of targeted therapeutics for different types of ICH.
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CHAPTER 7
Discussion & Future Directions

7.1: Summary and overview of the literature.
CAA represents a fascinating area of research, having a wide variety of seemingly
unrelated risk factors, impacting some individuals and not others, and leading to cognitive
decline via multiple, potentially overlapping mechanisms. The etiology of the disease is not
well understood, and there are no disease-modifying treatments available to CAA patients.
Our studies represent an attempt to cast a light over the earliest stages of this disease, to
determine where, when and how the initial induction of amyloid pathology can occur in
individuals with ischemic stroke. While the picture is still incomplete, this work serves as a
starting point for a unified mechanism of CAA induction, and new treatment strategies for
this devastating disease.
The story of CAA began when the famed pathologist Rudolph Virchow first
described amyloid deposits in 1854.23 Over 50 years later, in 1906, a clinical psychiatrist and
neuroanatomist named Alois Alzheimer discovered brain atrophy when he came across the
case of Auguste Deter, a 55 year-old woman who suffered from rapidly progressive memory
disturbances, sleep disruption, mood changes and increasing confusion before her death.307
At a major medical conference, he described these findings as a “peculiar severe disease
process of the cerebral cortex” and theorized that her amyloid deposits were the underlying
cause of her symptoms.307 Like most revolutionary thinkers, his presentation went largely
unnoticed; fortunately, progress in the field quietly continued forward.307 Just three years
later, a pathologist named Gustav Oppenheim found that cerebral amyloid deposits tended to
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occur in two distinct extracellular locations: the parenchymal tissue between neurons, as well
as the perivascular regions around cerebral vessels, a type of pathology later termed ‘amyloid
angiopathy’.23 Subsequent investigations confirmed that CAA was an independent disease
process distinct from Alzheimer’s disease.23 Finally, in 1979, a neuropathologist named
Haruo Okazaki was the first to associate CAA with vessel wall stenosis, microinfarction,
microhemorrhages and lobar hemorrhage in dozens of autopsy cases at the Mayo Clinic,308
bringing us to our current general understanding of the pathogenesis of CAA.
Since then, the most significant advances in CAA research, from a medical
perspective, have to do with the detection of disease. In 1982, C.Q. Mountjoy developed the
first CAA grading scheme, which assigned an ‘amyloid score’ based on the number of
amyloid positive vessels in autopsy cases.309 However, this needed further refinement, as it
did not significantly predict cognitive decline prior to death.309 In 1991, John Vonsattel
developed a more sensitive/specific grading scheme for CAA, based on brain biopsy.19,20 In
contrast with the earlier scheme, this method examines individual blood vessels for multiple
characteristics of CAA, including the amount of amyloid present, the thickness of the tunica
media, as well as the degree of vessel leakage and fibrinoid necrosis.19 Later, in 1995, John
Olichney developed a separate scale, which grades the severity of CAA purely based on how
many leptomeningeal and cortical vessels in a given brain section exhibit amyloid deposits,
as well as how large the amyloid deposits are on each vessel (Olichney 1995).310 While the
latter two methods remain in use today, and are required to establish definitive CAA
diagnosis, the use of non-invasive imaging has spurned an additional leap forward in the
early detection of CAA.
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In 2001, Steve Greenberg published validation of the ‘Boston criteria’, which can
make a non-invasive diagnosis of CAA by counting the number of MRI-visible
microhemorrhages.31 Since then, these criteria have been updated to include the presence of
lacunar infarction, leukoairaiosis, superficial siderosis, cortical atrophy and enlarged PVS.311
Future diagnostic strategies include measurement of CSF Aβ1-40,150 as well as PET imaging
with fluorbetapir, a compound that binds amyloid deposits in the brain.312 Additionally, the
development of blood biomarkers for distinguishing CAA hemorrhage from hypertensive
hemorrhage could further improve the diagnosis of CAA in patients, as we have found in our
research (see Chapter 6).
While earlier and more sensitive diagnosis of CAA has already improved patient care,
in contrast, the search for a cure has raised as many questions as answers. The bottom line is
that, while we can now detect earlier disease, the progressive vessel damage and cognitive
decline cannot be stopped with current therapies. We still do not understand how this disease
progresses, and why it impacts more than half of individuals over the age of 80. These
outstanding questions largely have to do with a poor understanding of the underlying cause
of CAA. For example, why does amyloid pathology develop around the cerebral arteries,
and not the veins? Why do these arterial plaques first tend to develop in the cortex and
cerebellum, rather than other areas of the brain? Is there a common thread running through
the multitude of genetic and cardiovascular risk factors for CAA? Why does sporadic CAA
only affect the elderly? In isolation, without predisposing risk factors, do focal events such
as stroke induce amyloid pathology, or merely accelerate an existing disease process?
I began my search for answers by examining the literature, and found that a newly
discovered system of perivascular flow, termed the ‘glial lymphatic’ (or glymphatic) system,

	
  

173

bathes the basement membrane of cortical arteries, arterioles and capillaries in a constant
supply of fresh CSF.125 My research led me to find papers indicating that CSF contains
waste products such as Aβ1-40,149,150,313 and to wonder whether small amounts of Aβ1-40 could
recirculate through the arterial basement membrane. Previous work suggested that stroke
modifies basement membrane composition,90 but much of this earlier work was studied in the
context of angiogenesis155,258 or trafficking of immune cells through the BBB.166,169
Furthermore, the impact of aging on post-stroke basement membrane remodeling had not
been defined, providing a few potential areas to add to the literature. Given that CAA is
associated with basement membrane alterations,280 that pathology is initiated within the
superficial cortical PVS,20,314 and that elevated levels of CSF Aβ1-40 represents the earliest
biomarker of CAA development,250 I proposed that we could build a coherent mechanism of
CAA based around this newly discovered physiology.

7.2: Review and critical analysis of current research findings.
Upon beginning our work at UT Health, I first independently confirmed the existence
of perivascular CSF flow in a series of early experiments, detailed in Chapter 3. We used
intracisternal Evans blue dye injection to grossly examine CSF flow pathways through the
cisterns that surround the brain, and then sectioned the brains to confirm that this dye rapidly
penetrated into the deepest brain structures. Next, we verified that this dye influx occurred
along perivascular routes by simultaneously labeling plasma and CSF with fluorescent dyes,
and found that they co-labeled vascular structures. With this basic knowledge in hand, we
then performed a series of quantitative time-course experiments to examine the influx
kinetics of small tracers into the brain, as well as the clearance of Αβ1-40 relative to larger

	
  

174

proteins. Over the course of these experiments, we discovered something interesting: CSF
solutes were partitioned into separate layers of the basement membrane based on size. This
unexpected finding provided us with early evidence that the basement membrane plays an
active role in regulating the distribution of CSF solutes, which could have significant
implications for our current understanding of how and why Αβ1-40 deposits within the
basement membrane in certain individuals.
Based on both my literature review and these exciting preliminary data, I developed a
new hypothesis that a family of stroke-induced basement membrane changes, broadly
defined as fibrosis, could impact the perivascular flow of CSF in two major ways. First, I
imagined that overall hypertrophy of the basement membrane could provide focal
interruptions in the flow of CSF through these perivascular pathways. This might be similar
to how a blood clot occludes an artery, but outside of the vessel. Second, I predicted that
increases in perivascular fibronectin, a common component of blood clots, amyloid plaques
and the injured basement membrane, could bind CSF Aβ1-40 at physiologically relevant
concentrations, forming the beginnings of perivascular pathology. Together, these
phenomena could lay a trap for CSF Aβ1-40 as it circulates through the basement membrane
after stroke. This could further worsen in aged animals due to their reduced CSF turnover
and increased propensity to form fibrotic glial scars after injury, explaining why aged
individuals are particularly vulnerable to CAA.
After some debate, we decided to model experimental stroke by using permanent
DMCAO, a well-established experimental model of cortical infarction,253 which I had been
introducing to our laboratory as a new technique. While the injury size in the ischemicsensitive Balb/c mice proved to be too large for accurate physiology measurements, we found
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that C57BL/6 mice exhibited a loss of just 10-15% of brain tissue within the injured
hemisphere, which was not modified by aging. The latter combination provided an ideal
model for several reasons, including a restricted cortical location, greater reproducibility of
injury size for our physiological measurements, low mortality for our longer-term studies,
and no significant impact of aging on injury volume.
Upon beginning our experiments, we quickly found that DMCAO increased the
expression of fibronectin and its co-receptor integrin-α5, and also increased tomato lectin
binding to the basement membrane (presumed to be due to increased vascular HSPG
content). In particular, integrin-α5 and lectin+ matrix was highest in aged animals with
stroke, which had not been shown previously. When we measured CSF influx using
fluorescent 3 kD dextran particles, we discovered that aging and stroke both dramatically
restricted the distribution of these solutes. The intensity of basement membrane lectin
staining exhibited a weak, but statistically significant negative correlation with dextran influx
in aged mice with stroke. This was our first suggestion that basement membrane proteins
could impact perivascular CSF flow. At the same time, when we co-injected fluorescent Aβ140,

we found that they formed superficial, perivascular deposits in aged mice with stroke.

This was particularly apparent in vessels around the infarct, as well as more broadly in an
astrocyte and fibronectin-rich region of the brain called the glia limitans. In contrast to
dextran, we found that the degree of Aβ1-40 deposition strongly correlated with lectin
intensity. We also found that Aβ1-40 deposits strongly colocalized with fibronectin and
integrin-α5 staining. Additionally, we tested the affinity of fibronectin for Aβ1-40 in vitro, and
found that they bound each other at physiological concentrations. These fibronectin-Aβ1-40
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conjugates deposited more readily into the brains of naïve young mice, indicating that
fibronectin contributes to the deposition of Aβ1-40 in aging and after stroke.
The above experiments support our hypothesis that the basement membrane
specifically impacts the transport of CSF Aβ1-40, which was particularly evident in aged mice
with stroke. A major strength of this study is the use of a disease-relevant injury model in
aged animals, which adds significant translational value to our findings. Another strength is
that, unlike many of our contemporaries,208 we used recombinant Aβ1-40 in addition to sizematched dextran molecules. This proved to be important, as we found that the behavior of
Aβ1-40 differed significantly in vivo, highlighting the need to use the actual peptide to draw
any relevant conclusions about its transport through the brain extracellular space.
My decision to use wild-type mice, which do not develop amyloid pathology with
aging, provides some interesting benefits and drawbacks to our study. We chose to use these
mice over the existing transgenic AD model mice because we were most interested in
studying the very earliest stages of CAA pathology. My choice to inject recombinant Aβ1-40,
rather than relying on genetic overexpression, allowed us to precisely control the timing and
route of exposure, providing us with the ability to specifically study the behavior of CSF
Aβ1-40 in the absence of any pre-existing amyloid pathology. However, there are downsides
to our approach. The biggest weakness is that it raises the question as to whether or not we
are really modeling CAA—we have no way of knowing whether these small deposits, which
form over the course of just 30 minutes, are stable and could develop into mature CAA
plaques. Since these wild-type mice cannot develop CAA pathology, we could not directly
study the impact of CAA on post-stroke cognitive function. Additionally, due to the need to
remove the brain to measure tracer distribution, we were restricted to single time-point
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studies and therefore could not study the growth of these deposits over time (this has since
been remedied by the establishment of an in vivo two-photon microscopy core). We are
currently working to address these weaknesses by performing DMCAO in multiple strains of
AD model mice, including Tg2576, TgSwDI, and APP/PS1, then staging plaque pathology
and measuring cognitive function. This will be further elaborated in later discussions of
future directions.
The other major weakness is the lack of fibronectin knockout experiments, which
would be a useful final confirmation of the importance of fibronectin in the context of stroke.
While we had considered this experiment, we concluded that it was not feasible for us,
because fibronectin knockout is embryonically lethal, and alternative strategies, such as
antibody therapies, do not cross the BBB efficiently. Future studies could be performed to
engineer an inducible knockout of fibronectin using a cre/flox system, but establishing these
lines is very expensive and time-consuming, forcing us to conclude that it was beyond the
scope of my fellowship. However, this weakness is partially addressed in the next set of
experiments, which indirectly reduces perivascular fibronectin expression by inhibiting
upstream signaling pathways with a more translational approach.
After establishing the role of basement membrane fibrosis in impairing the transport
of CSF Aβ1-40, I next sought to better understand how basement membrane composition is
regulated in the brain, and whether manipulating these upstream pathways can reverse poststroke increases in fibronectin in young and aged animals. Returning to the literature, I
found that astrocytes, endothelial cells and pericytes all play potential roles in regulating the
composition of the basement membrane,90,196 and that TGF-β is a major inducer of
fibronectin expression and CAA pathology.219,251,280,304 However, it was not known which
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cell types that TGF-β stimulates to produce fibronectin, or whether inhibiting TGF-β
signaling would sufficiently reduce these changes after stroke. Earlier on, I had acquired
some preliminary data showing that stroke increased perivascular GFAP expression, which is
a nonspecific marker of astrocyte activation, and that this activation primarily occurred on
astrocytic endfeet apposed to perivascular fibronectin deposits. This led me to hypothesize
that TGF-β activates astrocytes to remodel the basement membrane, impair the perivascular
flow of CSF, and produce fibronectin to trap CSF Aβ1-40. Based on this idea, I further
hypothesized that delayed inhibition of TGF-β could reduce perivascular gliosis, reverse
basement membrane fibrosis and improve perivascular CSF flow.
We first examined how aging and stroke interact to induce astrocyte reactivity by
performing DMCAO in young and aged mice, then examining GFAP and vimentin
expression seven days later. We found that aging increased astrocyte reactivity at baseline
and following stroke, and that this phenomenon also occurred in perivascular astrocytes.
Surprisingly, while aging did not increase total TGF-β expression, it did alter the downstream
signaling pathways to a potentially detrimental Smad3 phenotype. To better understand how
ischemia, TGF-β and Aβ1-40 interact to regulate astrocyte phenotype (defined as A1 and A2),
we then cultured primary murine astrocytes and exposed them to those stimuli in various
combinations. We found that Aβ1-40 and ischemia induced opposing phenotypes (A1 and A2,
respectively), and that TGF-β played more of a modulatory role in altering the expression of
a variety of ECM proteins and cytokines. Beyond these acute changes in astrocyte
phenotype and gene expression, we also found that chronic exposure to TGF-β induces
astrocytes to express fibronectin and integrin-α5 at high levels, which colocalized with
fluorescent Aβ1-40 in vitro. We further found that TGF-β altered AQP4 polarization, and
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reduced water uptake by astrocytes, which has been shown to also be important for
maintaining efficient CSF flow by other laboratories.125 We confirmed our findings by
injecting TGF-β into young mice in vivo, and found similar effects of treatment. Overall,
these studies uniformly support a detrimental role of TGF-β on basement membrane fibrosis,
Aβ1-40 distribution and CSF flow.
Based on all of this information, we finally sought to determine whether inhibiting
TGF-β could rescue the stroke-induced changes in astrocyte reactivity, basement membrane
composition and CSF Aβ1-40 transport that we had repeatedly observed in our previous sets of
experiments. We initially bred GFAPcre/wt x TGFβR2flox/flox mice to specifically inhibit TGFβ signaling to astrocytes, but found that peripheral treatment with a TGF-βR1/R2 antagonist
was a far more effective strategy. As predicted, we found that TGF-β inhibition reduced
astrocyte reactivity, downregulated perivascular fibronectin expression, rescued CSF flow
and reduced the binding of CSF Aβ1-40 to the basement membrane. These final experiments
confirm the role of TGF-β in mediating these changes, but leave a question hanging over the
sole importance of astrocytes in this process.
One strength of these experiments is the use of primary cells for our in vitro models,
which we feel better represents the function of astrocytes in our animal models than
immortalized cell lines. An additional strength is that we confirmed our most important
findings with both in vitro and in vivo systems, further improving our confidence in these
data. Finally, another strength is the use of a peripheral TGF-β antagonist following stroke,
which provides a more translational approach for drug delivery than other potential
strategies.
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However, there are also some weaknesses in our approach. First, while gliosis was
higher in the aged animals, the absolute levels of TGF-β did not change. We attribute this
discrepency to different patterns of Smad activation, but we were not able to confirm this
with Smad mutant mice as it was beyond the scope of my aims. This could be examined by
more robust follow-up studies involving knockouts of these various downstream signaling
pathways. An additional potential weakness is that we elected to use in vitro stimulation of
primary astrocyte cultures, rather than a more intensive approach involving in vivo
stimulation of astrocytes, followed by ex vivo cell sorting techniques used by other
laboratories.240 While in vivo stimulation may provide a more accurate representation of in
vivo cellular responses,239 we selected our approach because it allowed us to study the
behavior of these cells in isolation over longer periods of time. This gave us a chance to also
measure the impact of chronic stimulation on protein expression, Aβ1-40 deposition and water
uptake. However, other cells, particularly pericytes and endothelial cells, could also be
playing a role in vivo, necessitating further studies of other cell types. Finally, the biggest
weakness of these studies is that GFAPcre/wt x TGFβR2flox/flox genotype was significantly less
effective than the inhibitor studies in our hands. While our initial experimental design
dictated that we induce the knockout a full seven days after stroke to avoid detrimental
effects due to increased inflammation,229 pre-stroke induction may be more effective at
inhibiting TGF-β signaling. In addition to these technical issues, other cell types may
respond to TGF-β in similar ways, potentially compensating for the effects of the conditional
knockout compared to the more effective global inhibitor strategy.
As we completed these animal experiments, I also began to examine whether
molecules associated with basement membrane fibrosis could be used as clinical biomarkers
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of CAA in the serum of human ICH patients. A review of the literature revealed that there
were very few studies of serum biomarkers for CAA, with the majority examining the levels
of serum amyloid species and finding contradictory results.315 I hypothesized that serum
levels of levels of fibronectin, TGF-β and MMPs would correlate with CAA diagnosis, injury
severity and functional outcomes. I was fortunate to collaborate with a clinical researcher
who had collected serial serum samples and obtained extensive medical records from ICH
patients. Based on a combination of imaging and histopathological criteria, we were able to
classify patients with lobar hemorrhages due to probable CAA, and compare those with
patients who had deep hypertensive hemorrhages. We found that MMPs positively correlated
with injury severity in a univariate analysis, TGF-β negatively correlated with functional
outcomes even with multivariate correction, and when all cytokines were included in a
preliminary ROC analysis, we found that they provided a panel for CAA diagnosis that was
sufficiently sensitive and specific to reliably discriminate CAA from other types of ICH.
The strengths of our study include the use of prospective ICH cohorts from two
separate institutions, which allowed us to independently validate our findings with respect to
the ROC analysis. Also, the use of plasma allows for minimally inavasive screening of
CAA, compared to other strategies that involve expensive and time-consuming MRI, or
potentially dangerous collection strategies such as lumbar puncture to collect CSF, or even
invasive brain biopsies requiring removal of the skull and cortical tissue. An additional
strength was the overall novelty of the findings and the immediate potential for translation to
human patients. The lack of a realistic and reliable screening test for patients represents a
major roadblock to early intervention in the pathogenesis of CAA, which can only be
remedied by the development of more reliable blood biomarkers such as these molecules.
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Of course, this study has some important limitations. First, due to limited sample
availability, we were faced with some underpowered comparisons and an overall lack of
statistical significance of individual cytokines between CAA and hypertensive hemorrhages.
This weakness will be remedied in future follow-up studies with larger patient cohorts, for
which we are already seeking funding. Second, missing time-points over the five day
collection period required us to average values from each patient, rather than directly
comparing individual time-points. While this is not ideal, we found that cytokine values
were stable over this collection period, with no statistically significant variation with time,
mitigating this problem. Finally, we were unable to obtain histopathological confirmation of
CAA in all of the ‘probable CAA’ patients, as it would have required an invasive brain
biopsy that was sometimes not needed by the patient. This required us to rely on suboptimal
MRI biomarkers to define CAA in a subset of our patients. This will be addressed in future
studies with larger cohorts, which will allow us to require a definitive, biopsy-confirmed
positive or negative diagnosis in all patients.
Overall, while each study has their own unique strengths and weaknesses, as a whole
they provide an interesting take on CAA that deserves further study. From recombinant
peptides, to cultured cells, to mouse models, and all the way up to human patients, our
experiments consistently demonstrate the importance of these molecules in influencing the
spread of amyloid pathology after injury. In the remainder of this discussion, I will attempt
to synthesize these results with the existing literature into an updated model of CAA
pathogenesis. Then, I will describe several exciting new areas of investigation, a few of
which are already underway in our laboratory.
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Figure 7-1: Working model of CAA pathogenesis. CAA can be divided into multiple
phases, with early CAA being characterized as “pre-pathology” and advanced CAA
characterized by perivascular amyloid plaques and microhemorrhages.

7.3: Developing a new model of CAA pathogenesis.
While previous disease models begin with perivascular amyloid pathology, my data
indicate that there are predictable, early changes that occur within the basement membrane
before this pathology develops. This provides a potential unified mechanism that could
predict areas that are susceptible to CAA before significant damage occurs. Based on my
findings and the most current literature, CAA can be broken down into three general stages:
early, intermediate and late. In the early stages of CAA, insults such as ischemic stroke
increase TGF-β expression, which signals to astrocytes to induce basement membrane
fibrosis. These fibrotic changes include an increase in fibronectin, integrin-α5 and overall
lectin+ matrix. In the intermediate phase, fibrosis promotes the initial sequestration of CSF
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Aβ1-40, which freely circulates through perivascular flow networks under normal conditions.
As Aβ1-40 deposition increases, plaque size in affected vessels begins to increase rapidly.
Finally, in the late stages of CAA, mature plaques induce chronic inflammation that leads to
microhemorrhage and/or lobar ICH, as well as cognitive decline.
This proposed pathogenesis of CAA is analagous to atherosclerotic plaque formation,
which occurs due to the deposition of cholesterol within areas of fibrosis that line the vessel
lumen.316 In the early stages of atherosclerosis, the walls of vessels become fibrotic due to
repeated insults, including hypertension, hyperglycemia and free radicals. In the
intermediate stage, cholesterol deposits within this scarred area and forms an atherosclerotic
plaque. Finally, in the late stages, this deposition causes a local inflammatory response that
can result in thrombi and acute ischemia. This simple model has led to the development of a
plethora of disease biomarkers, pharmacological treatments and even surgical interventions
to protect patients from advanced atherosclerosis, unstable plaque formation and blood
clotting. Application of these ideas could lead to similar advances in the diagnosis or even
treatment of CAA.
If this new model of CAA is correct, then the underlying disease process which drives
cognitive decline in stroke survivors could be targeted in several places. The most
straightforward method would be to prevent damage from occuring in the early stages of
disease, most effectively by primary prevention of stroke and other risk factors such as
hypertension, hyperglycemia and hypercholesterolemia. Following stroke, the intermediate
phase could be targeted by reversing overall basement membrane fibrosis (for example, with
a TGF-β antagonist) or by directly inhibiting individual receptors that bind to CSF Aβ1-40
(fibronectin, integrin-α5 or HSPGs). An alternative strategy would be to develop drugs that
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reduce the levels of CSF Aβ1-40, which may at least slow the development of the plaques,
analagous to the use of statins in patients with hypercholesterolemia. Once the disease
reaches the later stages, where secondary vessel damage has occurred and the patient has
multiple microhemorrhages, it may be too late to intervene with these strategies.
Unfortunately, most patients are not diagnosed with CAA until this very late stage of disease,
highlighting the need for early detection.315 However, we found that these molecules are
useful biomarkers for CAA in this population, which may help to identify at-risk patients and
reduce the prescription of anticoagulant drugs, which could put them at further increased risk
of repeated hemorrhage.
While this new disease model is interesting, there are several areas that require further
discussion and more research to refine it into a useful predictive tool. First, translating this
work to AD model mice would help to confirm that these early and intermediate changes in
the basement membrane lead to CAA plaques in AD model mice. Second, a better
understanding of how multiple basement membrane receptors for CSF Aβ1-40 interact to
favor the development of CAA would help to develop more selective therapeutics. Third, the
number and function of different basement membrane sub-layers, and how disrupted
perivascular flow in each compartment contributes to CAA pathogenesis, needs to be better
understood. Further evaluation of the regulation of CSF Aβ1-40 levels could also lead to the
development of an alternative class of therapeutics for CAA. Overall, given the evidence
that we have obtained from our experiments, post-stroke CAA may share mechanisms with
so-called ‘sporadic’ CAA, which could significantly expand the applicability of our findings
to numerous other patients, beyond stroke survivors.
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7.4: Exploring the contribution of reactive astrocytes to CAA pathology.
My previous work found that TGF-β stimulates astrocytes to deposit fibronectin
within the extracellular matrix in vitro, which is associated with reduced fluid uptake and
increased Aβ1-40 deposition. We further found that inhibition of TGF-β reduced fibronectin
expression, improved CSF flow and reduced CSF Aβ1-40 deposition following stroke in aged
wild-type mice. While this research indicates that basement membrane fibrosis occurs prior
to Aβ1-40 deposition, we do not yet know whether these changes accelerate CAA plaque
formation. Furthermore, we also have not yet determined the long-term impact of CAA
pathology on basement membrane composition, perivascular flow, recovery from stroke or
overall cognitive function. Finally, we also do not know whether long-term TGF-β inhibition
can rescue these phenotypes associated with advanced CAA.
Therefore, to better understand the significance of these findings on overall CAA
pathogenesis, we propose to study the impact of DMCAO and TGF-β inhibition in Tg2576
mice, an animal model of Alzheimer’s disease, using in vivo two-photon microscopy and
cognitive testing. We hypothesize that DMCAO will accelerate CAA progression in Tg2576
mice, leading to worse cognitive function after stroke. We further hypothesize that these
phenotypes will be rescued by inhibiting TGF-β signaling in Tg2576 mice with stroke.
To characterize whether stroke-induced deposition of CSF Aβ1-40 contributes to CAA,
we will first place a cranial window in Tg2576 and wild-type animals, then perform
DMCAO or sham surgeries one month later. Since Tg2576 mice do not generally develop
CAA pathology until 13 months of age, we will examine the impact across different stages of
pathology by using 3, 9, 13 and 18-month-old age-matched controls for all experiments. To
evaluate CAA pathology, mice will be repeatedly injected with Methoxy-X04 (a congo red-
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derivative amyloid staining fluorescent dye) and imaged by two-photon microscopy over one
month. Cognitive testing (Fear conditioning, Y maze, novel object recognition test [NORT],
Barnes maze) will also be performed on these animals prior to sacrifice. Finally, we will also
perform IHC after sacrifice to determine how genotype, age and surgery interact to alter
basement membrane composition.
In a second set of experiments, mice will receive an intracisternal injection of FITCAβ1-40 at the time of two-photon imaging to determine whether CSF Aβ1-40 contributes to the
development of these mature CAA plaques. Finally, in a third set of experiments, instead of
DMCAO, both genotypes will receive ICV injections of recombinant TGF-β, and the impact
of treatment on the above histopathological and behavioral measures will be assessed over
one month. We expect that DMCAO and TGF-β treatment will similarly increase MethoxyX04 labeling of vessels in Tg2576 mice, which will colocalize with intracisternally injected
FITC-Aβ1-40. If successful, these experiments could definitively show that stroke is an
independent risk factor for CAA, and that this acceleration occurs, in part, due to the
deposition of CSF Aβ1-40. It could also show that TGF-β alone is sufficient to induce these
changes, paving the way for subsequent experiments exploring the impact of TGF-β
inhibition on plaque development.
Then, to determine whether inhibiting TGF-β signaling reduces CAA development
after stroke, we will perform DMCAO in Tg2576 mice and treat them with a TGF-βR1
antagonist (GW788388) or vehicle control via continuous peripheral and/or central infusion.
Our previous data in aged wild-type mice found that peripheral treatment with this inhibitor
reduced perivascular gliosis and fibronectin expression, as well as improved perivascular
CSF flow. We expect that TGF-βR1 antagonism will have similar effects on Tg2576 mice,
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with the added benefit of reducing CAA development and improving long-term cognitive
function. If successful, these experiments would indicate that peripheral TGF-βR1
antagonism can blunt the impact of stroke on accelerating CAA pathology, potentially
leading to a new therapy for CAA that could be explored in higher-order model systems. In
the future, drugs like this could be given prophylactically to patients with stroke or other
types of acute brain injuries who are at risk of developing CAA.
Overall, these experiments represent a critical next step for our research program, and
we are excited to have secured NIH/NIA R01 grant funding to continue this work over the
coming years. While we already have some data suggesting a potential benefit of TGF-βR1
antagonism on perivascular CSF flow, these experiments could show that these benefits
extend to histopathological and behavioral improvements in animal models of CAA. There
is significantly more work to be done, but following these confirmatory experiments, our
findings could be rapidly translated to clinical populations, given the ongoing use of
combinatorial TGF-β antagonists in other diseases, including cancer and pulmonary fibrosis.

7.5: Modulation of basement membrane receptors to improve CSF flow and reduce CAA.
While previous work has documented that basement membrane changes correlate
with the severity of CAA pathology, our findings newly demonstrate that aging and stroke
produce upregulation of fibronectin and its receptor, integrin-α5. Importantly, these changes
occurred prior to the development of pathology. We further found that these changes
correlated with increased perivascular distribution of CSF Aβ1-40 and reduced CSF flow,
suggesting a structure/function relationship between these basement membrane changes and
perivascular transport. These new findings provide significant insight into the pathogenesis

	
  

189

of CAA, as it suggests that these changes could be a cause, not a consequence, of the
development of amyloid pathology.
As one future direction, we could continue to develop this pathway as a therapeutic
target by examining the impact of fibronectin and/or integrin-α5 knockout on the progression
of CAA. For example, to test the hypothesis that astrocytic fibronectin accelerates CAA
pathology, conditional fibronectin knockouts (GFAPcre/wt x FN1flox/flox) could be crossed with
a rapidly progressing CAA model mouse, such as the TgSwDI strain, and
pathology/cognitive deficits examined across the lifespan, at 3, 6, 12 and 24 months of age.
Cognitive impairment could be measured using a battery of tests, including NORT, Barnes
maze and contextual fear conditioning. Amyloid pathology could also be quantified
histologically by staining brain sections with Thioflavin S, Congo Red or anti-amyloid
antibodies such as 4G8 monoclonal antibody. I expect that fibronectin knockouts would
exhibit less CAA pathology and better cognitive function by 12 months of age, and would
most likely be resistant to other potential amyloidogenic stimuli such as stroke or advanced
age. If these experiments are successful, an interesting next step would be to
pharmacologically target fibronectin using intracisternal administration of antibody-based
inhibitors, although the precise binding site of Aβ1-40 to fibronectin would need to be
determined by synthesizing mutant fibronectin type I domain in vitro, followed by repeated
binding assays with each isoform. Additionally, integrin-α5 small molecule inhibitors
already exist (ATN-161), and could be used to reduce the binding of fibronectin to integrinα5. This may also help in a more selective way by preventing the deposition of fibronectinAβ1-40 aggregates, without a need to identifying the exact binding site for Aβ1-40 on
fibronectin.
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An additional, ongoing area of study is using unbiased proteomics to discover new
ECM proteins that may be involved in regulating perivascular flow. The glia limitans is an
ECM-rich area that forms a barrier between the meningeal/vascular compartments and the
brain interstitial fluid. As such, it may provide a first line of defense against the penetration
of damaging CSF waste products, or toxic products that could enter from the peripheral
circulation into the brain. We previously found that lectin staining strongly increased within
the glia limitans and basement membrane following DMCAO in aged animals, indicating
increased expression of glycosylated residues. This finding suggests that the composition of
the glia limitans is changing, but, beyond increases in fibronectin and integrin-α5, we do not
know how many other ECM proteins may be involved. Therefore, we hypothesized that
aging and stroke would alter the glia limitans proteome, in large part due to abnormal
production of ECM proteins. To test this hypothesis, we performed DMCAO in young and
aged mice, then sacrificed them at 30 DPI and collected fresh brain tissue, plasma and CSF.
We then sectioned the brain tissue on a cryostat, mounted it onto a PEN membrane and
performed H+E staining to visualize the glia limitans. Next, we performed laser capture
microdissection to isolate the outer glia limitans from the rest of the brain. We are currently
awaiting LC/MS results, but our preliminary findings indicate detection of >1200 unique
peptides in our test samples. Upon completion of this project, we expect that it will generate
a significant amount of new information about the protein composition of the glia limitans at
baseline, as well as how it changes with aging and stroke. This could provide new targets,
which could then be assessed for binding potential to Aβ1-40, using similar techniques as
described in Chapter 4.
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7.6: Brain perivascular flow dynamics may have a molecular size sensitivity.
Our experiments indicate that the perivascular flow rate is size-dependent, and occurs
in different basement membrane layers. We found that larger particles (70 – 2000 kD)
traveled through the outer region of the basement membrane, and cleared slowly from the
ISF. In contrast, smaller particles (0.5 – 4.5 kD), including Aβ1-40, were associated with the
inner basement membrane and cleared more rapidly from brain tissue. These findings were
surprising, as previous studies suggested that CSF solutes are transported by bulk flow,
which dictates that all particles will move at the same rate, regardless of mass.125,199,200 The
best interpretation of these data is that passive diffusion interacts with bulk flow to produce a
dynamic process that cannot be described as purely one or the other.
It is important to recognize that this process of perivascular flow and solute exchange
is actually dependent on two distinct compartments: the vascular basement membrane
compartment (between endothelial cells and astrocyte endfeet) and the interstitial
compartment (between astrocyte endfeet and other cells such as neurons and
oligodendrocytes). If one were to track the movement of a single particle, initially, it may be
rapidly distributed through the perivascular compartment by a process that has been
historically attributed to bulk flow. However, our data suggest that this process is modified
by certain biophysical properties of the basement membrane (collectively termed ‘tortuosity,’
reviewed in Section 1.8), which generate a size-exclusion property within the perivascular
compartment.202 Our data indicate that the certain regions of basement membrane are more
selective for small particles, while the others permit the transport of very large particles.
This property could be a function of tortuosity, which largely depends on the conformation of
the ECM, which itself depends on composition. This tendency for particles to diffuse at
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different rates through different regions of tissue is called anisotropy, and is best measured
by sensitive techniques such as TMA iontophoresis.202 However, even without this
technique, we can infer from our data that the structure of the outer basement membrane
must differ from the inner basement membrane to produce this divergent physiology.
Following this process of perivascular distribution, which is partly driven by bulk
flow, CSF solutes must then exchange with ISF solutes. To accomplish this, particles must
diffuse between the perivascular and interstitial compartments. We found that large
molecules (2000 kD dextran) did not travel into the interstitium, while small molecules (3 kD
dextran) easily traveled into the interstitium. If this process were solely governed by bulk
flow, then one would expect that both particles would travel equally far from the PVS.
Given the fact that this does not occur, and that travel distance is strongly dependent on the
hydrodynamic radius (or ‘size’) of the diffusing particle, then this process must be governed
by the forces of passive diffusion (as predicted by the Stokes-Einstein equation).202 In
addition to molecular size slowing down the process of diffusion, our data also suggest that
the glial endfeet, which form the border between the perivascular and interstitial
compartments, could also provide an anisotropic size-exclusion barrier to larger particles.
This property may also contribute to the much slower clearance of intraparenchymally
injected albumin, which is a measure of the reverse phenomenon: ISF-CSF exchange. An
alternative interpretation is that the entire interstitial compartment excludes large particles,
not just the glial endfeet. However, it is not currently possible to discern which interpretation
is most accurate from the present data, and would require additional, careful studies with
more sensitive techniques, such as TMA iontophoresis.
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This size-exclusion barrier between basement membrane sublayers, as well as
between the perivascular and interstitial compartments, may have important consequences
for the pathogenesis of CAA. In CAA, there is initially a selective build-up of Aβ1-40 within
the outermost layers of basement membrane of the outermost cortical vessels, which then
moves inward in both directions as pathology advances.94 This suggests that these sizeexclusion properties could safeguard the vessels against this perivascular pathology, but this
later becomes dysregulated and ultimately fails in CAA (potentially due to fibrosis). While
monomeric Aβ1-40 is small enough to travel within the inner basement membrane layer, the
assembly of these monomeric particles into oligomers and eventually much larger aggregates
could form mature CAA plaques that are excluded from the inner membrane and exist within
the less efficient outer membrane.
Furthermore, the segregation of the perivascular and interstitial compartments may
explain the propensity of cortical pathology to begin with vessels,317 as these larger
oligomers may be able to distribute perivascularly through the outer basement membrane, but
not be able to spread into the interstitial space. However, when the plaque becomes large
enough to cause inflammation and damage this barrier, oligomers can spread into the
interstitium and further spread pathology throughout the surrounding area. This concept is
somewhat similar to metastasis of cancer, as amyloid pathology in one region of the brain
(such as the hippocampus) may eventually disrupt these insulating barriers and allow for
toxic oligomers to ‘infect’ the CSF and spread to distant sites via perivascular flow.
The biggest unanswered question from these experiments is: which proteins are
responsible for generating this size-exclusion property? Previous studies have shown that
HSPGs within the glycocalyx support the repulsive properties of the BBB,90,241 but it is not

	
  

194

know whether the HSPGs contained within the basement membrane also produce this
function of size-exclusion of CSF solutes between membrane sublayers. As a next step, this
question could be answered by electron microscopy, which would allow us to visualize the
ultrastructure of these ECM proteins. Immunogold labeling of specific classes of basement
membrane proteins (collagens, laminins, fibronectin, glycosaminoglycans) could demonstrate
potential differences in the composition of these basement membrane sub-layers. Then,
knocking out individual proteins that are enriched in these different layers, and examining the
relative perivascular transport of small and large gold-labeled dextran particles, could begin
to address the physiological significance of these differences in structure/composition within
the specific sub-layer.
For example, if protein A were found to be enriched in the inner basement membrane,
and knockout of protein A enabled the diffusion of high molecular weight dextran particles
within the inner basement membrane, then one could conclude that protein A was responsible
for generating this size-exclusion property of the inner basement membrane. Alternatively,
knockout of protein B could completely abolish perivascular flow, indicating that it is
required for maintaining a structure that permits the flow of CSF and solutes. Similar
approaches could be used to compare the structure/function relationship of size-exclusion by
the glial endfeet and/or intersititial compartment.

7.7: CSF Aβ1-40 levels may increase in aging and after stroke be by multiple mechanisms.
Our findings demonstrate that aging and stroke induce the deposition of CSF Aβ1-40
within the basement membrane. This difference in deposition occurred even though we
injected the same amount of fluorescent Aβ1-40 into the CSF of each animal, suggesting that
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alterations in the intrinsic Aβ1-40 binding capacity may be altered by pathological states.
However, it is important to consider that the absolute levels of CSF Aβ1-40 may also change
with aging, stroke and CAA. Previous work has shown that early increases in CSF Aβ1-40
occur before the onset of CAA in human patients.149 If aging or stroke were to also increase
the levels of CSF Aβ1-40 relative to baseline, this could further magnify the perivascular Aβ140

deposition that was seen in our animal studies. As a potential future direction, we could

examine how aging and stroke alter choroidal permeability and/or meningeal CSF clearance
pathways, and determine whether blocking these changes could slow CAA development.
The CP undergoes several major changes with normal aging, which could lead to
increases in the concentration of CSF Aβ1-40. Beginning in old age, the barrier between the
plasma and CSF becomes thinner.318,319 Additionally, basement membrane fibrosis occurs in
both the epithelial and endothelial layers, potentially contributing to reduced absorptive
capacity of the basolateral membrane.319 Furthermore, aging causes the epithelial cells to
become invested with lipofuscin granules and protein inclusions, which may also impair the
secretory function of the microvilli and reduce CSF production in aging.320 Together, these
changes contribute to an approximately 30% reduction in CSF secretion with aging, despite
increases in total CSF volume within the ventricles and subarachnoid space, which often
occur due to cerebral atrophy.318,319 Furthermore, Alzheimer’s disease is associated with
more rapid aging of the CP, with amyloid plaque formation occurring within the PVS of CP
capillaries, reminiscent of CAA.320 These changes are associated with a 50% reduction in
CSF turnover compared to the normal aged CP.321 The net effects of these changes are
reduced CSF turnover and higher CSF protein concentration with aging.322 These reductions
in CSF turnover could lead to increased transit time for Aβ1-40 particles to be cleared from the
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brain, which would increase the concentration of CSF Aβ1-40 that is recirculated along the
basement membrane and lead to CAA.
Brain injury may further reduce the turnover of CSF. Following stroke, increased
cellular debris can act to clog meningeal outflow, leading to increased intracranial pressure
(ICP) and damage to the CP.323–325 Increased ICP further triggers a negative feedback loop
involving several vasoregulatory hormones, including atrial natiuretic peptide,326
vasopressin,132 and fibroblast growth factor,327–329 which all act to reduce CSF formation.
While this does prevent worsening of ICP, this feedback effectively reduces the turnover of
CSF, and dysregulation of these pathways may contribute to increased CSF Aβ1-40 levels
following brain injury.
In addition to slowing the clearance of CSF Aβ1-40, brain injuries can increase the
permeability of the blood-CSF barrier and expose the brain to systemic waste products such
as Aβ1-40. One study found that TBI increased CP peremeability to plasma solutes, leading to
increased osmotic uptake of water and elevated ICP.330. Following stroke, the CP
upregulates lysosome expression and appears highly vacuolated, the width of the intercellular
spaces increases, and the microvilli become enlarged.331 These morphological changes are
also associated with increased trafficking of immune cells through the CP, including
increased numbers of cytotoxic T cells in aged animals.332,333 Similarly, the CP epithelium
also provides a route for monocyte-derived macrophages to enter the brain and influence
post-stroke recovery.334 While it is clear that stroke has dramatic effects on the permeability
of the CP to immune cells, the effects of stroke on permeability to Aβ1-40 are not known. In
older individuals, these changes could have an additive effect with baseline impairments in
CSF turnover/clearance and further increase CSF Aβ1-40 levels.
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As one potential new direction, we could test the hypothesis that stroke disrupts the
blood-CSF barrier, newly exposing the brain to peripheral Aβ1-40. To test this hypothesis, we
could first perform DMCAO, and then intravenously inject 125I-Aβ1-40 into the peripheral
bloodstream. Then, we could block CSF outflow pathways by intracisternally injecting
glycerol, and collect freshly filtered CSF by a microdialysis catheter placed in the lateral
ventricle. Following this, in a separate group, we could intravenously inject gold-labeled
Aβ1-40, then section the brain and examine CP morphology by electron microscopy to
determine whether Aβ1-40 was being taken up transcellularly through receptors like
lipoprotein receptor protein-1 (LRP1), P-glycoprotein (PGP) or receptor for advanced
glycation endproducts (RAGE), or whether this uptake was occurring paracellularly. I
predict that DMCAO will increase the uptake of 125I-Aβ1-40 into the CSF. Depending on
what route Aβ1-40 is taken up by, different treatment strategies such as anti-inflammatory
drugs to reduce damage to the CP and paracellular uptake could be explored, or utilize
specific knockouts/inhibitors of the transcellular uptake processes. If successful, these
experiments would determine whether stroke increases CP permeability to Aβ1-40, and by
which route this occurs. Depending on the outcome, new drugs could be utilized to reduce
the uptake of Aβ1-40 into the brain after stroke.
As an additional future area of research, we could also test the hypothesis that stroke
releases necrotic debris that reduce the outflow of CSF through the dural lymphatics,
impairing the removal of CSF Aβ1-40 and worsening vascular amyloid pathology and
cognitive impairment. To test this hypothesis, we could place a cranial window over the
dural lymphatic vessels of Tg2576 x GFP mice, then perform DMCAO. Following this, we
could then measure lymphatic outflow by intracisternally injecting fluorescent quantum dots
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and measuring their flow velocity by two-photon microscopy. I would predict that DMCAO
would reduce lymphatic outflow acutely after injury due to the presence of GFP-positive
cellular debris within the lymphatics. We could then test whether installing a
ventriculoperitoneal shunt could help to normalize CSF outflow and allow for the debris to
clear more rapidly from the brain. Then, we could determine whether this treatment
improves post-stroke cognitive function, and whether this impairment is greater in the
transgenic Tg2576 mice. If successful, shunting could be used to improve the clearance of
Aβ1-40 in human CAA patients, particularly after an acute injury like stroke.
In conclusion, CSF Aβ1-40 levels fluctuate over the course of CAA, with high levels
observed in the early stages of disease. Degradation of the blood-CSF barrier, reduced CSF
turnover and impaired outflow of through the meninges all likely contribute to early
increases in Aβ1-40 within the CSF with CAA. Aging, brain injury and Alzheimer’s disease
may be associated with alterations in these parameters, which could favor a build-up of CSF
Aβ1-40, worsening CAA. Further work must be done to assess how these changes in the CP
impact that uptake and/or clearance of Aβ1-40 after stroke. This could provide an additional
target to reduce CSF Aβ1-40 levels and CAA development.

7.8: Concluding remarks.
This work represents an early step in developing a new understanding of how CAA
develops in survivors of ischemic stroke. CAA may be a late sign of disease within the
perivascular glymphatic system, which opens up a plethora of potential treatment strategies
to treat the underlying problems that are driving vascular amyloid pathology in these patients.
New strategies to detect early reductions in perivascular CSF flow by imaging or serum
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biomarkers could expand the treatment window for CAA. If early disease is detected, then
reducing the levels of CSF Aβ1-40 by reducing distribution or enhancing clearance may help
to slow the progression of amyloid pathology in distal perivascular beds. We have also
shown that targeting the basement membrane with anti-TGF-β therapies can be an effective
strategy for reducing perivascular amyloid burden after focal injury, which could one-day be
translated to the clinic.
Overall, this work is a testament to the value of collaborative research. This project
began as a far-fetched idea, but was shaped into a coherent project with much help from Dr.
McCullough, Dr. Urayama and my thesis committee. With the help of other lab members,
and a great deal of patience, we were able to accomplish what I once believed to be a very
long shot—to reverse impairment in the perivascular drainage of waste products after stroke.
Over the course of these experiments, I shared my findings with others in our research group
and helped to obtain new grants, which have delivered funding that will ensure these new
projects continue to grow in the coming years. While this chapter in my life is ending, it also
provides a new beginning for the next wave of researchers with their own ideas. Already,
others in our research group have begun to probe the contributions of diverse other systems
to CAA pathogenesis, including neuroimmunology, gut microbiology and respiratory
physiology. This work will provide even more of the missing pieces to the puzzle of CAA,
which we can assemble into a new strategy to end dementia in the 21st century.
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